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ABSTRACT 
Skin cancer is a neoplastic disease comprising a variety of histopathological cutaneous 
forms, which can be broadly categorised as melanomas and non-melanomas. The most common 
non-melanomas are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). 
Malignant melanomas are the most aggressive and invasive, of which cutaneous melanomas 
have a better prognosis. Cutaneous melanomas are still relatively rare, but incidence rates are 
steadily increasing in Caucasian populations around the world. Progression into severe 
malignant stages occurs under the combined action of environmental risk factors and 
individual's genotype, phenotype and degree of immunocompetence. The single most important 
environmental risk factor for skin cancer is sunlight exposure. The genetic component is seen in 
the inherited genodermatoses, such as Xeroderma Pigmentosum (XP), where there is a 1000-
fold increased risk of skin cancer. Nucleotide excision repair (NER), the pathway responsible 
for removal of UV-induced DNA damage, is defective in XP patients. The XPB and XPD 
helicases are essential components of the NER pathway. Frequent polymorphisms have been 
reported in NER genes and polymorphisms in ERCC2, ERCCI and XPF have been investigated 
for association with melanoma, non-melanoma skin cancer and cancer of the lung, brain and 
bladder. My study investigated the possibility of an association between XPB and XPD and 
melanoma in a case control study. The study addressed the hypothesis that polymorphisms in 
NER genes leading to altered proteins might be a cancer risk factor because of altered 
interactions between repair proteins and the cell cycle control machinery. No variation was 
found in the XPB gene. Sequence variation has been detected in XPD exons 6, 22, 23, 18 and 
20. Analysis of the polymorphisms in exon 6, 22 and 23 showed that in each case, one allele 
was over-represented in the melanoma group. The exon 6 (156Arg) and exon 22 (71 lAsp) 
changes were silent while the exon 23 change altered the protein sequence (Lys75lGln). The 
association did not extend to the closest flanking markers, suggesting that susceptibility to 
melanoma might be due to the XPD gene itself. Human lymphocyte cultures with different exon 
23 genotypes were studied to investigate the possibility that the XPD exon 23 alleles might 
interact differently with p53 to effect the response to UV-induced DNA damage. Although the 
p53 assay works, the results were inconclusive and more work needs to be done to investigate a 
possible relationship between p53 response and XPD polymorphisms. The results presented in 
this thesis need confirmation from a larger study group and additional functional assays. 
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1.1.1. Structure of the skin 
The skin is the largest organ of the human body. It is composed of tissue that grows, 
differentiates and renews itself constantly. Skin is divided into 3 rather distinct layers. From 
inside out, they are the subcutaneous tissue, the dermis and the epidermis. The subcutaneous 
tissue is a receptacle for formation and storage of fat with a highly dynamic lipid 
metabolism. It supports the blood vessels and nerves that pass from tissues beneath to the 
dermis above. The dermis or Corium is made up of connective tissue, cellular elements and 
ground substance. It has a rich blood and nerve supply and it is the origin site for sebaceous 
glands and the shorter hair follicles. The epidermis is less than 1mm thick and it is the 
thinnest out of the three layers. Epidermis is divided into 4 living layers and one dead end 
product called the horny layer. From inside out the living epidermis is composed of basal 
layer, prickle layer, granular layer and lucid layer. 
There are two cell types in the epidermis, keratinocytes and dendritic cells. 
Keratinocvtes are found in the basal layer and give rise to all the other cells of the stratified 
epidermis. There are three types of dendritic cells: melanocytes (melanin-forming cells), 
Langerhans cells and indeterminate dendritic cells. Because melanocytes are relevant to the 
thesis they will be described in detail below. Melanocytes are found in the basal layer, 
sandwiched between the more numerous keratinocvtes. Ultrastructurally, melanocytes are 
characterised by the presence of melanosomes, specialised melanin-producing organelles. 
1.1. 1.1 Melanocvtes. general description, function and regulation 
Melanocvtes derive from the neural crest cells that during embryonal development 
differentiate toward melanoblasts along their migration to the skin in a pathway marked and 
modified by mesenchyme. After reaching the dermis they migrate to the epidermis or the 
hair follicle and differentiate into nevomelanocytes. The main function of epidermal 
melanocytes is production and transfer of melanin granules to the surrounding keratinocytes 
within an epidermal melanin unit (Boyle et al., 1995). Recent evidence supports the concept 
that epidermal melanoc tes are involved in maintaining cutaneous homeostasis, by acting as 
sensory and regulatory cells against any disturbances. Unstimulated epidermal melanocytes 
in vivo are mitotically inactive but can proliferate as a response to UV radiation. The 
follicular melanocytes are characterised by cyclic proliferative and melanogenic activity that 
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is strictly coupled to the growing phase of the hair follicle (anagen) and determines the 
colour of the mature hair shaft. The function of the dermal nevomelanocytes is unknown. It 
has been suggested that 70% of cutaneous melanoma derives from epidermal melanocytes 
and 30% from nevomelanoc tes but not from follicular melanocytes (Boyle et al., 1995). 
Melanin formation starts from the amino acid tyrosine, which is oxidised by the 
copper-binding  enzyme tTosinase to dopa, then dopa is oxidised to dopaquinone by the 
same enzyme. From dopaquinone after several metabolic processes melanin is formed. The 
rate-limiting step in melanin formation is the oxidation of tyrosine to dopa and of dopa to 
dopaquinone. Other proteins associated with melanogenesis are tyrosinase-related TRP-1 
and TRP-2. Melanin synthesis is tissue specific and this is achieved by melanocyte-specific 
transcription of the tyrosinase gene and TRP-1 and -2 genes (Boyle et al., 1995). This 
process is controlled and upregulated via the cyclic adenosine 3', 5'-monophosphate (cAMP) 
signalling pathway by a melanocyte stimulating hormone (a—MSH) from the pituitary, the 
most potent melanising agent. a—, 3—, y—MSH and adrenocorticotropic hormone (ACTH) are 
bio-active peptides of the melanocortin family, all deriving from a large precursor peptide, 
pro-opio-melanocortin (POMC). POMC is synthesised in the pituitary and hypothalamus, 
gastrointestinal tract, gonads and skin (Abdel-Malek et al., 2000). Essential for the 
melanogenic activity are the 4-10 amino acid residues of the C-terminus of ct—MSH, f3—MSH 
and ACTH. Other melanogenic factors, such as endothelin-1 (Eli, via the PKC pathway), 
prostaglandms. thymidine dinucleotide and histamine are released from keratinocytes and 
other cells surrounding the melanocytes (Sasaki et al., 2000). There are two types of melanin 
in human skin eumelanin (brown/black pigmentation), which is photoprotective and 
phaeomelanin (red/yellow pigmentation), which may contribute to cancer risk because it 
generates free radicals following UV exposure. The proportion between the two types is 
regulated by the extension locus that encodes the a—MSH receptor (MCI R) (Ichii-Jones et 
al., 1998). a—MSH stimulation of MC1R in melanocytes induces eumelanogenesis, which is 
important to the tanning response following UV exposure. Apart from MC IF, 4 other 
melanocortin receptors have been identified. They are located in different tissues and have 
different affinities for various melanocortins. MC2R is the receptor for ACTH, which is 
expressed in the adrenal cortex. Similar to the MC1R, MC4R has affinity for a—MSH. 
Competitive antagonists of the MC receptors are agouti signalling protein (ASP) and agouti-
related protein (AGRP). ASP, the product of the agouti gene is a 132 amino acid protein with 
high affinity for MCIR and MC4R and lower affinity for MC3R and MC5R. AGRP has high 
affinity for MC3R and MC4R and very little affinity for MC5R and MCIR (Abdel-Malek et 
al.. 2000) and (Wikberg et al., 2000). 
3 
The human MCI R gene is located at 16q24.3  and codes for a predicted 317 amino 
acid seven pass transmembrane (G protein coupled) receptor. MCI R is expressed mainly in 
melanocytes, but also in endothelial cells and keratinocytes. It is known that at least in 
mouse there are two physiological ligands, which interact with the MC1R: a—MSH, a 
tridecapeptide cleavage product of pro-opio-melanocortin (POMC), which activates the 
receptor; and agouti, which antagonises the actions of ct—MSH. The activated receptor 
regulates the production and ratio of the two types of melanin. Mouse MC 1 R loss of function 
mutants are associated with red or yellow coat whereas gain of function mutants are 
associated with black coat due to increased eumelanin production (Rees, 2000). 
In man a number of loss of function mutations have been described, whilst activating 
mutations of the MCIR have not been yet identified. Of the 30 MCIR alleles identified 
Val60Leu, Arg142His, Argl5lCys, Argl60Trp and Asp294His appear to be loss of function 
mutants (Frandberg et al., 1998). The allelic variants of MC1R appear to cluster in three 
areas of the gene. These areas are: the first trans-membrane domain/first intracellular 
loop/second trans-membrane domain, the second intracellular loop and the seventh trans-
membrane domain (Smith et al., 1998). Population studies show association between the 
Argl5lCys, Arg160Trp and Asp294His variants and red hair and fair skin (skin type 1, 11) 
(Valverde et al.. 1995), (Box et al., 2001), (Smith et al., 1998), (Bastiaens et al., 2001). In 
man MCi R loss of function is associated with red hair and UV-sensitive skin type, which 
increase the risk of melanoma and non-melanoma skin cancer Palmer and (Bastiaens et al., 
2001). However, the association between MC1R variants and melanoma and non-melanoma 
skin cancer is questionable, as studies confirming it are later disproved by lack of 
reproducibility. For instance, Valverde et al., (1996) found that carriers of Asp84Glu variant 
allele have an increased risk of malignant melanoma, whilst Ichii-Jones et al., (1999) and 
Palmer etal., (2000) were not able to confirm this association. Similarly, Smith et al., (1998) 
found that Asp294His variant allele is over-represented in a small group of NMSC patients, 
which could not be confirmed by Ichii-Jones etal., (1999) in a group of BCC patients. 
1.1.2 Skin carcinoenesis 
Cancers are categorised according to their origin or state of differentiation. Tumours 
arising from epithelial cells are termed carcinomas. Melanomas arise in melanocytes. Basal 
cell carcinoma (BCC) and squamous cell carcinoma are commonly referred to as non-
melanoma skin cancer (NMSC). This type of skin cancer is most frequently induced by UV 
radiation, in combination with genetically determined phenotype such as fair skin and red 
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hair. BCC is the most common malignancy of the epidermal appendages, accounting for 
75% of all NMSC. It develops from both follicular and interfollicular epithelium. It has a 
cure rate close to 100% if treated early and accurately. BCC almost never metastasises, 
although it can produce significant local destruction and disfigurement and in most severe 
cases it can invade bones and metastasise. SCC is a malignant neoplasm of keratinocytes. It 
consists of cells that have traversed the basement membrane of the epidermis and infiltrated 
the dermis in a detached growth pattern, which confers metastatic potential (Miller & 
Maloney, 1998). Cutaneous SCC grows more rapidly than BCC and could progress into SCC 
in situ, followed by invasive and finally metastatic SCC. Sun induced SCC has a low rate of 
metastasis compared to other types of SCC (SCC de novo, SCC on oral mucous membranes). 
The skin differs from non-epithelial organ sites in that most cells undergo apoptosis and even 
if the cells have acquired mutations they are eliminated before tumours develop. The stem 
cells of the basal layer replenish the skin with new cells, which will move outward 
svnthesising a succession of different types of keratin. Eventually the nuclei degenerate 
leaving an outer barrier of dead, keratinised cells that are continually shed from the surface. 
The lifespan of epidermal keratinocytes is 2-4 weeks and is in itself a protective mechanism 
against carcinogens (Miller & Maloney, 1998). 
1.1.2.1. Risk factors 
It is known that multiple genetic mutations acquired over long periods of time in 
genes involved in mechanisms essential for the integrity and survival of the cell are the main 
trigger of the carcinogenesis process. Skin cancer as other types of cancer can be induced by 
exogenous and endogenous factors. 
Endogenous mutagenic events are generated by defective repair and replication and 
genetic syndromes predisposing to skin cancer such as xeroderma pigmentosum, nevoid 
BCC and Bazex's syndrome. Xeroderma pimentosum (XP) is an autosomal recessive 
genodermatosis with hypersensitivity to UV and increased propensity to skin cancer. NMSC 
occurs in 57% and melanoma in 22 % of patients with XP. Also a history of cutaneous 
melanoma increases the risk of BCC and SCC. Other predisposing settings for BCC are burn 
scars, chronic ulcers, non healing wounds and for SCC are Actinic keratoses (AK), 
keratoacanthomas and Bowen's disease. 
Common exogenic carcinogens are I) human papilloma viruses associated with skin 
cancer in immuno-compromised hosts, 2) chemical carcinogens: coal and petroleum 
products, dyes, various solvents, arsenic, 3) radiant energy, UV and gamma radiation. 
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The UV radiation spectrum is divided into three wavelength bands: UVA (320-
400nm), IJVB (280-320nm), UVC (200-280nm). Solar radiation consists mainly of UVA 
and UVB, of which UVA induces oxidative DNA damage and has low impact on skin 
cancer. UVB represents a small percentage of solar radiation, but it is the major determinant 
of skin cancer. UVC is filtered out by the ozone layer and moisture in the stratosphere and 
does not reach the earth's surface. UV radiation is a component of the natural sunlight and is 
a major etiologic factor in skin cancer development, because the skin is often exposed to 
sunlight, in some cases extreme exposure causing sunburn. It has been demonstrated that UV 
radiation is the major environmental factor responsible for induction of most SCCs and 
BCCs. At the cellular level, UV radiation causes specific mutations in oncogenes and/or 
tumour suppressor genes and increases cellular proliferation. UV radiation is a complete 
carcinogen because it can cause skin cancer without additional initiators or promoters; it 
contributes to skin cancer development by carcinogenic and immuno-suppressive effects. 
The understanding of mechanisms underlying UV-induced BCC or SCC come from 
experimentation on animal models, as UV radiation can be easily and safely administered, 
the dosimetry can be accurately measured and does not require metabolic activation. At the 
DNA level, UV radiation induces formation of typical photoproducts, which if not repaired 
by the nucleotide excision repair (NER) pathway lead to UV specific mutations. These 
mutations are C->T and CC->TT transitions at dipyrimidine sites and are caused mainly by 
direct action of UVB. UV signature mutations are found in non-melanoma skin tumours. 
indicating UV radiation as a causative factor in their development. Another important aspect 
in skin carcinogenesis is the position of mutations within individual genes. Studies in 
experimentally induced tumours in rodents, cell lines and tumours at various stages of 
development confirmed that the neoplastic status is generated by multiple genetic alterations 
occurring within proto-oncogenes and/or tumour suppressor genes. 
Protooncogenes encode proteins, which act as growth regulators, receptors, 
extranuclear proteins involved in signal transduction, kmases and nuclear transcription 
modulatory factors, involved in cellular processes such as normal cell div son. differentiation 
and apoptosis. Protooncogenes become activated to oncogenes by genetic alterations such as 
point mutations, gene amplification or rearrangements. In skin cancer ras-oncogenes often 
undergo amplification and c-myb is often rearranged. In human skin, activated ras-oncogene 
has been detected in melanoma, sporadic non-melanoma, BCC, SCC, Bowens disease (SCC 
in situ) and benign self-regressing keratoacanthomas (Miller & Maloney, 1998). 
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Tumour suppressor genes act as negative growth regulators and mutations or 
deletions in such genes are found in numerous cancers, as tumours are associated with 
abnormal growth and proliferation rates. 
p53 is a tumour suppressor gene involved in maintaining genome integrity. It is 
highly inducible by UV radiation in a wavelength specific pattern: UVA (320-400nm) 
induces p53 in the basal layer, UVC (200-290nm) induces p53 in the granular layer and 
upper stratum spinosum of the epidermis and UVB (290-320nm) induces p53 diffusely and 
equally intensely throughout the epidermis (Miller & Maloney, 1998). Upon damage of the 
cell, p53 protects against tumour development via the p21 pathway, inducing cell cycle arrest 
and allowing the repair of the damage or via the apoptotic pathway, which is induced by 
tmrepaired DNA damage, In the skin, apoptotic keratinocytes are seen as sunburn cells and 
are induced by excessive sun exposure. Mutations in the p53 gene occur mostly in the region 
encoding the DNA binding domain or the tetramerization domain. Most of the mutations are 
somatic but there is a germline mutation described in cancer-prone Li-Fraumeni syndrome. 
The consequences of the mutations are inactivation of the tumour suppressive properties, 
acquisition of oncogenic properties, or inactivation via protein-protein interactions. Most 
forms of skin cancer have p53 mutations and seven out of nine mutational hotspots in p53 
are skin cancer specific (Ziegler et al., 1993). Specific UV type mutations have been 
detected in 9% of melanoma tumours and 60% of actinic keratoses, BCC and SCCs. p53 
mutations appear to be an early genetic event in non-melanoma skin cancer, whereas in 
melanomas they tend to be a late event, characteristic of tumour progression. Mutated p53 
protein levels can be detected by immunohistochemistry, although immunostaining does not 
always correlate with the presence or absence of mutations. This lack of correlation can be 
attributed to the mutated p53 protein, which is less stable and susceptible to degradation, or 
to the cross-reaction of the antibodies with wild-type p53. 
The lNK4aJp 16 gene is another tumour suppressor gene, which is mutated in 15% of 
primary sporadic melanomas and in some melanoma families. The human patched gene 
(PTC) is another tumour suppressor gene, associated with the inherited form of BCC. This 
gene maps on chromosome 9q22.3 and is involved in the control of cell differentiation and 
proliferation. The mutations detected in sporadic BCC are nonsense mutations, deletions and 
insertions, leading to a truncated FTC protein; the nevoid BCC syndrome has gennline 
mutations of PTC, which are often rearrangements (Bodak et al.. 1999). Because FTC gene 
is not altered in SCC and p53 is mutated in both BCC and SCC, this links FTC expression to 
a keratmocyte population, that will specifically give rise to BCC (Bodak et al., 1999) 
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1.12.2. Role of ageing 
Another aspect of skin carcinogenesis is age and ageing. It has been observed that 
most cutaneous malignancies develop between 30 and 80 years of age and there is an age-
related logarithmic increase in cancer formation (Miller & Maloney, 1998). Ageing skin 
undergoes structural and functional changes. The main structural change seen with ageing is 
the decline in number of different cell types of the skin. Keratinocytes become 
heterogeneous in size, shape and staining properties. Langerhans cells decrease with ageing 
affecting cellular immuno-responses. Also epidermal melanocyte, fibroblast, mast cell and 
macrophage numbers decrease with ageing. The structural integrity of dermal 
microvasculature declines with ageing, undergoing disorganisation, collapse, or total 
disappearance of dermal blood vessels. Functional changes in ageing skin are seen in the 
immune response and in DNA repair rates. Ageing skin shows enhanced immune tolerance 
and less efficient DNA repair in both unexposed and UV-exposed skin, HRC assays on 
cultured fibroblasts and lymphocytes showed that ageing is associated with age-related 
reduction in DNA repair capacity (Wei et al., 1993), (Grossman, 1997). Unrepaired genomic 
mutations accumulate and can lead to preoncogenic or oncogenic transformation. Structural 
and functional deterioration of the skin with age combined with UV-exposure account for the 
increased incidence of skin cancer seen in the elderly population. 
1.1.2.3. Epidemiology of UV radiation 
1.1. 2.3.1. Descriptive epidemiology 
The most common cutaneous malignancies in humans are BCC, SCC and 
melanoma. Out of these three types, melanoma is the most aggressive and accounts for the 
vast majority of skin cancer deaths, followed by SCC and last by BCC. Melanoma incidence 
rate varies 100 fold internationally with the highest rates being reported in Australia, with a 
rate approaching 40 per 100,000 per annum. In Australia melanoma is the third or fourth 
most common cancer. The incidence of cutaneous malignant melanoma in the UK is 
approximately 10 per 100,000 per annum. Case control studies in Europe and UK indicate 
that intermittent sun exposure is a risk factor for melanoma development (Boyle et al., 
1995). (Lear et al., 1998). These studies show that high social class (1 and 2), indoor 
occupation, sunburn and sunbathing are risk factors for melanoma, emphasising the 
importance of intermittent and not cumulative sun exposure in relation to melanoma. The 
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malignancies of the epidermis, although having a high incidence have lower patient fatality, 
because skin is the most ready available organ for visual inspection and any change of its 
structure and appearance can be detected and treated in early stages. 
Skin colour is the major determinant of both incidence and mortality for melanoma. 
SCC and BCC. Melanoma is a neoplastic disease of the white skin, commonly seen on the 
trunk in males and the lower limbs in females. In the US, melanoma incidence among 
Caucasians is 15 times the incidence among African Americans. Native and Hispanic 
Americans living in SW US have lower rates of melanoma in comparison to Caucasians 
living in the same region (Miller & Maloney, 1998). Population studies show that the greater 
the sun exposure the higher the incidence of BCC, especially in individuals with fair skin, 
blue eyes, blond hair, poor tanning ability and male sex, although the incidence rates do not 
rise so rapidly as in SCC. 
1.1.2.3.2. Geographic variation 
The general geographic distribution of melanoma, BCC and SCC are determined by 
the geographic distribution of racial and ethnic groups and by the geographic distribution of 
sun exposure. In the descriptive epidemiology the latitude is the most important determinant 
of the distribution of sun exposure. Accordingly, populations with the same ethnic 
backgrounds have different melanoma incidence rates, such as the incidence rates in the 
population in Australia and the rates in England and Wales, suggesting the association 
between sun exposure and risk of melanoma (Miller & Maloney, 1998). The risk for 
melanoma relates to the latitude in Australia and the US, the white population living near the 
Equator being at higher risk. This correlation is less clear in Europe, where rates in 
Scandinavia and Switzerland are higher than in France and Italy. This observation sustains 
the hypothesis of skin pigmentation and intermittent sun exposure as risk factors in 
melanoma development. Also, the risk for melanoma is increased in northern European 
migrants to Australia or Israel. In both countries, increasing incidence was related to the 
duration of stay and the age of the migrants (Boyle et al., 1995). SCC and BCC show a 
similar correlation between latitude and incidence, with higher rates and early age at 
diagnosis in regions with intense sunlight exposure. 
There is a world-wide increase in melanoma incidence in both sexes. Particular 
countries might show slightly different incidence rates. For example, in Scotland, England 
and Wales a slightly greater incidence of melanoma in women in comparison to men has 
been seen but the values are low compared to those for Australia (Miller & Maloney, 1998), 
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(Boyle et al., 1995). The US cancer registry 1977-1994 entries show a fourfold increase in 
SCC incidence in men and a fifteen fold increased incidence in women (Miller & Weinstock, 
1994). The UK cancer registry 1988-1998 entries for South Wales show a twofold increase 
in BCC and SCC. Men had a comparatively higher number of SCCs on the face and women 
had a much higher incidence of both malignancies on the leg (Holme et aL, 2000). In 
Australia, where the overall skin cancer incidence is the highest, a 51% increase in SCC 
between 1985 and 1990 has been observed (Marks et al., 1993). The overall male to female 
ratio is about 1.5:1 for BCC and about 3:1 for SCC. Females have a greater percentage of 
SCC on lower legs than men, whilst men have greater percentage of SCC on the ears. 
Scottish Melanoma Group published in 1997 a study on incidence, mortality and 
survival on 6288 patients with invasive melanoma (level 2 or deeper) registered between 
1979 and 1994. This study shows increased CMM incidence in men of all ages during the 
study. In 1997 malignant melanoma of the skin was the 12 th most common cancer in males 
and the 8  t most common cancer in females In women under 65 years of age the incidence 
rate appear to have stabilised since 1986. The age of onset of malignant melanoma of the 
skin is earlier than many other cancers. Over the period 1986-1995 it was the third most 
common cancer in the 15-34 age group, in which it accounted for 9.6% of male cancers and 
15.5% of female cancer. Mortality from CMM shows a continuing rise in men and a 
downward trend in women. In men, melanoma free survival was 69% at 5 years and 61% at 
10 years; in women the corresponding rates were 82% and 75%. In comparison to Scotland, 
England and Wales show a lower incidence rate and similar mortality rate of melanoma. This 
is possibly due to a better registration of melanoma in Scotland or is indeed a difference in 
incidence, because a high percentage of the Scottish population is fair skinned and more 
susceptible to melanoma (MacKie et at., 1997). 
1.1.2.3.3. Other epidemiologic factors 
Another important factor in the UV epidemiology is age. The current status is that 
melanoma risk increases with age; it is rare before adolescence then becomes increasingly 
common with advancing age. A similar pattern is seen in BCC and SCC, although the 
steepest increment with age is seen in SCC (Miller & Maloney, 1998). 
The anatomical distribution of melanoma, SCC and BCC has a different pattern. 
SCC and BCC are generally found on sun-exposed skin as 90% of all BCCs and over 50% of 
all SCC occur on the head and neck. BCCs on the trunk are more prevalent than elsewhere 
on the body while SCC are most common on the head and neck and less frequent on hands 
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and forearms (Miller & Maloney, 1998), (Mukhtar, 1995). BCC is much less common than 
SCC on the hands, lips and genitals, but it is more common than SCC on the eyelids. 
Melanomas are much less common on the chronically sun-exposed skin of the face and more 
common on the trunk and legs. Anatomic distribution of BCC and melanoma is attributed to 
intermittent sun exposure, whilst SCC distribution suggests an influence of continuous 
exposure (Mukhtar, 1995). 
1.1.3. Melanoma 
According to the histological criteria, cutaneous malignant melanoma (CMM) is 
classified in the nevus cell tumour category and makes up only 1% of all skin cancer. From 
the clinical point of view melanoma is a nodule, which can vary in colour, be flattened or 
pedunculated. 
1.1.3.1 Histo1ov 
The histological features are usually used in describing melanoma and in 
differentiating between malign and benign forms. Melanoma cells are neoplasticallv 
transformed melanocytes, which can be found in intradermal, dermal or subcutaneous 
location. The intraepidermal component of cutaneous malignant melanoma consists of nests 
of melanocvtes, which vary in size and are distributed irregularly along the basal layer, 
lacking the vertical orientation of their benign counterpart. The majority of melanomas have 
areas where melanocytes are not confined to the basal layer of the epidermis, they are found 
above the basal layer, in the granular zone or stratum comeum. The intraepidermal growth 
tends to vary with the body site and the sun exposure. The superficial spreading melanomas 
(SSM) localised on the trunk and extremities, often present pagetoid involvement of the 
epidermis with extension into the upper epidermis. The pagetoid pattern refers to a chaotic 
scattering of individual cells or small nests through all layers of the epidermis, resembling 
the Paget's disease of the breast. If melanoma develops on severely sun-damaged skin, 
neoplastic melanocytes have little tendency for nesting and upward migration. Instead they 
can proliferate diffusely along the basal layer, confluently replacing basal keratinocytes in 
confluent runs and extending to involve the epithelium of hair follicle and eccrine ducts. The 
dermal component of melanoma consists of large confluent nests of neoplastic cells deep in 
the dermis (Metcalf, 1996). 
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The organisation and density of melanocytes are classified into: 1) pagetoid 
dispersion of single atypical melanocytes and small groups of melanocytes throughout all 
epidermal layers, 2) lentiginous proliferation of atypical melanocytes in the basal layer, 3) 
nested arrangements of cells in the epidermis, 4) infiltrative or aggregative (nodular) patterns 
in the dermis and subcutis (Miller & Maloney, 1998). Melanomas usually show a high 
degree of histological heterogeneity, as any cell type and combination of types may be seen 
in melanomas. This heterogeneity is also seen in the cytological features of melanomas. 
Melanoma cells can be epitheloid with abundant cytoplasm, spindled, or ballooned, 
dendritic, nevus-like, small, clear, Spitz-nevus-like, heavily pigmented or amelanotic, larger 
or smaller than the benign counterparts. The nuclei of melanoma cells tend to be enlarged 
and irregular in size and shape and to contain abnormal melanosomes and melanisation, 
increased numbers of mitochondria with modified internal structure, containing large 
nucleoli (Metcalf, 1996). 
1.1.32. Clinical presentation 
1.1.3.2.1. Clinical subtypes of melanoma 
The standard classification of primary melanoma is based on histological, clinical 
and pathological features. This classification includes melanoma tumours with a radial 
growth phase that precedes vertical growth and these tumours are: Lentigo Maligna 
Melanoma (LMM), Superficial Spreading Melanoma (SSM), Acral Lentiginous Melanoma 
(ALM) as well as nodular melanoma (NM) a melanoma that grows only vertically (Miller & 
Maloney, 1998), (Sagebiel & Metcalf, 1996). SSM and NM are the most common types 
accounting for 85-94% of all cutaneous melanomas. Therefore, these two histogenetic types 
have been intensively studied and represent the basis for most prognosis models. 
SSM comprises 80% of all melanomas (MacKie. 2000). SSM develops from an in 
situ lesion, presents as an asymmetric brown plaque with a notched border. This subtype can 
be present for long periods of time, usually on the back of males and lower leg of females, 
growing and progressing slowly. The main risk factor is intermittent sun exposure, although 
chronic exposure could also be a risk factor. 
NM comprises 7-10% of all melanomas. By definition NM does not have radial 
growth (Miller & Maloney, 1998). It presents as a rapidly growing, symmetrically-shaped, 
dark coloured papule or nodule found in any location on the skin, more frequent in males 
(MacKie, 2000). As it grows NM thins the epidermis and can develop ulceration. 
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LMM comprises 4-7% of all melanomas. Lentigo maligna (LM) is the precursor 
lesion of LMM. LM begins as a flat, pigmented lesion on sun-damaged skin, on the head and 
neck region of older individuals. LM is considered melanoma in situ because the atypical 
melanocytes are confined to the epidermis and anexal epithelium and there is no dermal 
invasion. Some LM lesions can progress into LMM, which represents the onset of the 
vertical growth phase. LMM has a slow growing rate and good survival rate (Miller & 
Maloney, 1998). 
ALM accounts for 1-2% of all melanomas and is relatively rare in Caucasian 
population, more frequent in Asian populations. ALM lesions are found on the palms, soles, 
around the nails and on mucous membranes. It often begins as an irregularly pigmented 
macule. which can develop into a tumour with increased size, asymmetry and colour 
variability reaching ulceration and metastasis stages. 
1.1.3.22. Less Common clinical subtypes of melanoma 
Desmoplastic neurotrophic melanoma (DNM) is an uncommon melanoma variant 
seen in less than 1% of melanoma cases. It presents as a scar-like non-pigmented lesion, seen 
in light skinned persons on the head and neck or upper back. 
Other types of melanoma, each accounting for less than 1% of all melanomas, are 
rare variants such as: mucosal lentiginous melanoma arising in the oral or genital mucosa, 
melanoma arising in giant congenital nevus and melanoma arising in cellular blue nevus 
(Malignant blue nevus) and amelanotic melanomas. 
1.1.3.2.3. Melanoma Variants 
The melanoma variants are: melanoma in situ, amelanotic melanoma and metastatic 
melanoma. Melanoma in situ is a pathologic entity characterised by intraepidermal 
melanocvtic proliferation of at least 2-3mm with melanocytes showing atypia and a chaotic 
growth pattern. The pattern of melanocyte proliferation can be pagetoid, lentiginous, nested 
or combination of them. Amelanotic melanoma is a low incidence tumour, charactensed by 
underproduced pigment. Metastatic melanoma is an important variant as it is crucial to 
distinguish between a primary and a metastatic tumour. A metastatic melanoma is located in 
the reticular dermis and subcutis. The melanocytic pagetoid proliferation pattern is less 
common, usually the dermal component extends laterally beyond the intraepidermal 
component. The cells show a monomorphous appearance. Tumours are small, commonly 
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less than 10 mm, occasionally less than 4nmi often with vascular invasion. Host response is 
often minimal. In contrast, primaries are located in the epidermis. The melanocytic pagetoid 
proliferation pattern is common and prominent and the epidermal component extends beyond 
the dermal component. The cells show a pleomorphous appearance. Tumours are almost 
always bigger than 4 mm, commonly bigger than 10 mm, with rare vascular invasion. Host 
response is frequent. 
1.1.3.2.4. Melanoma Simulants 
Documented simulants of melanoma are dysplastic nevus, spindle and epitheloid cell 
(Spitz) nevi, cellular blue nevus and spindle-cell tumours. All these simulants can be 
confused with melanoma and conversely many melanomas can be misdiagnosed as Spitz 
nevi, for example. Therefore, to differentiate between the simulants and melanomas 
histomorphologic analysis on size, symmetry, maturation, zonation and cytology of the 
lesion should be used, as well as clinical information, age, clinical appearance and anatomic 
location. 
1.1.3.3. Prognosis 
In terms of prognosis, LM has the best prognosis, followed by SSM, NM and the 
worst outcome is for ALM. Prognosis is based mainly on the histology type, but also lesion 
location, spreading into regional lymph nodes, age, gender, race and skin colour are 
considered. 
Melanomas on the thorax, upper arm, neck and scalp have a poor prognosis in 
comparison to melanomas on lower arm, leg and thigh. Sub-ungual and plantar melanomas 
have particularly poor prognosis and so have melanomas in unusual sites such as the vulva, 
gastrointestinal tract, cervix and nasopharynx. 
The patients with melanoma localised on the skin have better prognosis than in cases 
where the disease spreads to the regional lymph nodes. The number of affected nodes 
appears to be decisive for survival, as the more nodes are affected the less the percentage of 
patients to have a 10 year survival. CMM, which is beyond the confines of regional lymph 
nodes remains incurable. These patients have an extremely poor prognosis, with a shorter 
survival. CMM can metastasise in viscera, bone, lung, central nervous system and liver and 
the prognosis depreciates dramatically from viscera to liver (Garrison et al., 1996). Tumour 
thickness can be an indicator of the presence of clinically occult lymph node metastases. 
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Thicker melanomas are more likely associated with lymph node and distant metastases at the 
time of presentation (Garrison et al., 1996). 
Tumour thickness is the most important prognostic feature of CMM. It is measured 
by the method of Breslow with a calibrated ocular micrometer, from the surface of granular 
zone of epidermis to the deepest point of invasion (Metcalf, 1996). Repeated studies found 
an inverse relationship between survival and tumour thickness of the primary melanoma. 
Patients with tumours thinner than 0.5mm very rarely have further problems with local or 
distal recurrence (MacKie, 2000). 
Age and sex are prognostic factors, which are to be used in conjunction with others, 
such as tumour thickness. Studies show that younger patients have a better prognosis than 
older ones and so have women in comparison to men. 
The number of primary or recurring melanomas is another prognostic factor 
indicating an increased risk for developing further melanomas. Multiple primary melanomas 
are present in 5% of cases and are commonly found in melanoma families. Familial 
melanoma syndrome account for 8-12% of the total CMM cases and it is characterised by 
younger age of onset of the disease, dysplastic nevi, increased likelihood of primary 
melanomas and additional neoplasms, such as pancreatic carcinomas. 
1.1.3.4. Risk factors 
The risk factors involved in melanoma development are environmental and 
constitutional. In comparison with non-melanoma skin cancer, melanoma is well 
documented in cancer registries in many countries. Current statistics show increasing rates of 
incidence and mortality. 
The most important constitutional factors are ethnic origin, pigmentation 
characteristics and sensitivity to sunlight. Melanoma is essentially a cancer of the white skin. 
It is rarely seen in blacks or Asians. Among white skinned people there are differences in 
melanoma risk. Individuals from Southern Europe show decreased risk in comparison to 
those of Celtic and Scandinavian origin, suggesting that the skin colour or tone is the 
determining factor for melanoma risk (Miller & Maloney, 1998). Also increased melanoma 
risk is seen in fair individuals and red hair, in particular appears to be associated with high 
risk of melanoma. Tendency to bum rather than to tan is a well recognised independent risk 
factor for melanoma. All these host factors are related to the major environmental risk factor, 
which is sun exposure or UV radiation. Also suntan and sunburn history, actinic skin 
damage, freckling and acquired nevi in conjunction with IJV radiation are associated with 
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melanoma risk. A positive association has been seen between sunburn and melanoma 
(MacKie & Aitchison. 1982), (Elwood et al., 1990). Freckling, either in adulthood or in 
childhood and acquired nevi are independent determinants of melanoma risk, which is even 
higher if these two factors are present together. The number of acquired nevi on the skin is 
regarded as a precursor of cutaneous malignant melanomas and remains the best predictor of 
sporadic cutaneous melanoma risk (Seykora & Elder. 1996), (Miller & Maloney, 1998). 
Acquired nevi are susceptible melanocytes, which have undergone transformation and 
proliferation into nevi and this process directly depends on the sun exposure. In hot climate 
such as Australia, nevi reach their maximum density at an early age in children when 
compared to temperate or low sunlight areas. It has been observed that high nevus 
prevalence in children with fair-complected phenotype, sun sensitivity and history of 
sunburn are all risk factors for melanoma in adults. 
The single most important environmental risk factor for melanoma development is 
solar UV radiation, accounting for 80% of melanomas in North America and 90% in 
Australia (Armstrong & Kncker, 1993). Research all round the world shows that intense 
episodic exposure in childhood and in adults who are at risk is associated with increased 
melanoma risk. Sunburn is an indicator of acute and episodic sun exposure and case-control 
studies associate it with melanoma risk (Marks, 2000), (Miller & Maloney, 1998). 
Epidemiological studies of other factors such as, diet, smoking, hair dyes, 
fluorescent lighting, hormone therapy, stress and use of sunscreens are not clearly associated 
with risk of melanoma. A recent evaluation of the efficacy of sunscreens in skin cancer 
prevention shows inconclusive evidence on protection against melanoma and BCC. Limited 
evidence has been observed in protection against SCC and this has been shown in two 
randomised trials where sunscreens had a protective effect against actinic keratoses, the 
precursor lesions of SCC. The study concludes that because sunscreens protect from 
sunburn, the intentional sun exposure can be longer and the actual risk for skin cancer is 
higher (Vainio et al.. 2000). 
1.1.3.4.1. Precursor melanocvtic lesions 
A distinct and important risk factor is represented by the precursor melanocvtic 
lesions. Potential precursors and risk markers of melanoma are considered to be melanoc tic 
nevi. These nevi are benign formations of the skin composed of nests of nevomelanocytes. 
Although most nevi are and remain benign formations, in some cases nevi may progress to 
melanoma. Progression to malignant state is a four-stage process, in which nevi become 
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dysplastic and primary melanomas are formed. Primaries will first grow radially then 
vertically and finally will transform into metastatic melanomas. This stepwise tumour 
progression is commonly seen in the majority of melanoma. As it is known that melanoma 
risk is determined by genetic predisposition, environmental exposures and size of population 
of cells at risk, all these are reflected by nevi. They are a population of nevomelanocytes at 
risk, as it has been seen that melanoma can develop from a nevus or nevus cells contiguous 
with a melanoma. Genetic predisposition is seen in the nevus phenotype associated with 
increased risk in melanoma families. Increased number of nevi is a risk factor for melanoma 
and solar exposure increases both nevus counts and melanoma risk. The most prevalent 
classes of nevi are congenital nevi, acquired nevi and dvsplastic nevi. 
Congenital nevi are present at birth or become clinically visible within the first 
months of life (Miller & Maloney, 1998). Clinically they are skin lesions extremely 
heterogeneous in terms of colour, size, texture and shape and are thought to represent 
developmental anomalies rather than environmentally induced or hereditary lesions. Large 
congenital nevi are often seen to be the site of melanoma development, suggesting that 
malignant transformation took place within the nevus. Small congenital nevi can be less than 
5mm, with subsequent growth at a rate that parallels the anatomic site-specific growth, i.e. a 
nevus on the leg will grow bigger than one on the scalp. Small congenital nevi are associated 
with melanoma risk rather weakly, but clinically significant in adulthood and minimal in 
childhood. The main obstacle in relating melanoma and small congenital nevi is the fact that 
they are often confused with acquired nevi and because melanomas occur predominantly in 
adulthood it is difficult to differentiate at that stage between acquired and congenital nevi. 
Acquired nevi appear in early childhood and increase in number, mainly due to sun 
exposure, in the second decade of life. Distribution of acquired nevi and melanoma are in 
direct correlation as far as the anatomic distribution and sun exposure are concerned. Like 
melanoma nevi occur on trunk and proximal extremities and nevus count is associated with 
intermittent sun exposure especially in childhood. The difference is that melanoma has a 
longer incubation time when compared to nevi. The most prevalent categories of acquired 
nevi are common acquired nevi and dysplastic nevi (Miller & Maloney, 1998). Common 
acquired nevi (CAN) are the most common, less than 5mm in size, round with well defined 
borders. Histologically CAN originate in the basal layer of the epidermis. They may evolve 
from a junctional nevus (a lesion confined to the epidermis at the dermal-epidermal junction) 
to a compound nevus (a lesion with dermal and epidermal components) to a dermal nevus 
(an intradermal lesion lacking the epidermal component). This process is called maturation 
or senescence (Miller & Maloney, 1998). Progression to melanoma is rare in any acquired 
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nevi and even rarer in mature dermal nevi. The number of CAN is associated with melanoma 
risk. Dysplastic nevi (DN) are larger than CAN, display irregular, indistinct borders, present 
cytologic atypia and induce a host response that include characteristic patterns of fibrosis and 
a patchy infiltrate (Miller & Maloney, 1998). DN are seen in the general population and in 
the dvsplastic nevus/familial melanoma syndrome. In the general population, 2-18% has DN. 
One case control study in Scotland and a few others in USA, Germany and Sweden showed 
elevated melanoma risk in patients with DN (Miller & Maloney, 1998), (MacKie et al., 
1989). DN/familial melanoma syndrome is seen in individuals with family history of 
melanoma and large numbers of DNs. In these families 50% are affected by the DN trait, 
which appears to be inherited in an autosomal dominant fashion (Miller & Maloney, 1998). 
Melanoma risk in DN individuals with relatives diagnosed with melanoma is extremely high 
and also in DN affected individuals with personal melanoma history (Bataille. 2000; Seykora 
& Elder. 1996). 
1.1.3.4.2. Patients at risk 
Patients at risk are an important category for follow-up evaluation. Amongst this 
category of patients are patients with precursor lesions such as: congenital melanocvtic nevi, 
acquired nevi and atypical (dysplastic nevi), family and past history of melanoma and 
excessive sun exposure. Congenital melanocytic nevi are seen in approximately 1% of births 
and can be of various sizes, ranging from small, less than 1.5cm to giant, more than 9cm. 
I-listologicallv, nevus cells extend into reticular dermal collagen and are found in close 
association with pilosebaceous units (Miller and Maloney. 1998). A common estimate is that 
a small percentage, less than 10% of giant nevi progress into a malignant state and an even 
lesser percentage is observed in small or intermediate sized nevi. A large number, up to 100, 
of either acquired nevi or dysplastic nevi represents a risk for melanoma development and 
these individuals should attend regular follow-up. At increased risk of developing 
melanomas are patients with family and past history of melanoma and excessive sun 
exposure. These patients should be periodically assessed for large and atypical number of 
nevi, as well as for other potential precursor lesions in melanoma development. 
1.1.3.5. Pathogenesis of melanoma 
The vast majority of melanomas arise from transformed epidermal melanocytes or 
nevic cells. Neoplastic transformation occurs under the combined action of environmental 
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risk factors and individual's genotype, phenotype and degree of immunocompetence. There 
are four stages histopathologically and clinically recognised in melanoma development and 
progression. These are 1) development of dysplastic or atypical nevi, 2) unregulated 
proliferation of melanocytes within the dermis in melanoma in situ, 3) acquired competence 
to invade and proliferate within the dermis in primary invasive melanoma and 4) 
development of metastatic capacity (Miller and Maloney, 1998). This stage-wise model tries 
to correlate clinical appearance with molecular alterations. At the molecular level, 
melanocvtes or nevomelanocytes accumulate genetic damage and instability due to 
combined action of exogenous and endogenous damaging factors. In the next stage, 
melanocvtes or nevomelanocytes acquire transformation and deregulated proliferation 
potential, to progress into the malignant stage characterised by invasiveness and metastatic 
capacity. It is worth mentioning that melanomas have a long latency period, reflecting 
temporal accumulation of specific genetic defects correlated with exposure to environmental 
damaging factors. Cases where tumour regression has been seen reflect that the 
immunoresponsiveness of the host is a factor involved in melanoma development. 
The first event in melanocyte transformation is alteration of specific genes, tumour 
suppressor genes and/or oncogenes, which can occur due to endogenous or exogenous 
damaging factors. In the non-malignant cell these genes contribute to regulation of cellular 
process, such as replication, repair, mitosis and cell cycle control. Normal epidermal 
melanocvtes rarely divide in adult skin. Therefore if the melanocyte genome acquires DNA 
damage this has little impact in terms of further tumoungenesis. In contrast, if the DNA 
damaged melanocyte cell is induced to divide, then depending on the nature of the damage 
and other additional factors, the cell can undergo malignant transformation. UV radiation is a 
DNA damaging agent and an inducer of melanocyte proliferation. In a normal cell, after UV 
induced DNA damage, the cell cycle is stopped and repair systems are activated. Once the 
damage is repaired, the cell cycle resumes. If the damage cannot be repaired the cell can 
undergo apoptosis. However, damage can be repaired but not completely and this results in 
melanocytes with a genetic lesion. If these melanocytes acquire proliferation potential, then 
transformation is highly likely to occur, as more proliferation implies accumulation of more 
genetic defects. Deregulated proliferation is commonly seen in atypical nevi and in 
melanoma in situ and is attributable to defects in genes involved in GO, GI and S phase 
transitions. This type of defect leads to shortening of GI and inappropriate entry into S, 
predisposing to propagation of genetic damage and tumour growth. Development of the 
invasive potential of melanoma cells is acquired spontaneously during the progression stage 
of the tumour. This leads to invasion into the underlying dermal layer, which is the first step 
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towards metastasis. Physical invasion of melanomas depends on disregulation of surrounding 
tissue interactions and architecture. This is achieved by disruption of the extracellular matrix 
of the dermis via direct production of matrix metalloproteinases, senne proteases, lysosomal 
proteases and indirectly by producing mediators that stimulate the production of the same 
enzymes in surrounding fibroblasts. Biochemical invasion of melanoma cells is based on 
their ability to abrogate or attenuategrowth and motility inhibitors. The mechanism by 
which invasive melanoma acquires resistance to interleukins, tumour necrosis factor or TGF-
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in their signal transducing pathway. The fourth phase in molecular progression of melanoma 
is development of metastatic and migratory potential. Metastatic melanoma cells are capable 
of invading, surviving and proliferating in tissues and organs distant from the site of origin. 
They are capalle of migration, inhibit immune systems, develop new vascularisation, escape 
into the bloodstream and re-emerge into a new organ. The integrins, lectins and collagenase 
IV activity expressed by melanoma cells play a role in melanoma metastases. 
1.1.3.6. Genetics 
Genetic studies show that disruptions in genes located on chromosomes 1. 6, 7. 9, 
11, 10 and possibly 22 and Y could contribute to the malignant transformation of the 
melanocvtes 
1.1.3.6.1. INK4 genes 
On chromosome 9. the 9p21-22 region is found to be associated with cutaneous 
melanoma. Losses or rearrangements are seen at the 9p locus in atypical nevi, primary and 
familial melanoma (Miller and Maloney, 1998). Several tumour suppressor genes map in this 
region and these are INK4aJp16, [NK4a/p14ARF, lNK4bIp15. ThK4c/p18 and INK4d!p19. 
The rNK4aJp16 gene, known as cyclin-dependent kinase inhibitor 2A (CDKN2A) or 
multiple tumour suppressor 1 (MTS 1) is located on chromosome 9p21 and is composed of 3 
exons. It codes for the cyclin dependent kinase inhibitor, p16 protein a regulator of cell cycle 
progression localised in the nucleus. p16 protein binds cyclin-dependent kinases 4 and 6 
(CDK4and CDK6) which are involved in cell cycle regulation. CDK4 complex formation 
with D-type cyclins is required for Gl/S transition. The CDK4/cyclinD complex 
phosphorylates Rb protein, which results in release of E2F transcription factors. p1 6/CDK4 
complex inhibits formation of CDK4/cyclinD complex, therefore blocks Rb phosphorylation 
FTIJ 
and GuS transition. p16 acts a tumour suppressor, by inhibiting the phosphorylation of Rb. 
It is involved in cellular senescence, because a higher frequency of genetic alterations is 
observed in tumour cell lines compared to primary tumours and of p16 protein accumulation 
in ageing cultured cells. lNK4aJpl6 is the first gene to be linked with CMM. Germline 
mutations in the coding sequence are found in —30% of CMM families world-wide and are 
related to pathogenesis of familial melanoma. 25% of these mutations are frameshift or 
nonsense mutations in exon 2, resulting in a truncated, non-functional protein. Other 
mutations are missense or inflame deletions and insertions, considered, but not tested, to be 
non-functional (Castellano et al., 1999). 
UK studies show that, although there is a strong linkage between the INK49ene and 
melanoma, mutations in this gene have not been found in all melanoma families studied. For 
instance, in one study on 27 families. 12 had three or more cases and in those only S had 
germline mutations in INK4 gene. Of the 15 families, with either two or one case with 
multiple primaries, only one had a germline mutation in INK4 gene (Newton Bishop et al., 
1998). The same group shows germline deletion of INK4a exonl, the pI4ARF coding exon 
but an intact lNK4a gene in one UK family with melanoma and neural system tumours 
(melanoma-astrocytoma syndrome) (Randerson-Moor et al., 2001). Another study on 
melanoma families, recruited between 1989-1999 from England and Wales confirms the 
results from (Newton Bishop et al., 1998) and reports no CDK4 mutations and three new UK 
families with INK4a mutations. Arg24Pro, Met53Ile and a novel Gly67Arg (Newton Bishop 
et al., 1999). A study in Scotland reports INK4a gene mutations in 6 of 16 melanoma 
families (recruitment based on Scottish melanoma group records for West Scotland) and 2 of 
17 patients with primary melanomas. The identified mutations are Arg24Pro, a stop codon at 
codon 44 and Met531le (MacKie etal.. 1998). 
A recent study on Canadian melanoma families and individuals with primaries 
showed a mutation in the 5' UTR of INK4AJp 16 gene, which creates an aberrant initiation 
codon and predicts a truncated protein of 4kD with no homology to the wt p16. The G (-34)-
>1 mutation segregates with melanoma in families and it is not seen in controls. It is thought 
to predispose to melanoma, either by directly affecting protein expression or because it is in 
linkage disequilibrium with another mutation within the same gene or another gene located 
nearby (Liu et al., 1999). 
Sporadic melanoma also has INK4aJp 16 mutations of the UV signature type and p16 
protein is absent in —50% of primary melanomas (Castellano et al., 1999 Halach.mi & 
Gilchrest, 2001). However, a large proportion of 70% of CMM families shows wild-type 
INK4a/p 16 gene, suggesting the existence of multiple genes in melanoma predisposition. 
Other candidates will be INK4aJp 1 4ARF, INK4b/p 16 but no germline mutations in either of 
these two genes have been found in melanoma prone families with wild-type INK4aJpl6 
(Castellano et al., 1999). 
INK4aJp 16 can use two alternative first exons El a and El f3, located upstream of 
exon 2. Consequently two transcripts can be obtained encoding two different protein 
products. The a transcript encodes p16 and the J3 transcript is translated into a different 
reading frame to a protein with unrelated amino acid sequence, named pI4ARF (Soufir et 
al., 2000). p14ARF has an inhibitory role in GI and G2 but does not bind CDKs (Castellano 
et al., 1999). Being transcriptionally regulated by E2FI, p14ARF provides a link between 
p53 and RB pathways. It has been shown that pI4ARF inhibits p53 degradation by binding 
MDM-2, thereby inducing p53-dependent cell cycle arrest or apoptosis depending on the 
stimulus (Soufir et al., 2000). The relationship between INK4aJp14ARF and melanoma is 
not well determined. It is known that most mutation occurs in exon 2, which is shared by p 16 
and pI4ARF. It has been observed that melanoma cell lines with large deletions in exon 1 
lack p16 and p1 4ARF (Castellano et al., 1999). Although the general trend is that there are 
no mutations affecting pI4ARF and not p16 in melanoma, a UK study detected germline 
deletion of INK4a exonl, the pI4ARF coding exon but intact INK4a gene in a family with 
melanoma and neural system tumours (melanoma-astrocytoma syndrome) (Randerson-Moor 
etal., 2001). 
The INK4b/p 15 gene, known as cyclin-dependent kinase inhibitor 2B (CDKN2B) or 
multiple tumour suppressor 2 (MTS2) maps 20kb centromeric to [NK4aJpl6 gene on 
chromosome 9p22. It encodes the p15 protein, a protein highly homologous to p16, with 
similar roles in the cell cycle: it binds CDK4 and CDK6 and mediates transforming growth 
factor-n (TGF-) induced cell cycle arrest (Castellano et al.. 1999). Similar to the 
INK4aJp 1 4ARF gene, both INK4b/p 15 and lNK4aJp 16 genes are mutated in melanoma cell 
lines and very few cases of sporadic melanoma show [NK4b/p15 gene mutations. This 
suggests that INK4aJp16 plays the important causative role in CMM development. 
1.1.3.62. Additional candidate genes 
CDK4 is a candidate gene functionally linked to [NK4aJp16 and INK4b/p15. It maps 
on chromosome 12q14 and encodes a cyclin-dependent kinase, which is the target of p16 
protein. A very low frequency of CDK4 mutations has been reported in sporadic and familial 
melanomas (Castellano et al., 1999). Three melanoma families with germline CDK4 
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mutations have been reported world-wide (Newton Bishop et al., 1999). Mutated CDK4 will 
not bind p16. therefore Rb phosphorylation leads the cell through G  to S. 
Rb and p53 are expected candidates in CMM development. Germline and somatic 
mutations in the Rb gene are seen at a very low frequency and a similar situation is seen for 
the p53 gene (Castellano etal., 1999; Halachmi & Gilchrest, 2001; Halaban, 1996). Studies 
on p53 mutations suggest that p53 has a heterogeneous status in melanoma and non-
melanoma skin cancer, as often the immunocvtochemistrv data do not correlate with the 
sequencing data. Mutation positive samples could appear negative on immunocytochemistr 
and vice versa, samples positive on immunocytochemistry could have no detectable 
mutations. 
Chromosome Ip has been linked with familial melanoma, particularly the critical 
region Ip36 which is linked with DN/familial CMM syndrome. In melanoma rearrangements 
of chromosome ip have been detected. Although no gene that is mutated in DN/CMM and 
mapped at this locus has been identified, a candidate locus PITSLRE has been mapped to 
lp36. This locus consists of 3 tandemly duplicated genes that encode related p58 kinases 
with roles in the cell cycle. Studies at this locus on melanoma cell lines have indicated a 
potential mutated or deleted PITSLRE during melanoma progression (Miller and Malone'. 
1998) 
Chromosome 6 is the second most often rearranged chromosome with losses and 
gains on the p and q arms in melanoma. A putative and disputable susceptibility melanoma 
gene has been attributed to region 6p within the HLA region. Studies on WAF/p2 1, a general 
CDK inhibitor that maps on 6p and a potential candidate, have proven negative. Cytogenetic 
alterations and loss of heterozygositv (LOH) of the 6q region have been reported in sporadic 
melanomas, indicating 6q as another candidate region (Castellano et al., 1999). 
Cvtogenetic analysis of chromosome 7 frequently shows duplications and 
multiplications, especially in the late stages of melanoma. An association between 
chromosome 7 and melanoma has been advanced based on the increased copies of this 
chromosome and overexpression of the EGF gene, mapped on 7pl 2-13. The presence of 
extra copies of 7q and absence of 7p in some melanomas may point to the localisation of a 
tumour suppressor gene on the 7q arm. 
Chromosome 10 band q23-26 is often rearranged in atypical nevi and early 
melanoma lesions (Miller and Maloney, 1998). A candidate tumour suppressor gene, 
phosphatase and tensin homologue/mutated in multiple advanced cancer, PTEN/MMAC 1 
maps on 10q23. PTEN/MMACI is a lipid/protein phosphatase, which regulates GI 
progression by blocking the phosphatidylinositol-3-kinase (P13-K) pathway. It is a 
23 
competitor of the ras gene and an upstream regulator of P13-K, frequently activated in 
tumours. PTEN/MMAC1 mutations have been identified in several tumours; somatic 
mutations are detected in 40% of melanoma cell lines and in 26-44% of primary melanoma; 
germline mutations have been detected in Cowden's disease and congenital hamartomas 
(Halachmi & Gilchrest, 2001). 
Chromosome II seems to be involved in sporadic melanoma. LOH studies show 
allelic loss at I 1q22-23 in 30% of sporadic melanomas (Castellano et al., 1999). A tumour 
suppressor gene PPP2R1B, mapped in this region, shows alterations in primary lung and 
colon cancer but no data are available for melanoma (Castellano et al., 1999). 
Analysis of ras genes in melanoma did not show the same high levels of LTV-
induced activated ras genes seen in non-melanoma skin cancer. 50% of congenital nevi and a 
small percentage of melanomas carry N-ras codon 61 activating point mutations, which 
appear to correlate with the vertical growth phase of melanoma (Castellano et al., 1999). 
C-mvc is a nuclear phosphoprotein encoded by the c-,nyc gene. An increased copy 
number of this gene has been seen in nodular melanomas. This overexpression correlates 
with tumour thickness and outcome of disease. Because myc-responsive genes are involved 
in cellular proliferation, differentiation and apoptosis it is still unclear which of these 
pathways are altered in the oncogenic phenotype (Halachmi & Gilchrest, 2001). 
Melanocortin 1 receptor (MC1R) is the receptor for the melanocyte-stimulating 
hormone,  which regulates the proportion between the two types of melanin in 
human melanocytes. MCIR was first detected in melanoma cell lines and melanoma 
tumours. The expression levels of MC1R in normal melanocytes appear to be 10-20 fold 
lower than in malignant melanocvtes (Wikberg et al.. 2000). The MC1R gene exists as 
several different alleles and combinations of these determine skin type and hair colour. A 
specific variant. Asp48Glu is strongly associated with sporadic melanoma development, 
although given the high number of variants and their phenotypes, the reproducibility of risk 
studies is not good (Valverde et al., 1996), (Ichii-Jones et al., 1998). It is still unclear 
whether the correlation between CMM and MCI R variants is direct or is a result of the fair-
complexioned phenotype, which is in itself a risk  factor for CMM (Castellano et al.. 1999). 
A large study in the Australian population shows evidence for association between MCI R 
variants. Argl5ICys, Argl60Trp, Asp294His, red hair and melanoma. This study also 
suggests that this association is independent of skin type (Palmer et al., 2000). A Danish 
study reported that the same MCIR variants, red hair and fair skin are independent risk 
factors for NMSC (Bastiaens et al., 2001). 
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Other genetic defects are believed to be associated with melanoma, as melanoma 
families often develop secondary cancer such as breast, throat, pancreas, Non-Hodgkin 
lvmphoma and also melanoma is a common primary after retinoblastoma (Bataille, 2000). 
1.2.1. DNA damage 
Numerous exogenous factors, such as chemical agents or various types of radiation 
and endogenous factors can induce  a wide variety of lesions at the DNA level. The damages 
range from point mutations to extensive modifications, such as frame shift mutations or gene 
rearrangements. As a result many cellular processes such as transcription and replication are 
altered resulting in cell-cycle arrest, apoptosis and genomic instability. Further consequences 
of these alterations are seen in genetically inherited diseases. neoplastic transformation and 
ageing (de Boer & Hoeijmakers, 2000). To restore the normal DNA base sequence and 
structure and to prevent the consequences of the damaged DNA, living organisms have 
evolved and specific DNA repair mechanisms developed, which are not completely error-
free, they possess an inherently low rate of error themselves. 
DNA damaging factors can be spontaneous, endogenous and exogenous. 
Spontaneous damage arises from mispairing of bases during replicative synthesis or less 
frequently from the natural chemical instability of the DNA molecule (Miller and Maloney. 
1998). Potentially damaging endogenous factors are reactive oxygen species, which can also 
result through normal cell respiration and after ionising radiation exposure. Exogenic factors 
include chemicals, such as alkylating agents, polvcyclic aromatic hydrocarbons, aromatic 
amines, afiatoxins, UV and ionising radiation, cross-linkers, such as mitomycin, nitrogen 
mustard, photoactivated psoralens. 
The most important and naturally occurring exogenous factor is UV radiation, which 
is the carcinogenic factor in skin cancer. The UV spectrum has three components, UVA, 
UVB. UVC (table 1). 
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Table 1. Natural UV spectrum and correlation with non-melanoma skin cancer from (van 
Steeg & Kraemer, 1999) 
UV-band Wavelength Relative occurrence Induced DNA lesions Skin cancer 
UV-A 31 5-400nm -.95% primarily oxidative Low,<25% 
UV-B 289-31 5nm 5% 25% 6-4PPs, 75% CPD High,>75% 
UV-C 100-289nm not detectable 25% 64PPs, 75% CPD none 
UVB, the mid-wave radiation is absorbed directly by DNA and results in 
photolesions, mainly pyrimidine dimers and pyrimidine-pyrimidone 6-4 photoproducts but 
also cytosine photohydrates and purine photoproducts. The most frequent are cyclobutane 
pyrimidine dimers (CPDs) (fig. 1). The T-T CPDs are formed most readily, followed by T-C 
or C-T, whilst C-C dimers are least abundant. One can obtain an idea of the extent of 
distortion of DNA chain structure caused by CPDs by noting that, in the diagram of a T-T 
CPD below, the cyclobutane ring, shaded in light blue, should have sides of approximately 
equal length. Thus the two adjacent pyriniidines must be pulled closer to each other than in 
the normal DNA structure. 
Fig. 1. Structure of the UV-induced CPD 
In the diagram below of the T-C 64PP, notice that the amino group, originally from 
the 4 position of the cytosine, ends up at the 5 position of the thymine. Although it is not 
PTO 
evident from this crude diagram, the structural distortion generated by 64PPs (a DNA bend 
of 44 degrees) is significantly greater than that produced by CPDs (bend of 7-9 degrees). 
U 
Fig.2. Structure of the UV-induced 64PP. 
CPDs and 64PPs are repaired by the nucleotide excision repair pathway. 
Another consequence of UV radiation is alteration of gene expression, which can be 
either amplification, as is the case of the ras and fibs cellular oncogenes, or inactivation of 
tumour suppressor genes, as is the case of the p53 gene. p53 loss of function mutations are a 
common event in NMSC and melanoma skin cancer. UV exposure also induces epigenetic 
modifications of cells, which are generation of reactive oxygen intermediates and depletion 
of endogenous antioxidants. The impaired immunological functions following UV exposure 
are attributable to reduced number and function of the epidermal Langerhans cells. 
The cellular response to DNA damage is divided into 3 categories: 1) Reversal of 
DNA damage, 2) Excision of DNA damage and 3) Tolerance of DNA damage. The simplest 
of the three is reversal of the DNA damage. It is found in prokaiyotes and lower eukaryotes 
and is highly specific and error free. Excision of DNA damage is well defined in prokaryotes 
and eukaryotes and is specific and error-free. It has 3 component mechanisms Base-, 
Nucleotide- and Mismatch excision repair. Tolerance of DNA damage is found in 
prokaryotes and eukaryotes and is highly mutagenic. It is achieved via replicative bypass of 
template damage (with gap formation and recombination) or via translesion DNA synthesis. 
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I.2.2.DNA repair- Nucleotide Excision Repair 
Nucleotide excision repair is a versatile and heterogeneous cellular repair process, 
which removes DNA damages of different structures, induced by environmental factors. 
NER removed lesions are primarily UV-induced photoproducts, cyclobutane pyrimidine 
dimers (CPDs) and pyrimidine (6-4) pvrmidone photoproducts (64PPs). which are 
mutagenic and tumourigenic. CPDs are equally induced in both nucleosome core and linker 
DNA, whilst 64PPs induction is six-fold greater in linker than in nucleosome DNA in UV 
irradiated human chromatin. 75% of the photoproducts are CPDs and the remainder is 6-
4PPs. which although less abundant, are repaired 5-fold faster because of the greater 
distortion of the double helix they induce. 
Two overlapping pathways have been identified in the NER process: rapid 
transcription-coupled repair (TCR) of expressed genes directed to the transcribed strand and 
slower global genome repair (GGR) of the lesions over the entire genome. Both pathways 
are essentially the same, the difference resides in the proteins which recognise the damage. 
XPC/HHR23B recognises the damage in GGR, while TCR uses the stalled RNA polymerase 
II complex as a damage recognition signal. It is believed that CSA and CSB proteins are 
involved in processing the stalled RNA polvmerase II complex (de Boer & Hoeijmakers, 
2000). This hypothesis is based on the interaction seen in vivo between CSB and RNA 
polvmerase II and on the fact that mutations in CSA or CSB genes lead to defective TCR and 
the Cockayne Syndrome phenotype. Repair of 64PPs is believed to be via TCR, although 
this is not fully resolved, as some experiments indicate GGR as being the pathway to remove 
them. XP-C cells, proficient in TCR only, repair 64PPs, but threefold slower, compared to 
normal cells (van Hoffen et al., 1995). In assessing the repair pathway for 6-4PPs a technical 
difficulty intervenes, i.e. high doses of UV (30-40 JIm2) are required to generate enough 6-
4PPs for detection. This high UV dose induces GGR, which overrides TCR and explains the 
efficient repair of the 64PPs. (Balajee & Bohr, 2000). 64PPs removal rate is a marker of 
UV hypersensitivity of human and rodent cell lines. CPDs require less UV irradiation (10-20 
Jim2) to be produced and appear to be repaired by both pathways. In addition to CPDs and 
bulkv chemical DNA adducts some oxidative base damage is removed by TCR (Cooper et 
al.. 1997). TCR is a general and biologically important repair mechanism and it is observed 
in bacteria, yeast, fish and mammals. TCR has been demonstrated only for RNA polymerase 
H transcribed genes in mammalian cells. Experiments with a-amanitin, an inhibitor of RNA 
polymerase II eliminates TCR (Christians & Hanawalt, 1992). The repair patch lengths are 
similar for TCR and for repair in non-transcribed DNA, consistent with a common 
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mechanism for the steps that follow recognition and verification of the lesion (Bowman et 
al., 1997). Two important aspects in ICR pathway are TFIIH and stalled RNA polvmerase 
II. TFIIH participates in NER, via its helicase components and in transcription initiation of 
RNA polymerase II transcribed genes with role in promoter clearance. This multi-protien 
complex exists in different forms and configurations within the cell, which have not yet been 
fully characterised (Balajee & Bohr, 2000). Another important aspect of TCR is stalled RNA 
pol II. It is not yet resolved whether or not the stalled RNA polymerase II is dissociated 
during TCR. Several hypotheses have been advanced. One model predicts that RNA 
polymerase II backs up few nucleotides to allow the repair machinery to enter the lesion 
(Hanawalt et al., 1994), whilst other suggests that RNA polymerase 11 is aborted and 
transcription resumed after repair (Bregman, 1996). Another aspect of the stalled RNA 
polymerase II raised by Hanawalt, (2001) is whether or not stalling RNA polymerase II is 
sufficient to recruit the DNA repair machinery or there is a way of distinguishing between a 
natural, sequence-dependent pause site and a true lesion. If the former is true, then the 
"gratuitous TCR" repair might occur at a pause, lesion-free DNA site (I-lanawalt, 1994). This 
remains to be determined and if so, "whether cells might use such a process to intentionally 
generate high levels of mutations in specific genomic regions" (Hanawalt, 2001). An 
important factor in NER regulation and efficiency is p53. GGR of CPDs is more dependent 
on p53 activity than is GGR of 6-4PPs, repair of which is nearly independent of p53 
expression (Hanawalt, 2001). Cell survival is dependent on both NER pathways and p53. A 
stalled RNA polymerase might constitute a signal for p53-dependent apoptosis thus, cells 
TCR-deficient are more sensitive in UV-induced apoptosis that cells TCR-proficient 
(Ljungman & Zhang, 1996). This is the case of CS cells, deficient in TCR but proficient in 
GGR, which deals with most of the lesions and influences the low cancer susceptibility. In 
opposition, XPC cells are TCR proficient but deficient in GGR the signal for p53-dependent 
apoptosis is weaker and the end result is high mutation rate and cancer predisposition 
(Hanawalt, 2001). 
1.2.2.1 NucleotideExcision Repair mechanism 
Nucleotide excision repair is a multi-step process, which involves 20-30 proteins. 
The first step is damage recognition, followed by incision on each side of the lesion, which 
releases a 24-32 nucleotide fragment containing the lesion. The gap is filled by repair 
synthesis and covalentiv sealed by ligation (fig.3). 
Fig.3. Molecular model for the incision stage of NER (I) XPC-hHR23B (C) senses DNA 
helix-distorting NER lesions in global genome NER (GG-NER) leading to conformational 
alterations of the DNA. In transcription-coupled repair (TC-NER) lesions are detected by 
elongating RNA polymerase II blocked by, e.g., CPDs (NER lesions) and thymine glycols 
(non-NER lesion). (II) (Left) XPC-hHR23B at lesion attracts TFIIH [and possibly XPG (G)]. 
TFIIH creates a 10- to 20-nucleotide opened DNA complex around the lesion by virtue of its 
helicases XPB and XPD; this step requires ATP. XPC-hHR23B may be released at this or 
one of the subsequent stages. (Right) CSA, CSB, TFIIH, XPG and possibly other cofactors 
displace the stalled RNA polymerase II from the lesion, which now becomes accessible for 
further repair processing; depending on the type of lesion, repair is completed by NER or by 
other repair pathways. (III) XPA (A) and RPA stabilise the 10- to 20-nucleotide opening and 
position other factors. XPA binds to the damaged nucleotides, RPA to the undamaged DNA 
strand. Possibly, RPA binds in its 8- to 10-nucleotide binding mode and transition to the 30-
nucleotide binding mode (RPA stretching) plays an important role in full open complex 
formation. XPG stabilises the fully opened complex. (IV) XPG, positioned by TFIIH and 
RPA, makes the 3' incision. ERCCI-XPF (F), positioned by RPA and XPA, makes the 
second incision 5' of the lesion. (V) Dual incision is followed by gap-filling DNA synthesis 
and ligation. Drawn contacts between molecules reflect reported protein-protein interactions 
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The first step in the NER pathway is damage recognition. This is achieved by 
binding of the XPC/I-11I{R23B complex to the site of the lesion and as a result the helix is 
partially opened, facilitating the recruitment of other repair factors. In the next step the DNA 
helix around the lesion is opened in an ATP-dependent process. Three proteins, TFIIH, XPA 
and replication protein A (RPA) participate in the DNA opening. The TFIH-I complex 
participates via its helicase activities conferred by the two ATP-dependent helicases, XPD 
and XPB. working in opposite directions. TFIIH, a protein complex composed of nine 
subunits, also participates in initiation of RNA polymerase II transcription, where it makes a 
10-15nt opening. In repair, the opening is initially lOnt and extended to 25nt around the 
lesion with the contribution of XPA. RPA and XPG. RPA has two binding modes, the 8-1Ont 
mode and the 30nt mode, which is 100-fold more stable (de Laat etal., 1999). In NER. RPA 
is required for full opening around the lesion and for positioning and coordinating the 
nucleases. RPA binds to the undamaged strand with defined polarity, protecting the 
undamaged DNA from being cut. Also RPA has protein-protein interactions with the 
endonucleases required in the excision step and via these interactions RPA positions both 
endonucleases at the right side of the lesion. XPA contributes in the opening because it has 
high affinity for damaged DNA in an open conformation and interacts with TFIJH and RPA, 
arranging the repair complexes around the lesion. 
Once the DNA has been locally unwound and the endonucleases positioned and 
directed towards the corresponding sides of the lesion, a nucleotide fragment containing the 
lesion is excised. The excision step requires structure specific endonucleases, ERCC 1/XPF 
complex at the 5' side and XPG at the 3' side of the damage. Incisions are made 
asymmetrically, with the 3'incision occurring first 2-8nt and the 5' incision 15-24nt away 
from the lesion. The correct positioning of the endonucleases is achieved by binding to RPA, 
already bound to the undamaged DNA strand. Initial DNA binding occurs at the 5 '-oriented 
side of RPA. Further RPA stretch in the 3' direction to cover the 30nt segment. Bound to the 
undamaged DNA strand, the 3 'oriented side of RPA binds ERCC 1IXPF complex and the 
5'oriented side binds XPG (de Laat etal., 1998). It is believed that due to protein affinities, 
RPA stimulates and positions ERCC 1/XPF complex more than XPG, for which the RPA role 
is taken by TFIIH. 
In the last step, the excised fragment is replaced in a DNA repair synthesis reaction 
using undamaged strand as a template and mediated by DNA polvmerase 6 and/or E. Other 
proteins supporting de novo DNA synthesis are proliferating cell nuclear antigen (PCNA), 
RPA and replication factor C (RF-C). It has been seen that combination of RPA. PCNA, RF -
C and either polymerase was sufficient for repair synthesis in vitro. RF-C preferentially 
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binds to the 3' ends of DNA primers and facilitates binding of PCNA, followed by DNA 
polymerases. 
The final step is the ligation of the newly synthesised repair patch of about 30 
nucleotides to the original sequence. The ligation reaction is catalysed by DNA ligase I, 
which is believed to participate in NER, because mutations in this gene lead to the UV-
sensitive phenotype. 
The overall genome repair reaction has been reconstituted in vitro with recombinant 
human proteins. Full repair can be achieved in vitro by concomitant presence of 10 
components: RPA, XPA, XPC/HHR23B, XPG, ERCC1/XPF, TFIIIH. DNA polymerase 8 
and/or s, RFC, PCNA and DNA Ligasel (Araujo et al., 2000). However the repair efficiency 
of the reconstituted system is less than NER in whole cell extracts, where accessory proteins. 
like XP-E also take part. One important aspect in describing NER is how all the proteins 
involved, at least 10 in vitro and over 30 in vivo, take part in the repair process. Two 
hypotheses have been advanced: 1) NER components can be recruited sequentially or 2) 
preassembled in a so-called 'repairosome" or in smaller subassemblies. The repairosome 
hypothesis comes from yeast, where holoTFIIH and core TFIIIH contained smaller 
subassemblies of protein homologs to human ERCC l/XF, XPG. XPC. XPA. A similar 
preassembled repairosome has been identified in HeLa cells (human cervical carcinoma 
cells) (Balajee & Bohr, 2000). More evidence favours the sequential recruitment at the DNA 
damage site, based on the fact that key proteins, such as TFIIH. PCNA, RPA, DNA 
polymerases are involved not only in NER but also in replication and transcription. 
Moreover, the efficiency of cellular processes and cell viability are not compatible with large 
complexes, as large as 2.7MDa. Recent experiments argue against a preassembled 
repairosome. Karmarkar et al., (1998) showed redistribution of TFIIH in GI cells after UV 
damage. Houtsmuller et al., (1999) showed that ERCC1/XPF complex moves freely within 
the nucleus in absence of the damage and is transiently immobilised after UV damage, due to 
recruitment in the repair process. Also repair proteins can be relatively easy separated from 
human cell extracts (Balajee & Bohr, 2000). The conclusion is that NER operates by 
sequential recruitment of NER proteins  at the damage site and ERCC 1/XPF complex 
participates in repair in a distributive fashion. However, further studies on the kinetic 
movement of the proteins involved in damage recognition and incision steps are required to 
clarify this issue. 
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1.2.2.2 NER defects 
Defective or deficient NER is associated with three rare recessive syndromes, all 
having photosensitivity as a common feature: Xeroderma Pigmentosum (XP), Cockayne 
Syndrome (CS) and Trichothiodvstrophy (TTD). The difference among the three diseases 
resides in cancer susceptibility, with only XP patients developing skin cancer, whilst TTD 
and CS do not despite their skin photosensitivity and defective repair. 
1.2.2.2 a) Clinical symptoms 
is a rare disease, to date 800 cases have been reviewed (Tsao, 2000). XP clinical 
symptoms are high sun hypersensitivity with cutaneous manifestations on sun-exposed skin 
(such as parchment skin and freckles, progressive dryness, telangiectasia and atrophy) and 
degenerative alterations of the eves. XP is associated with >1000 fold risk of early onset of 
non-melanoma, predominantly and melanoma (5%) skin cancer on sun exposed areas, like 
face, neck and head. The mean age of onset is 8 years, nearly 50 years earlier than in the 
general population and the prognosis is poor, as XP patients have 10-20 fold increased risk 
of developing extracutaneous neoplasms, such as ocular non-melanoma and melanoma, 
sarcomas (brain), leukaemia, gastric carcinoma, lung cancer (Tsao, 2000). A proportion of 
XP patients. 20-40% has progressive neurological abnormalities, due to neuronal death. In 
this respect, XP-A is the most severely affected, while XPF and XPC do not tend to develop 
these types of symptoms. Fibroblasts from XP patients are highly sensitive to UV and unable 
to repair UV induced damage, therefore the level of mutations is high. 
CS patients are not predisposed to skin cancer. They have milder photosensitivity in 
comparison with XP or XP/CS, physical and mental retardation with progressive 
neurological degeneration and a short lifespan. Other CS symptoms are sensonneural 
hearing loss, pigmentary retinopathy, wizened facial appearance, impaired sexual 
development, growth failure (termed cachectic dwarfism, because the weight is affected 
more than length) (de Laat et al.. 1999). Cells from CS patients have UV sensitivity, repair 
deficiency and fail to recover transcription after UV damage, suggesting deficient TCR, 
while the GQR is unaffected. 
XP/CS patients have the same degree of UV-sensitivity as XP patients and in some 
cases can develop skin cancer. They do not develop primary neuronal degeneration nor 
ichthyosis or brittle hair. Other XP/CS symptoms are higher neurodysmvelination than in CS 
or TTD and mental retardation and dwarfism similar to CS or TTD. Cells from these patients 
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are more sensitive to l.JV killing even than XP-A cells, although the repair deficiency is 
similar to XP-D cells, which are less sensitive to UV killing (Lehmann, 200 1) 
lTD is not a cancer-prone disease, which includes several different autosomal 
recessive diseases, such as Pollitt, Tay, Amish brittle hair, Marinesco-Sjogren and Sabmas 
syndromes on the basis of hair dysplasia (Bergmann & Egly, 2001). lTD patients are 
generally categorised under PIBIDS, which stands for photosensitivity milder than XP or 
XP/CS, ichthyosis, sulfur- and cysteine-cysteine-deficient brittle hair, impaired intelligence 
(and mental retardation, spasticitv, tremor and ataxia), decreased fertility and short stature. 
The severity of the symptoms ranges from mild to severe with motor troubles and very poor 
mental performance. Extreme impairments lead to failure to thrive and/or death in early 
childhood. A clinical indication of TTD is a shiny, transparent skin at birth (collodion baby) 
(Bergmann & Egly, 2001). 
1.2.2.2 b) Genetics 
The cell fusion experiments identified seven complementation groups in XP (XP-A 
to G). two in CS (CS-A and CS-B), three (XP-B, XP-D. XP-G) in XP/CS, the combined XP 
and CS phenotype and three in TTD (XP-D accounting for the majority of TTD patients, XP -
B, lTD-A with no responsible gene identified vet). 
Mutations in the XP-B, -D and -G genes are associated with either XP, or XP/CS or 
TTD and each of these disorders has specific clinical symptoms. These mutations are most 
commonly single amino acid substitutions, located at various points on the gene sequences. 
Only XP is associated with increased risk of early onset skin cancer, some studies estimate 
more than 2000-fold increment in all forms of cancer compared to normal individuals (van 
Steeg & Kraemer. 1999). All three disorders possess a degree of defectiveness in NER 
capacity reflected in photosensitivity of the patients' skin. Most XP groups are deficient in 
both GGR and TCR., except for XPC group where only GGR is defective. CS groups are 
defective in TCR, while XP/CS group is defective in both. TTD groups are defective in 
transcription, while the NER level can be normal, intermediate or defective. 
1.2.3 Description of three NER genes relevant to this study 
The three NER genes relevant to this study are XPB, XPD and ERCC I. XPD and 
XPB are essential helicases and components of TFTIH complex involved in NER and 
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transcription. Mutations in both genes have been reported and some of these are associated 
with NER deficient syndromes. ERCC1 is an essential component in NER and maps on the 
same chromosome 19 as XPD, in a region spanning 250kb. Additionally, for each gene, 
several polmorphisms have been reported, opening the perspective of investigating the 
correlation between variants and cancer susceptibility. 
1.2.3.1 XP  
1.2.3.1a) XP  gene 
Human XPD maps on the long arm of human chromosome 19 bands 13.2-13-3, less 
than 250kb from ERCC1. The other genes located within 13.2-13.3 band (spanning —5,5Mb) 
are:XRCC 1 (component of base excision repair (BER) pathway, which removes base 
damage and DNA single strand breaks), the apolipoprotein (APO) genes, the muscle creatine 
kinase (CKMM) gene locus, mvotonic dystrophy and DNA ligase I. CKMM, XPD and 
ERCC 1 genes are physically linked within a segment of approximately 25 0kb, which does 
not include the APOC2 gene. XRCCI is located 2Mb proximal to XPD. The order of the 
genes is taken from Lamerdin etal.. (1996): 
cen-- 3 XRCCl 5 --APO-- 3 CKMA't- 3 XPD 5 '--3 ERCC1 5  --- DM--ter 
The human XPD gene is composed of 23 exons. It spans approximately 20kb and is 
transcribed from telornere to centromere like the nearby gene ERCC 1. XPD exon lengths are 
completely conserved in human, hamster, mouse and fish-Xiphophorus maculatus, whilst the 
intron lengths vary considerably. The human XPD gene has a high percentage of identity 
with its hamster (90%), mouse (89.8%) and fish (76%) counterparts (Lamerdin et al., 1996). 
The human, mouse and hamster proteins are completely conserved in the helicase motif 
functional regions and fish XPD has three non-conservative substitutions within one of these 
domains. The classic promoter elements, a reverse CAAT box (CCGATTGC) and a GC box 
(CCGCCC) are completely conserved in human, mouse and hamster. A forward CAAT box 
(GGCCAATRG) is present in hamster and mouse and (AGCCAATGG) in human and a 
TATA box has been identified only in the human gene (Weber et al., 1990). This study also 
identifies a pyrimidine-rich stretch of 34nt, (88% C+T) upstream of the canonical promoter 
elements, which is believed to regulate the gene expression. Regions of the same length 
(34nt) and composition, 82% C+T and 79.4% C+T have been also identified in mouse and 
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hamster. Fish XPD has a shorter pyrimidine-rich stretch of 30nt with 76.6% C+T (Lamerdin 
et al., 1996). The polyadenviaton signal of human XPD is identified within 70bp following 
the stop codon (Weber et al., 1990). Mouse and hamster XPD polyadenylation signals are 
found -1.2kb distal to the stop codon. Transcript size is not known for the hamster gene, the 
human transcript is 2.6-2.7kb (Northern analysis of HeLa RNA) and the mouse transcript is 
reported to be 4.1kb in mouse leukemia cell line (Lamerdin et al.. 1996). The human XPD 
gene specifically corrects UV sensitivity of XP-D cell lines. 
I.2.3.1.b) XP  protein 
The XPD gene encodes a 86.9 kDa 5' to 3' DNA helicase component of the nine-
subunit TFIIH complex involved in initiation of RNA polymerase II transcription, nucleotide 
excision repair and possibly in cell cycle regulation (de Laat et al., 1999). The XPD protein 
is composed of 760 aa. 
The main structural features of the 760 amino acid XPD protein are: ATP binding 
motif (amino acid 35-52), DEAH box (amino acid 234-237), putative nuclear localisation 
signal (amino acid 682-695) seven helicase motifs (amino acid 35-51, 69-88,225-240, 464-
478, 539-560, 587-611, 654-671) and DNA binding domain localised within helicase motif 
V (Ellis, 1997) and (Hoeijmakers. 1993b; Hoeijmakers, 1993a). 
The human XPD protein shows a high percentage of identity with hamster (98%), 
mouse (97%) and fish (83%) counterparts. Similar high percentage of identity is seen 
between hamster, mouse and fish and also between mouse and fish (Lamerdin et al., 1996). 
There is 51.7% identity and 64% similarity with yeast RAD3 and the percentage is higher 
within the helicase motifs, where human and yeast XPD are 73.8% identical and 88.5% 
homologous (Weber et al., 1990) 
The XPD protein has protein-protein interactions with XPB, p34, p44, p62 and XPG 
(Iver et al., 1996). The XPD N-terminus 300 amino acids interacts with the C-terminus 
domain of p53 (Leveillard et al., 1996). Helicase motifs have an important functional role 
and it has been shown that the majority of mutations causing XP, XP/CS or lTD phenotypes 
map within helicase motifs 1, II, Ill, V, VI (Taylor etal., 1997) 
I.2.3.l.c) XPD and NER syndromes 
Mutations in the XPD gene lead to three clinical outcomes, Xeroderma 
Pigmentosum, or Xeroderma Pigmentosum/Cockayne Syndrome, or Trichothiodystrophy. 
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XPD mutations have been analysed in 21 XP cases, 11 lTD and in 2 XP/CS cases. A recent 
compilation of NER disorders associated with XPD missense/nonsense mutations and 
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Fig.4. Compilation of the XPD mutation sites found in the NER diseases: TTD, XP and 
XP/CS. The diagram shows the XPD protein functional domains (blackened boxes); the 
amino acid changes resulting from the mutations found in the different pathological 
phenotypes are shown boxed, with the change shown as either white on black (for TTD) or 
black on white (XP)[dotted boxes] and for XP/CS (unbroken border). The changes 
responsible for the pathological phenotype, those resulting in deletions likely to affect 
cellular viability and mutations described by Taylor 1997 as being lethal are indicated by 
unbroken, dashed and dotted arrows, respectively. Number 1 and 2 after the patient code 
denote different alleles (Bona et al., 1998). 
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From fig.4 it can be seen that most of the mutations are in the C-terminus of the 
protein with considerably fewer in the N-terminus. There are no reports on mutations 
occurring in the region 260-460aa, which is a region with 50% identity to S.cerevisiae 
RAD3. Mutations might exist in that region, but so far have proven unidentifiable, due to a 
lack of an associated-phenotype or inviability of the mutated cell. Also from flg.4 it can be 
seen that most of the mutations are single amino acid substitutions located in the helicase 
domains I, Ia. II, IV, V and VI or within the nuclear localisation signal (e.g. Arg683) 
(Lehmann. 2001). A frequently mutated amino acid residue is arginine, with 75% of XP 
patients having changes at Arg683; other causative mutations in XP are at the following 
amino acids residues: 47, 234, 541, 542, 601, 683, 726, In TFD causative mutations are at 
the following amino acids residues: 112, 259, 658 (located within the helicase domain VI) 
673. 713. 722.725. frameshift 730 (Bergmann & Egly, 2001), (Botta etal., 1998), (Taylor et 
al., 1997). Of these the most frequent is Argi 12His, followed by Arg722Trp, Arg658His or 
Arg658Cys and -1 frameshift at codon 730. Mutations found in both XP and lTD patients 
behave as null alleles and are at the amino acid residues 616, Del 716-730 and Leu461Val. 
(flg.4). Mutations shown in flg.4 contribute to the compound heterozygote (different 
mutations in the two alleles of XPD gene) genotype seen in the majonty of patients with 
NER disorders. 
All the mutations in the XPD gene found in XP-D patients determine similar low 
NER levels, whilst in TTD patients there is a wide range of NER levels. Fibroblasts from 
XP-D patients carrying Arg683Trp mutation have low survival and UDS of 25% of controls. 
Fibroblasts from TTD patients with Argll2His have low survival and UDS levels of 5-12% 
of normal. Fibroblasts from TTD patients with Arg722Trp have intermediate survival and 
UDS levels in the range of 15-30% of normal. CPDs removal rate at low UV doses (5J/m) 
showed that TTD cells with Arg722Trp had 70% of the CPDs removed in 24hrs, whilst TTD 
cells with Argi l2His and XP-D cells with Arg683Trp have 40% of the CPDs removed 
(Bemeburg et al.. 2000b). These results show the levels of NER in cells from TTD patients 
vary and that NER levels in TTD ArgI l2His are similar to those in XP-D cells. XPD 
mutations found in XP/CS are Gly602Asp and Gly675Arg, of which Gly602Asp is located 
within helicase domain V (flg.4). Cultured cells from a patient with Glv675Arg were 
extremely sensitive to UV killing despite the residual repair rate of 3040%. A study on two 
XPD/CS cell lines, one carrying Gly602Asp and the other Gly675Arg show that, in both 
cases, UV radiation induces up to 80% suppression of ICAM-1 upregulation (intercellular 
adhesion molecule 1, which is inducible by gamma interferon). This study also shows that in 
XPD/CS cells generation of incision intermediates following UV irradiation is slightly lower 
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than normal cells and occurs even in the absence of repair synthesis inhibitors, suggesting 
that these cells can initiate but not complete NER (Berneburg et al., 2000a). 
The mutation distribution in fig.4 shows that there is no disease-specific mutation. 
An explanation for how mutations in the same gene lead to clinical heterogeneity is that 
different alterations in XPD structure affect its functions differentially, i.e. the site of 
mutation determines the clinical phenotype. If a mutation occurs for instance in the ATP-
binding site (Lys48Arg), the helicase activity is abolished, whereas transcription is not. An 
in vitro study shows that TFIII-1 with inactive XPD helicase is able to support basal 
transcription in a reconstituted system with purified components (RPA, XPA, 
XPC/I-ll-1R23B, XPG, ERCC1/XPF). Therefore XPD presence and not its enzymatic activity 
is required in transcription for maintaining the stability of the complex, whereas in NER 
XPD is required both physically and functionally(Winkler et al., 2000). The current 
understanding of the XPD genotype/phenotype correlation is that altered repair function 
causes photosensitivity and cancer proneness. XP, while TTD and XP/CS phenotypes are the 
result of altered transcription function. Additional evidence to support the site of mutation 
causing the phenotype comes from the lTD mouse. A transgemc mouse carrying a mutation 
common in TTD, Arg722Trp mutation, has many of the lTD features seen in humans: brittle 
hair, with sulphur-deficiency. Cells in culture show defects in DNA repair and UV 
sensitivity similar to human cultured cells. The TTD mouse had additional features of 
premature ageing, suggesting a potential role of XPD in ageing and were more susceptible to 
UV-B induced skin carcinogenesis. This feature is notable, although it is not seen in TTD 
patients and can be attributed to differences between the species in repair of mutagenic CPDs 
(Lehmann, 2001). 
1.2.3.2 .XPB 
1.2.3.2 a) XPB gene 
XPB gene, the human DNA repair helicase is mapped on chromosome 2q21. Other 
genes mapped in the same 2q21 band are: G-protein coupled receptor 17 (GPR17). lactase 
(LAC), minichromosome maintenance deficient 6 (MCM6), mannosvl-GP-Nacetyl 
glucosaminotransferase (MGAT5), G-protein coupled receptor 36 (GPR36), Sodium channel 
voltage-gated type VI alpha polypeptide (SCN6A), Spastic cerebral palsy (SCP), translin 
(TSN). XPB is composed of 14 exons ranging in size from 50 to 439bp and spanning a 
region of —50kb. The donor splice site of the third exon is a GC instead of a GT. 
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The promoter is located within a stretch of 259 nucleotides proximal to the putative 
transcription start site. It lacks the classical TATA and CAAT boxes, but contains GC boxes. 
The 5' flanking region contains the CTCAGGT/CCACA sequence motif, followed by a 
pyrimidine-rich stretch, presumably involved in transcription regulation. At the 3' end of the 
gene a 309bp non-coding region (including the stop codon TGA) contains the 
polyadenylation signal AATAAA which is situated 28bp 5' to the poly (A) addition site. In 
the 3' UTR region there is an AU-rich region, which does not influence the stability of 
mRNA Weedaeta1., 1991). 
XPB mRNA is 2.6kb and the gene is expressed at low levels in various cells and 
tissues and experiments on epidermal HeLa cells and short term cultured keratinocytes show 
that it is not UV inducible Weeda et al., 1991) . Its expression does not vary with the 
proliferative state or stage of cell cycle. XPB specifically corrects the excision repair defect 
in XP-B and in Chinese hamster ovary cell (CHO) ERCC mutants group 3. 
1.2.3.2 b) XPB protein 
The human XPB protein has 782 amino acid residues and it contains: a nuclear 
localisation signal (aa 6-18), four acidic domains (aa 20-28, 256-265, 697-701 and 721-728), 
the ATP binding site (aa 340-347), the DEVH box (aa 441-444), the DNA binding site aa 
(121-142) and seven helicase motifs (aa 333-349. 362-381, 432-447, 464477, 545-566, 597-
618 and 630-647) (Ellis, 1997). It belongs to the RAD251XPB family and has 66% 
homology with Drosophila haywire and 55% with yeast RAD25. Mouse and human XPB 
share 94% similarity and 95% identity. The C-terminus is less conserved but it seems vital 
for repair activity, since an inactivating frameshift mutation in the region spanning aa 741 to 
aa 782, leads to the XP/CS combined phenotype (patient XP11BE). 
It is an ATP-dependent 3' to 5' helicase with DNA binding and unwinding activities. 
It is identified as being the p89 subunit of the TFI[H complex and also forms a heterodimer 
with XPD. XPB has other protein-protein interactions with p34, p44, p62-all TFIIH subunits, 
XPG and p53. The XPB helicase motif III interacts with p53 C-terminus domain (Wang et 
al., 1995). 
1.2.3.2 c) XPB and NER syndromes 
Similar to XPD, XPB mutations found in NER disorders are single amino acid 
substitutions and one frameshift. The difference resides in the small number, actually only 
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three mutations have been described in the XPB gene and this indicates its importance for 
transcription and cell viability. Inactivation or loss of XPB homologues. RAD25 (yeast) and 
Drosophila haywire are lethal and an XP/CS like mutation is lethal for the mouse embryo. 
The XPB mutations found in the patient XPIIBE with XP/CS syndrome are Phe99Ser and 
an inactivating frameshift 740 mutation. XPB mutation found in L1] is Thr II 9Pro. All 
these three mutations are located in N-terminus, outside functional domains. They are 
compatible with life, although they induce severe clinical symptoms. Repair studies on 
fibroblasts carrying Phe99Ser mutation show low NER activity. Repair rate for CPD is 7% 
and for 64PPs 32% comparing to control (MRC5VISV cell line, CPD is 43% and for 6-
4PPs 100%). The UDS level in fibroblasts carrying Phe99Ser is 16.5% relative to wt (i.e. 14 
grain numbers/nucleus relative to 85.2). Fibroblasts carrying Thrl 19Pro mutation have a less 
severe effect on repair parameters, with 21% repair of CPDs and 84% for 64PPs and the 
UDS is 47.9% relative to wt (i.e. 40 grain numbers/nucleus relative to 85.2). Fibroblasts 
carrying both mutations (Phe99Ser and Thrl 19Pro) DNA repair parameters have 
intermediate levels of 49% 64pps and 7% CPD repair rates and UDS of 30.4% relative to wt 
(i.e. 25.9 numbers/nucleus relative to 85.2). Their studs' suggests that Phe99 and Thrl 19 are 
located within a domain involved in repair and required for repair of 64PPs and CPDs 
respectively. Cells with frameshifi 740 have defective CPD repair and almost undetectable 
repair of 64PPs (Riou et al., 1999). No other mutations in other regions of XPB gene have 
been reported and studies in cell culture show that mutations in helicase domains I to VI and 
in the potential DNA-binding domain abolish repair activity (Ma et al., 1994). 
I.2.3.3.Comparison between XPB and XPD 
There are numerous similarities between XPB and XPD proteins. Structurally, they 
are of similar size and both are composed of the same type of functional domains, i.e. 
helicase, DNA- and ATP-binding domains and nuclear localisation signals. XPD and XPB 
have seven helicase motifs and belong to the Superfamily 2 DNA helicases, characterised by 
the DEx.H-box motif, as does CSB (ERCC6). The seven helicase motifs span a region of 
300-500 amino acid residues. Of the seven motifs, motifs I and II are found in helicases and 
in any protein that binds nucleotide triphosphate, whereas motifs La and Ill-VI are specific to 
helicases and confer the helicase activity. DExH box (DExH=Asp-Glu-x-His) is localised in 
all helicases belonging to this class in motif II and XPB has a DEVH (Asp-Glu-Val-His) box 
whereas XPB has a DEAH (Asp-Glu-Ala-His) box. Both proteins show similar homology to 
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yeast counterparts and on this basis XPD belongs to the S.cerevisiae RAD25 family and 
XPB belongs to the RAD3 family. 
Functionally, both XPD and XPB are ATP-dependent helicases. Three models have 
been put forward to explain the DNA unwinding. The inchworm model explains the activity 
of monomeric helicases. In this model, each step of the unwinding reaction, ATP binding, 
hydrolysis and product release modifies the conformation of the protein, one step at a time, 
along the DNA substrate. The rolling model explains the activity of dimeric helicases. Each 
protomer of the dimer binds dsDNA or ssDNA depending on the bound ATP or ADP. The 
protein is thought to roll through duplex DNA, with alternating subunits to couple ATP 
hydrolysis with DNA unwinding (Hall & Matson, 1999). XPD and XPB work in opposite 
directions, 5' to 3' and 3' to 5', respectively. Both are components of the TFIIH complex, 
involved in transcription initiation and NER. XPD and XPB have similar protein-protein 
interactions, from in vitro and in vivo experiments. First of all they have interaction domains 
for each other, located in both proteins in the N-terminus. Both interact with p34, p44 and 
p62 components of the TFIIH and XPG, a NER protein. These interactions support the dual 
functions of TFIIH in transcription and repair. Both proteins interact with p53 in vitro and in 
vivo suggesting a functional interrelation. The p53 C-terminus domain interacts with both 
XPD (N-terminus 300 aa residues) and XPB (helicase motif III). An in vitro experiment 
showed that p53 modulates TFIIH helicase activity by binding to TFIH-i components, XPB 
and XPD (Wang et al., 1995). This suggests an active role of p53 in repair and also that the 
helicases are involved in p53-dependent pathways, such as apoptosis. Experiments on 
fibroblasts from XP-B and XP-D patients, who carry a germline mutation in XPD or XPB 
genes, show defective p53-mediated apoptosis (Wang et al., 1996). 
The biological importance of the two proteins is different, as is seen from the 
number of mutations in both genes. Clinically, mutations in XPD or XPB are associated with 
NER syndromes. XP, CS and TTD, characteristic of which is NER deficiency. The number 
and frequency of mutations in XPD gene are quite large in comparison with XPB gene, for 
which very few mutations have been reported. A similar situation occurs in yeast, where 
many mutations have been isolated in RAD3, whilst mutations in RAD25ISSL2 have been 
difficult to isolate. Most of the XPD mutations lead to XP and some of them to lTD. The 
three reported mutations in XPB have either XP/CS or lTD. Mutational analysis of human 
and yeast XPD and XPB genes show that the helicase function of XPD is not critical for 
transcription, but is important for repair, as seen in classic XP-D, while XPB is more 
important for transcription than repair (Weeda et al., 1997), (Winkler et al., 2000). 
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1.2.3.4. ERCCI 
I.2.3.4.a) ERCC 1 gene 
The human ERCCI gene maps on chromosome 19, band q 13.3, closely linked to 
XPD. It is 15kb in size and composed of 10 exons ranging in size from 60 to 216bp. The 
promoter is located I 7Obp upstream of the transcription initiation site and it does not contain 
the classical elements such as CAAT. TATA, GC boxes. The 5' flanking region contains a 
CTCAGGT/CCACA sequence motif, followed by a pyrimidine-rich stretch involved in 
transcription regulation. The 3' UTR region contains a CAYTG box and a T-rich element 
near the second AATAAA, presumed to be better target for 3'end processing. 
ERCCI is expressed at low levels in various cells and tissues and the major 
transcript is a 1.1kb mRNA. mRNA of 3.4 and 3.8kb have been identified by Northern blot 
using cDNA probes and are believed to represent differential polyadenviation (van Duin et 
al., 1987). It has been shown that it is not UV-inducible and does not complement XP or CS 
cell lines. Studies on the ERCC I gene failed to show any disruptive mutations in the gene or 
in its transcript in XP patients. 
I.2.3.4.b) ERCCI protein 
The ERCC 1 protein is a 3 3k protein, composed of 297 amino acid residues. Based 
on primary amino acid sequence. ERCC 1 structural features are: a nuclear localisation signal 
(an 17-23), which localises it in the nucleus, a potential DNA-binding domain (an 134-156) 
and a double helix-hairpin-helix motif (236-289). It belongs to the ERCC I/RADIO/S WIlO 
family and there is 85% identity and 88% similarity between human and mouse ERCC I 
proteins. The first 214aa align with the entire 210aa RADIO polypeptide; the remaining 83 
residues show in the first part homology with E. coli UvrA and the 60 C-terminus residues 
show homology with C-terminus of UvrC (Hoeijmakers. 1993b; Hoeijmakers, 1993a). 
ERCC 1 protein alone does not bind UV-damaged or -undamaged double-stranded 
DNA. It takes part as a subunit of protein complexes, active in the two main NER processes, 
DNA damage recognition and strand incision. DNA damage is recognised by XPA, which 
via its N-terminus directly binds ERCC1 (amino acid residues 93-120). A ternary complex of 
RPA. XPA and ERCC1 has been detected in vitro (Saijo et al., 1996), (Nagai et al., 1995). It 
is believed that RPA helps position the NER endonucleases, preventing incisions in 
undamaged DNA. 
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ERCC 1 (aa 224-297) forms a tight complex with the C-terminus of XPF, which has 
structure-specific endonuclease activity and makes the incision in the 5' side of the damage 
site. It is believed that ERCC 1 catalyses the cleavage due to the presence of the double helix-
hairpin-helix motif in its C-terminus. As it is seen that disruption of the same motif in E coli 
UvrC leads to impaired incision but normal cleavage (de Laat etal., 1999). 
1.2.4. p53 and NER 
1.2.4.1 y53 gene 
The human p53 gene maps on the short arm of human chromosome 17, bands p13-
13.1. spanning 16-20kb. It is composed of 11 exons, ranging in size from 22 to 1,268bp 
(Lamb & Crawford, 1986). The first exon is non-coding and located 8-10kb away from 
exons 2 to 11. The non-coding exon is also found in mouse and rat p53 genes. Human p53 
gene appears to have two promoters, one located 100-250bp upstream of the 218-bp non-
translated first exon and the other located within the 5' 1.2 kbp of intron 1. CAT 
(chioramphenicolacetyltransferase) activity and expression of CAT RNA in K562 cells lines 
(human leukemia cell line) show that the second promoter functions 50-fold more efficiently 
than promoter 1 (Reisman et al., 1988). To date no biological roles have been associated 
with the presence of the two promoters, but it is possible that they participate in regulation of 
p53 expression according to the cell status. Another study on the p53 promoter advances the 
idea that the second promoter is for a second gene, which resides partly or entirely within the 
first intron of the p53 gene (Tuck & Crawford, 1989). Similar to ERCCI and XPB promoter 
sequences, p53 promoter does not have recognisable CAAT, TATA or GC rich boxes 
(Bien.z-Tadmor et al., 1985). The human p53 mRNA contains an AIu repeat in the 3'-UTR 
region and this results in a product of 2.8kb, 800bp longer than the mouse mRNA, due to a 
larger 3-UTR region (Oren, 1985). p53 is considered a housekeeping gene and it is 
expressed in all tissues and organs. 
p53 mutational spectrum in human cancer is extremely variable. There are tumours 
with svt p53, inactivated p53 and mutant p53. p53 missense mutations occur more frequently 
in exon 24 and 9-11 than in exons 5-8 (Harris, 1996). Wilm's tumour, retinoblastoma, 
testicular cancer. neuroblastoma and acute lymphoblastic leukemia are the most curable 
cancers and rarely contain p53 mutations. Inactivation of p53 can occur via DNA viruses, 
like HPV or via MDM-2. HPV positive cervical, penile and rectal carcinomas have inactive 
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p53. MDM-2 acts in a feedback loop to limit p53 function by inhibiting its transactivatmg 
activity and stimulating its transport out of the nucleus into the cytoplasm, where it is 
targeted for degradation. MDM-2 is often overexpressed and amplified in certain sarcomas. 
Tumours with mutant p53 generally have poor prognosis and human cancer of lung, prostate, 
colorectal, breast, head and neck, lymphomas, pancreatic, stomach, melanoma frequently 
carry p53 mutations. These cancers are listed according to incidence in the US and lung 
cancer has the highest frequency of mutated p53, melanoma the lowest and head and neck is 
in between, closer to melanoma. 
In skin cancer, recent figures show that >90% SCC and >50% BCC have mutated 
p53. Most of these mutations are UV-signature type (C to T or CC to U transitions, at 
pvrimidine-pvrimidine sites), which link sun exposure with development of NMSC in a 
causal relationship (Harris, 1996), (van Steeg & Kraemer. 1999). Most of these mutations 
map in the central domain of the protein and result in amino acid substitutions; a few of 
them, found in SCC, BCC and melanoma are listed below. p53 mutations have been found in 
SCC precursor lesions Bowen's and actinic keratoses. In Bowen's disease Ginl92stop, 
Arg248Trp, Pro250Pro, Leu265Pro, Arg2731-eu, Pro278Ser, Glu286Lys have been found 
(Campbell et al., 1993). In actinic keratoses (AK) Phel09Ser, Argi lOCvs. Ser215Arg. 
Arg248Trp, Pro278Thr, Arg342stop have been found (Taguchi et al., 1994). p53  amino acid 
substitutions found in Basal Cell Carcinomas are: Arg 1 96stop. Arg342stop, Gin 1 O0stop, 
Pro177Leu. Arg248Gln, Pro46-47Glv..stop. Pro278Ser, His l78Asn, Leu-Glu257/258Leu-
Lys, Glu258Lys, Arg28OLys, Asp28 lAsn, Arg282Trp, Arg249Trp. GluS Istop, Glu294stop 
and Pro278Leu, Arg282Trp, argl90Stop. Ser24lPhe, H.is297Tyr, Pro98Ser (Zhang et al., 
2001), (Ziegler et al., 1993). 
In cutaneous malignant melanoma p53 mutations are not so common, they are found 
in only 0-6% of melanomas, of which primaries seem to have the highest frequency. 
Mutations found in melanoma cell lines are: Arg2l3Gln. Met246Arg, Cys238Tyr, 
Asn247Thr, Arg248Trp, Pro3 lSLeu, Arg290His and Arg248Gln. In primary melanomas the 
following mutations have been found: Gly266Glu. Arg290His in NM; Cys182Cys and 
Prol9lPro in LMM; Alal89Alaand Gly187Ser in SSM (Zerp etal., 1999). 
I.2.4.2.p53 protein 
The p53 protein is a 53kDa protein, composed of 393 aa. The protein has 4 domains: 
domain I, highly acidic (Asp-Glu rich, aa 1-880), domain II, hydrophobic (Pro rich, aa 81-
150), domain III, central (aa150-323), nuclear localisation signal (aa3 11-323), domain IV, 
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highly basic (aa 319-393) involved in specific DNA binding. The N-terminus is mainly 
involved in transcription transactivation. whilst the C-terminus is the regulatory region, 
involved in oligomerisation, nuclear localisation, recognition of the DNA damage and 
induction of apoptosis. The central region is involved in specific DNA binding. A Pro-rich 
region exists between the N-terminus and the central domain and it is involved in p53-
dependent growth arrest and apoptosis (fig.5). Mouse and human p53 share 78% identity and 
80% similarity, with the highest homology within the central domain. 
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FigS. Schematic representation of the p53 domains  and post-translational modifications. The 
functional domains are: TA = transactivation. PRD = Pro-rich domain, DBD = DNA-binding 
domain. NLS = nuclear localisation signal. CTD = carboxy-terminus domain. The Ser 
residues, which are phosphorylated by ATM, CK1, CAK, Cdk, PKC/PP112a are shown. The 
Lys residues, which are acetvlated by pCAF and p300 are shown. The Ser residues that are 
presumed (question marks indicate this) to be phosphorvlated in vivo under UV and IR 
exposure are also shown. The 376Ser residue is believed to be dephosphorylated under IR 
exposure (Giaccia & Kastan. 1998). 
p53 protein is post-translationally modified and this has a major impact on the 
protein, affecting protein levels, conformation (hetero- or homo-oligomerisation), function, 
protein-protein interactions and DNA-binding affinity. p53 protein can be reversibly 
phosphorylated, both in vitro and in vivo, at Ser residues located in the N- and C-terminus 
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domains,  Several different kinases phosphorylate numerous serine and threonine residues 
within N-terminus and C-terminus regions of the protein p53 in vitro and this is believed to 
modulate p53 functions (Giaccia & Kastan, 1998). For instance, Cdk2-cyclin A and Cdk2-
cyclin B phosphorylate p53 at the Ser3 15 residue and this stimulates p53 binding to p2  1 and 
GADD45 sites. The Cdk2-Cyclin E do not phosphorylate p53 and this is consistent with 
results of under-phosphorylated p53 in the GI phase of cell cycle (Harris. 1996). It is 
believed that simultaneous phosphorviation occurs in vivo at several sites, in the basal state 
and as a response to various stimuli. It is presumed that IR, for instance induces 
phosphorviation at Ser15 and dephosphorylation at Ser376, whilst UV induces 
phosphorviation at Ser 15, 33 and 392. Phosphorylation at Ser20, or 37 or 15 increases 
protein stability via disruption of MDM2-p53 complexes. Functional studies of the different 
phosphorvlation sites are not clear, probably due to variability in cell types and p53 proteins 
used. For instance, mutations at 392 reduce the ability of p53 to suppress transformation 
whilst the growth suppressive function is not affected. Also loss of phosphorylation sites 
show either no effect or diminished ability to modulate cell cycle progression or growth 
inhibition. One study investigated the possibility of combination of mutations at many sites 
and their effect on the p53 functions. In this study, a mutant p53, with substitutions in both 
N- and C-terminus phosphorylation residues had no detectable phosphorylation, whilst 
mutants in either N or C-terminus had reduced phosphorylation. Also, SerlS proved to be a 
major phosphorvlation site as mutation at this site reduced phosphorylation to the same 
extent as all other mutations in N-terminus together. (Ashcroft et al., 1999). The same study, 
using the transactivation assay and p53-responsive promoters, showed that there was no 
difference in the functionality of the phosphorylation site mutant p53 compared to wt p53. 
U'V exposure or actinomvcin D treatment induced stabilisation of p53 mutated at critical 
phosphorviation sites with kinetics similar to those of the wt protein. These findings indicate 
that phosphorylation is not absolutely necessary in transcriptional activation by p53 or for 
regulation of its stability. This suggests the existence of other mechanisms, which act 
independently or in co-operation with phosphorylation to regulate p53 and candidate 
mechanisms would involve MDM2 phosphorylation or blockage via p14/ARF interaction. 
Another post-translational modification in p53 is acetylation. It has been shown that 
members of the histone acetvlase family, p300/CBP bind p53 and enhance p53-dependent 
transcription. In vitro experiments show that p300 and PCAF acetyl transferases acetylate 
p53 at Lys382 and 320 respectively and that acetylation works better on a phosphorvlated 
p53 and is also inducible upon DNA damage. Redox modulation allows p53 protein to take 
part in defense mechanisms against oxidative (generation of hydrogen peroxide) and redox 
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(lack of oxygen) stress, such as ischemia and reperftision injury of the brain, heart (Giaccia 
& Kastan. 1998). Redox status of p53 is achieved via Cys residues. It has been shown that 
oxidised p53 loses DNA specific binding activity, whilst bivalent metal cations bind to the 
reduced state of the protein. Other redox factors such as nitric oxide, thioredoxin and DNA 
repair endonuclease (Refi) have been shown to affect conformation and/or transcriptional 
transactivation of p53 (Oren, 1985) and (Albrechtsen et al., 1999). The active p53 is a 
tetramer, with several phosphorylated and acetylated residues. It appears that a combination 
of C-terminus phosphorviation and acetylation of p53 influences its target selectivity in a 
given cellular context in response to a specific genotoxic agent. 
p53 is a nuclear protein and its expression and stability vary according to the cell 
status: In resting cells it is almost undetectable, whereas in transformed or proliferating non-
transformed cells it is easily immunodetected. Human p53 protein has multiple isoforms, 
reactive to different anti-p53 monoclonal antibodies and detectable on SDS-polvaciylamide 
gels. It is believed that the human isoforms could result from different post-translational 
modifications or are encoded by different mRNAs, although they co-migrate and possess 
identical sizes (Oren, 1985) 
p53 functions in multiple cellular processes, such as cell cycle, control of normal 
proliferation. DNA repair, apoptosis, transcription, senescence, transformation and 
tumourigenicitv. Its main role is to "guard" the genome and counteract the effects of endo-
and exo-genous mutagens. In response to genotoxic stress or in transformed cells p53 
becomes more stable, with up to five-fold increased half-life and increased mRNA 
translation. p53 functions in all cellular processes via protein-protein and DNA-interactions. 
It interacts directly with proteins involved in repair (XPD. XPB. RPA, p62. topoisomerase I, 
CSB), DNA synthesis. RPA. PCNA) or induces transcription of gene involved in cell cycle 
arrest (p21), orapoptosis. The most studied function of p53 is transcription transactivation of 
genes involved in cell cycle arrest or apoptosis upon DNA damage. DNA damage is 
repaired, during the growth arrest and if it fails, the cell is eliminated via apoptosis. 
p53-dependent cell cycle arrest occurs either before DNA replication in 01 or before 
mitosis in G2. GI arrest is mainly a consequence of p21 transcriptional transactivation. p21 
is a kinase inhibitor, which blocks CDKs. As a result. Rb is maintained in an under-
phosphorvlated state and Rb-dependent genes involved in S phase entry are not transcribed. 
p21 can also operate in S phase, by binding PCNA. As a result the elongation step in DNA 
replication is stalled and cell cycle progression slowed down. 02 arrest involves p21 via 
cyclin A and B interaction. Induction of p53-mediated apoptosis requires transcriptional 
transactivation of specific genes bax, fs/Apo, Killer/DR5, PIGs (Albrechtsen et al., 1999). 
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The decision between growth arrest and apoptosis depends on the severity of the DNA 
damage, cell type and presence of survival factors. 
Other genes involved in p53-dependent or -independent cell cycle arrest are [NK4a 
genes. ThlK4aJpl6. INK4aJp14ARF genes are encoded by the IINK4a locus. [NK4aJpl6 
protein is encoded by the exons lcx, 2 and 3. INK4aJpI4ARF is encoded by the exons 113.  2 
and 3, with exon 113 located 13-20kb upstream of exon lix. Both transcripts are similar in 
size but totally different in sequence because exon 113 is not in frame with sequences 
encoding INK4aJp 16. INK4a proteins have similar function to p21, they inhibit CDKs and 
induce GI cell cycle arrest. Of the two components, [NK4aJpl6 is the important tumour 
suppressor gene working via the Rb pathway. A recent study on tumour cell lines shows that 
H'1K4aIpI4ARF arrests the cell cycle in a p53-dependent manner, with upregulation of p53, 
MDM2 and p2  1. In their study co-transfection assay shows that INK4aJp 14ARF form a 
ternary complex with MDM2 and p53 and it is its binding with MDM2 that stabilises the p53 
protein. p53 in turn down regulates [NK4aJp14ARF, as it was only detected in p53-defective 
cell lines. p53 defective cell lines show resistance to pI4ARF-dependent growth arrest. 
Studies on mouse cells lacking p5  show resistance to pI9ARF (the mouse homologue of the 
p14ARF) induced cell cycle arrest. Also. ARF nulls have intact p53 response to IR and UV, 
suggesting that ARF does not activate p53 in response to damage. The proposed mechanism 
is that ARF acts upstream of p53. in connection with mitogenic signals. If these signals 
exceed a critical point, the p53 dependent response is triggered, leading to growth arrest or 
apoptosis. Oncogenic signals from ras and myc are believed to induce the ARF-p53 response 
(Sherr, 1998), (Stott et al., 1998). ARF is important in tumour surveillance, because of the 
ability to sense hyperproliferative stimuli and as a result to activate and induce a p53 
response. Loss of ARF is associated with cancer. Mice with disrupted INK4a exon 113 
develop normally but have a high incidence of spontaneous tumours. Human tumours such 
as melanomas, biliarv tumours. pancreatic, esophageal and non-small-cell lung carcinomas 
have INK4aJpl6 mutations. Other tumours, leukemias, bladder and nasophaxyngeal 
carcinomas, glioblastomas multiforme and astrocytomas frequently have rNK4aJp14ARF 
deletions (Sherr, 1998). 
1.2.4.3. p53 and NER 
UV radiation is a strong inducer  of p53. After UV radiation, either the stalled 
transcription machinery at the damage site or the strand breaks resulting from excision repair 
or replication past thvmine dimers trigger p53 induction and phosphorylation, mainly at the 
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residue Ser 392 (Giaccia & Kastan, 1998). The induction pattern, seen in mouse fibroblasts 
and human lymphoid and fibroblast cells shows that high levels of p53 are seen 6-8 hrs after 
UV radiation. Activated p53 stops the cell cycle and allows for the damage to be repaired by 
the GGR pathway. Little is known about involvement of p53 in the repair pathway itself. It is 
known however that p53 stimulates transcription of the p48 gene (disrupted in XP-E) 
irrespective of the DNA damage status. XP-E patients have a mild UV sensitivity but an 
increased risk for skin cancer. A studs' on p48 and p21 mRNA levels in p53+/+ and -I- cells 
showed that UV and IR induced transcription of p48 and p21 by a p53-dependent pathway. 
The p48 and p21mRNA levels in p53+1+ cells were higher than in p53-/- and after UV 
irradiation or ionising radiation they increased by several folds. p2l niRNA did not depend 
on p53. The p48 and p2lmRNA levels in p53-I- cells were restored when p53 was induced 
by a tetracycline-regulated promoter in the absence of UV or IR. The same study showed 
that XP-E cells had a similar NER phenotype to that of LFS cells: normal ICR, with 
efficient removal of CPDs from the transcribed strand, but reduced (JGR_ with defects in 
removing CPDs from the non transcribed strand. Therefore there is evidence that GGR of 
CPDs is p48 dependent (Hwang et al.. 1999) 
Evidence exists for p53-dependent and -independent pathways and for its 
participation in repair pathways via protein-protein interactions, p53-dependent repair is 
supported by survival experiments and by repair assays on Li-Fraumeni strains (LFS). 
Survival experiments show that fibroblast cell lines lacking or mutated in p53 have 
decreased survival after UV exposure, in comparison with normal fibroblasts. In the same 
study, wt-p53, mutated-p53 and null-p53 cell lines show CPD removal of 56%, 44% and 
37% (Wani et al., 1999). LFS p53 defective-fibroblast strains have been associated with 
deficient GGR and less recovery of DNA and RNA synthesis after UV radiation, features 
also seen in XP and CS disorders. Reduced GQR was observed in primary fibroblast cells 
expressing the HPV E6 oncogene, which stimulates the proteolytic degradation of p53 and 
blocks the p53-dependent response. p53 is also involved in TCR. Evidence comes from 
several experiments. Inhibitors of DNA polymerases generate strand breaks. These 
inhibitors can be used after UV irradiation, as a measure of excision of UV-induced DNA 
damage in specific genes. In LFS cells, this type of repair was reduced in the genome and in 
the c-myc gene, indicating that LFS cells are defective in GGR and TCR. In other 
experiments, LFS cells did not produce reactivation of the reporter gene. This implies a 
defect in TCR, as the reporter gene expression requires the removal of lesions which blocks 
transcription. These results suggest a role of p53 in TCR. Therefore, p53 might be also 
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involved in mRNA synthesis recovery, which after UV radiation is deficient in Cs and LFS 
cells (McKay et al., 1999). 
p53-independent repair is a contradictory issue, as proficient repair is seen in p53 
null mouse fibroblasts and in some p53 null tumour cell lines, whilst in other experiments 
p53 null fibroblasts and keratinocytes did have impaired repair. 
p53 could modulate repair via protein-protein interactions. Numerous p53 binding 
proteins and their interactions domains have been mapped following in vitro and in vivo 
experiments. It has specific inhibitory interactions with NER helicases, XPD, XPB, CSB. It 
also interacts with RPA and p62. Apart from CSB, XPD, XPB and p62 are components of 
the TFIIH complex involved in transcription initiation. RPA-p53 complex is disrupted by 
UV, leading to activation of p53 and subsequently to initiation of repair processes. The main 
function of p53 is transcriptional transactivation of p53 responsive genes therefore it binds 
specific DNA sequences. It has also affinity for ssDNA, the result of damaged DNA or of 
processing the damage. DNA damage recognition is mediated by the C-terminus, which is an 
important regulatory domain. p53 also binds dsDNA and ends of double strand breaks, 
Holliday junctions and DNA mismatches leading to DNA-bulges (Albrechtsen et al., 1999). 
One study reported that p53 has a 3'->5' exonuclease activity, conferred by the central 
domain, with possible roles in repair (Mummenbrauer et al.. 1996). 
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1.3.1. Variation in DNA repair genes and predisposition to cancer 
Increasing number of studies are reporting sequence variations in tumour suppressor 
genes and genes involved in NER or BER. At the molecular level variants within the genes 
result in amino acid substitutions or can be silent. To date, several variants have been 
reported in healthy individuals, in XPA, XPC, XPF, XPG, ERCC1, XPD, XPB, XRCC1, 
XRCC3 and XRCC4 repair genes, with allele frequencies ranging from 0.04 to 0.50 (Shen et 
al.. 1998), (Butkiewicz et al., 2000), (Khan et al., 2000), (Fan et al., 1999), (Ford et al.. 
2000). Relevant to this study are XPD, XPB, ERCCI, XPF. XRCCI and XRCC3 variants 
because these genes are involved in nucleotide- or base- excision or recombinational repair 
pathways and because there are studies on association between the variants and various types 
of cancer. 
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Silent and non-silent single nucleotide polymorphisms (SNPs) have been found in 
the XPD gene. The two silent SNPs are 156Arg in exon 6 and 71 IAsp in exon 22, both with 
allele frequencies of 0.25. Other variants have been reported in intron 4, 7, 18.19 and 22 with 
allele frequencies from 0.21 to 0.33. Four variants resulting in amino acid substitutions have 
been reported in exon 8, 10 and 23. These variants are: in exon 8, Ile I99Met and His2OlTyr 
with very low allele frequencies of 0.04; in exon 10, Asp3 l2Asn, allele frequency of 0.42; 
and in exon 23 Lys75lGln, allele frequency of 0.29 (Shen etal., 1998). All variants within 
coding sequences and especially 15 6Arg, Asp3 1 2Asn and Lys75 1 GIn have been investigated 
for correlation with risk of skin cancer. 
Two low frequency polymorphisms in the XPB gene have been found in a study on 
35 Polish individuals. Both result in amino acid changes located outside functional domains 
and they are Lys 11 7Arg and Glv402Cys (Butkiewicz et al., 2000). No studies on association 
between these variants and skin cancer have been reported yet. 
Only silent SNPs have been identified in the human ERCC1 gene in the coding 
sequences. Variants within the exons are 75Thr in exon3, 118Asn in exon4 and 154His in 
exon 5 and their allele frequencies are 0.04, 0.46 and 0.04 respectively. Variants reported in 
introns are in intron 3, 5. 6 and 3'UTR with allele frequencies ranging from 0.04 to 0.50 
(Shen et al.. 1998). Of these, the 1 18Asn and 3'UTR variants have been investigated for 
association with skin or other types of cancer. 
Several silent and only one non-silent variants in XPF gene have been published. 
One amino acid substitution variant is Pro379Ser, in exon 7, with low frequency of 0.08. The 
other variants are: T2063A in 5'U -FR with allele frequency of 0.46, two in intron 9 with 
same allele frequency of 0.38 and two in intron 1, of which one is rare and one with allele 
frequency of 0.46 (Shen et al., 1998). The 5'UTR and Pro379Ser variants have been 
investigated for association with risk of melanoma and lung cancer. 
XRCC1 variants have been described in coding sequences and non-coding 
sequences. Three amino acid substitutions have been also reported in exon 6, 9 and 10. Silent 
SNPs are 206Pro in exon 7 and 632GIn in exon 17, both with allele frequencies of 0.42. The 
rest of the variants map in intron3, two in intron 9, intron 11, intron 13, with high allele 
frequencies ranging from 0.17 to 0.42 and two with low frequencies in intron 6. Non silent 
SNPs are Argl64Trp in exon 6 and Arg399Gln in exon 10, both with allele frequency of 
0.25 and Arg280His in exon 9 with low frequency of 0.08 (Shen et al., 1998). Argl64Trp, 
Arg280His and Arg399Gln have been investigated for correlation with skin and other types 
of cancer. 
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Three SNPs that do not result in amino acid substitution and one amino acid variant 
have been detected in the XRCC3 gene in 12 healthy American individuals. Reported 
variants are in 5'U'l'R and in intron 6 with high allele frequencies of 021 and 0.38, 
respectively and in intron 4 with low frequency of 0.04. One amino acid substitution variant 
is reported in exon 7, Thr24lMet with allele frequency of 0.38 (Shen et al., 1998). Of these, 
5'UTR and Thr24lMet have been studied for association with melanoma and other types of 
cancer. 
Because some of the variants occur at high frequencies in the population they can 
have significant health consequences if proven to be of functional importance. None of these 
variants is identical to alleles previously associated with an inherited disease status 
(Mohrenweiser & Jones, 1998). At the cellular level, the non-silent polymorphisms via the 
subtle protein alteration they induce, can affect the metabolism of endo-and exogenous 
factors, metabolism and action of hormones, repair processes, immune and inflammatory 
processes, oxidant stress, signal transduction and cell-cycle control. Genetic polymorphisms 
are usually less penetrant than loss of function mutations but have higher prevalence hence, 
higher attributable risk. Therefore, polymorphic variation in these genes can be a biomarker 
for cancer susceptibility in the population. 
Molecular epidemiological studies on gene polymorphisms and cancer risk often 
result in contradictory results. Inconsistent results of case-control studies are likely to be 
generated by confounding factors such as selection criteria and size of patient and control 
group, age, gender, smoking and drinking status, histological subtypes, or other 
climcohistopathological features, if applicable. Population stratification arises when 
sampling is done without regard to ethnicity. This can cause artificial association because the 
case-control studs' contains genetically distinct subpopulations of which one coincidentally 
presents a high frequency of the studied allele. Another potential confounding factor is the 
effect of therapeutic agent and of cancer itself. Most case-control studies use cancer patients 
and this can introduce a bias, due to the treatment they have already received. This is 
particularly applicable in repair studies, where a patient undergoing chemo- or radio-therapy 
may have reduced repair, although the tumour itself may have increased repair, as it is 
known that tumours can be drug- or UV-resistant. Alternatively, the tumour itself might 
suppress or decrease repair activity through high metabolic rate which can affect 
lymphocytes and their repair values (Berwick & Vineis, 2000). 
Also some reports come from small studies with limited power, where association 
between polymorphism and risk of cancer is based on cases only, excluding controls, or from 
studies with discrepancies in the numbers of study subjects. False positive association could 
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also arise as a result of chance, due to small number of subjects or can be an artefact due to 
improper handling of the samples, or another nearby polymorphic gene can be in linkage 
disequilibrium with the studied gene. Moreover, the lack of functional studies of 
polymorphic variants makes it difficult to integrate different results obtained for the same 
gene in different research groups in different countries. Attempts on studying functional 
implications of NER gene polymorphisms have been made and have resulted in a generally, 
but not unanimously, accepted trend that NER polymorphisms are associated with reduced 
repair. 
1.3.1.1 Genetic variation in repair genes and association with cancer 
NER genes 
Of the seven known XPD polymorphisms 1 56Arg. Asp3 I 2Asn and Lys75 I Gin were 
more common and have been investigated for association with cancer. 
Positive association was found between 156Arg and adult onset gliomas. In a case-
control study, with variable number of cases (114 to 148 of glioblastoma multiforme, 
astrocytoma and oligoastrocvtoma) and controls (137-148), the 156ArgIArg variant was 
more frequent in all cases (OR=2.3) and more strongly associated with oligoastrocytoma 
(OR3 .2) than with astrocytoma (OR=2.8) or gliobiastoma (OR=2.4) (Caggana et al., 2001). 
Similarly, in a study on 66 BCC cases and 111 controls, 156ArgIArg non-variant was mildly 
protective against BCC, whilst heterozygote subjects were at --2-fold increased risk of BCC 
(P=0.056). Similar findings were obtained when only subjects with no family history of BCC 
were included: 156Arg/Arg non-variant was protective against BCC and subjects carrying 
156Arg!Arg variant or heterozygotes were at 3.3-fold increased risk of BCC (P0.007) 
(Vogel etal., 2001). 
The 156Arg/Arg variant was found to have a protective effect, 0R0.92, in a study 
in 189 SCCI-IN patients and 496 controls. The I56Arg/Arg variant was less frequent in cases 
(15.9%) than in controls (20.4%), compared to the heterozygote and I56Arg/Arg non-
variant, which were more frequent in cases (51% and 32.8%) than in controls (48.6% and 
31.1%) (Sturgis et al., Similar results and positive association between Argl56Arg 
and risk of non-melanoma skin cancer in psoriasis patients has been found in a study on 4 
groups of 20 individuals, patients with and without BCC and non-psonatics with 
and without BCC. 156Arg/Arg non-variant and heterozygote were associated with higher 
BCC risk only in psoriasis patients with OR5.33, P=0.078 and OR=3.26, P=0.138 
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respectively. The same correlation between 156Arg!Arg non-variant and early onset of BCC 
was seen in psoriasis patients (Dybdahi et al., 1999b) 
No association has been found between 156Arg and cutaneous malignant melanoma 
in a study on 125 cases (patients in stages II, III and IV) and 211 controls (Winsey et at., 
2000). 
Positive association has been found between Asp312Asn and lung cancer in a study 
in 96 non-small-cell lung cancer patients and 96 controls from Poland, matched for gender, 
age and smoking. 31 2Asp was more common in cases than in controls and the 31 2Asp/Asp 
genotype had twice the risk of lung cancer in comparison to Asp/Asn+AsnlAsn genotypes 
taken as reference (OR=l .86). Stratification by smoking habits shows that in light smokers 
with the Asp/Asp genotype the risk for lung cancer was higher (OR=5.32) than in those with 
Asp/Asn (OR= 1.7), when compared to AsnlAsn (Butkiewicz et al., 2001). 
Asp3l2Asn was associated with BCC only among subjects with family history of 
BCC (Asp/Asn+AsnlAsn 0R5.25, P0.027) in a study on 68 cases and 105 controls (Vogel 
et at., 2001). Asp3l2Asn was not associated with cutaneous mignant melanoma in a study 
on 125 cases (patients in stages II, III and IV) and 211 controls (Winsey et al., 2000). 
The Lys75lGln was not associated with risk of bladder-cancer in a study in 124 
patients and 85 controls (Lys/Gln+GlnlGln versus Lys/Lys 0R0.94, P0.69) (Matullo et 
al., 2001). Similarly, no association has been found between Lys751Gln and melanoma 
development in a study on 125 cases of melanoma (patients in stages II, III and IV) and 211 
controls (Winsey et at., 2000). 
Lys75 1 Gin has been genotyped in 189 SCCI-IN patients (primary tumours of the oral 
cavity, oropharynx, hypopharyrix and larynx with histopathologic diagnosis of SCC) and 496 
controls. 751GInIGln was more common in cases 16.4% than in controls 11.5% and was 
associated with a borderline increased risk (0R1.65) compared to no increased risk for 
Lys/Gln OR=112. 75lGlnlGln was more frequent in smokers and drinkers and associated 
with borderline risk OR'l .83 in current smokers and increased risk OR=2.59 in current 
drinkers and older subjects, 0R2.22. In comparison, 751 Lys/Gin and 751 Lys/Lys had the 
same frequencies in both groups and Lys/Gln+Lys/Lys versus GlnIGln genotype has 
OR= 1.55 and borderline increased risk (Sturgis et al., 2000). 
Positive association was found between Lys75 iGIn and risk of non-melanoma skin 
cancer in psoriasis patients. The study was carried out in 4 groups of 20 Danish individuals, 
psoriasis patients with and without BCC and non-psoriatics with and without BCC. 
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75 1 Lys/Lys was associated with the highest risk of BCC, OR=4.32, P=0.075, whilst Lys/GIn 
had OR=3.72, P=O. 118. Also 75lLys/Lys was associated with earlier onset of BCC than 
subjects with Lys/Gin or Gin/Gin (Dybdahi etal., 1999b). 
70 BCC cases and 117 controls were genotyped for Lys75 I Gln. Only subjects with 
family history of BCC and Lys/Gln±Gln/Gln genotype had a 3.6 fold increase in risk in BCC 
(OR=3.64, P=0.092) (Vogel et al., 2001). In opposition with Dybdahl et al., (1999b). where 
Gin had a mild protective effect. 
There are two common findings in the studies on association between XPD 
polymorphisms and cancer. First is that 156, 312 711 and 751 polymorphisms are linked 
(Caggana et al., 2001), (Vogel et al., 2001), (Dybdahl et al., 1999b). Second, there is 
association between 156, 312 and 751 polymorphisms and skin or non skin cancer, where in 
each case either the normal or variant allele showed protective effect, depending on the 
study. 
The XPF protein forms a complex with ERCC1 involved in incision at the 5' side of 
the DNA damage. XPF C2063T 51JTR and 824Ser variants have been investigated for the 
association with melanoma risk in a study of 211 controls and 125 cases of melanoma 
(patients in stages II, III and IV). Initial results show a significant association between both 
variants and melanoma: iT 5'UTR genotype. OR=1.65. P=0.038; 824Ser, OR'0.62, 
P=0.045. The association was reduced in significance, when the heterozygote frequencies 
were included and when corrected for multiple comparisons (P=0.38 and P=0.45). However, 
both XPF variants and XRCC3 241Met!Met seem to have an additive effect on melanoma 
development (Winsey et al.. 2000). 
The ERCC1 protein forms a complex with XPF protein, involved in incision at the 
5' side of the DNA damage. Variant 1 l8Asn has been screened for in 125 cases of 
melanoma (patients in stages II, III and IV) and 211 controls and has shown no statistically 
significant association with melanoma (Winsey etal., 2000). Polymorphism 3'UTR A8092C 
has been investigated for association with risk of adult-onset brain tumours. 122 glioma 
cases (oligoastrocvtoma, astrocvtoma, glioblastoma) and 159 controls were screened for the 
A8092C polymorphism. Prevalence of CC genotype was more common in oligoastrocytoma 
82%, followed by astrocytoma 63% and glioblastoma 48% comparing to controls 51%. The 
age-adjusted OR for CC genotype in oligoastrocytoma patients versus controls was OR=4.6, 
OR1 .7 in astrocytoma versus controls and OR=0.9 in glioblastoma versus controls. All 
cases versus controls had OR= 1 .4. In all three types of case the CC genotype was associated 
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with younger age of onset than cases with AA or AC. (P=0.04) (Chen et al., 2000). To date 
there are no other cancer risk association studies or functional studies on ERCC 1 variants to 
compare to the results of this study. ERCC1 3'UTR polymorphisms could affect ERCC1 
function, by introducing changes in ERCC 1 structure seen in mRNA levels, or alternative 
splicing. It is also known that the 3'UTR of ERRCI overlaps with the 3' end of ASE-
1/CAST gene, which encodes a protein of unknown function. The A/C polymorphism in the 
3'UTR of ERCC1 is located in the coding sequence of the ASE-1 gene, resulting in amino 
acid change Lys504Gln, which results in a reduction of a Lys/Arg repeat found in the 
structure of the protein and possibly a reduction of function. 
BER genes 
XRCC3 is structurally related to RadS 1. It is involved in the homologous double-
strand break repair pathway, where the repair process occurs through recombination between 
the damaged strand and a homologous sequence present on the second copy of the gene. 
XRCC3 deficient cells have genetic instability, manifested as chromosomal fragmentation, 
translocations or deletions, which are potential carcinogenic events. A recent UK study 
investigated the correlation between polymorphisms in XPF. XPD. XRCC1 and ERCCI and 
cutaneous malignant melanoma. Of these, it has been found that one of the two XRCC3 
polymorphisms studied is associated with development of melanoma. The two XRCC3 
variants Thr24 1 Met and 5' UTR were studied in 211 cadaveric renal transplant donors and in 
125 primary melanoma patients stages II, III and IV. Thr24 1 Met variant had allele frequency 
of 0.30 in controls and 0.43 in cutaneous malignant melanoma patients. Variant S'UTR had 
an allele frequency of 0.23 in controls and 0.22 in melanoma patients (Winsey et al., 2000). 
The paper found that the 241 Thr/Thr genotype was significantly associated with melanoma 
development (P0.004. OR=2.36, relative risk 1.74). 
Association between the Thr24 1 Met polymorphism and other types of cancer is 
uncertain. A study from Italy on 124 cases and 85 controls shows a positive association 
between this polymorphism and bladder cancer risk (OR=2.77, P=0.0007). The association 
was higher in non- and ex-smoker patients (0R5.2 and OR=4.8) comparing to current 
smokers (0R1.8) (Matullo et al., 2001). In another study in 96 non-small-cell lung cancer 
patients and 96 controls from Poland, matched for gender, age and smoking the Thr24 1 Met 
polymorphism was not associated with risk of lung cancer (Butkiewicz et al., 2001). 
XRCC3 could be a candidate gene for cancer susceptibility, as it is involved in DNA 
damage repair and it is known that unrepaired damaged DNA is the first event in radiation 
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induced carcinogenesis. As far as the particular association with primary melanoma is 
concerned, the statistical data of this study need to be extended and complemented by 
functional analysis of this XRCC3 polymorphism. 
XRCC1 is a repair gene involved in repair of ionising radiation damage. It maps on 
chromosome 19q13.2-13.3, the same region where the XPD, ERCC1 and LIG1 genes are 
located. XRCC 1 protein interacts with LIGIII in re-joining strand breaks generated by X-ray 
or by base excision repair. Two common XRCC1 polymorphisms. Arg194Trp and 
Arg399Gln have been investigated for association with risk of cancer. A study in 203 
squamous cell carcinoma of head and neck (SCCHN) patients and 424 controls study 
showed that 194Arg/Arg and 399GlnIGln genotypes are associated with increased risk of 
SCCI-IN (194Arg/Arg, 0R1.34; 399Gm/GIn, OR=1.59; and OR=2.02 for the combination 
of two). The adjustments for age, sex, ethnicity, smoking and drinking status showed that 
194ArgIArg and 399Gln/Gln are risk genotypes for individuals under 50 years of age and 
tobacco and alcohol users, a category where the 399Gln/Gln genotype seems to have an 
increased risk (OR=3.18 for tobacco and OR=2.12 for alcohol users) (Sturgis et al., 1999) 
No consistent association has been found between Arg194Trp and Arg399Gln 
polymorphisms and risk of bladder cancer. In one study in 124 Italian bladder cancer patients 
and 85 controls the Arg399Gln polymorphism was not associated with risk of bladder cancer 
(399Arg/Gln+399GlnJGln versus 399Arg/Arg give OR0.6 P0.69) (Matullo et al., 2001). 
In another study in 235 bladder cancer patients and 213 controls, Argl94Trp had a protective 
effect of borderline statistical significance, whilst a minor not significant decrease in risk has 
been seen for 399Gln/Gln, OR=0.7, P=0.35 (Stem et al., 2001). 
Argl94lrp and Arg399Gln variants did not show association with cutaneous 
malignant melanoma in a study on 125 cases (patients in stages II, III and IV) and 211 
controls (Winsey et al., 2000). 
I.3.2.Variation in NER capacity (reduced repair) and predisposition to cancer 
Cellular NER capacity can be measured and quantified using several in vitro assays, 
in which UV irradiation is the main genotoxic treatment. One of these is measurement of cell 
survival, usually by cloning efficiency. Cloning efficiency counts the number of cells, which 
after irradiation are able to give rise to a cellular clone. Another assay measures the 
unscheduled DNA synthesis after UVC irradiation. This assay quantifies NER level usually 
in mononuclear blood cells (monocytes and lymphocytes) by counting the amount of 
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replicated DNA corresponding to the synthesis of the 30-mer gap. The 30-mer gap is the 
result of the XPF/ERCC 1 and XPG endonuclease activity, which removes a DNA segment 
of 27-30 nucleotides containing the lesion. Host cell reactivation (HCR) assay is used in 
many epidemiological studies. This assay is based on the repair of a damaged plasmid 
transfected into human lymphocytes. The efficiency of repair is measured by quantifying the 
expression of the reported gene, usually chloramphenicol-acetyl-transferase (CAT), carried 
by the plasmid. Comet assay, or single cell gel electrophoresis measures the level and the 
repair of single-strand breaks induced by ionising radiation, but it can be also used to 
measure the early breaks produced in the NER process. The Comet assay has been used in 
epidemiological studies looking at DNA damage levels in human lymphocytes. Cytogenetic 
assays detect unrepaired mutagen-induced chromatid aberrations (breaks and gaps) in 
cvtogenetic preparations of metaphase lymphocytes. This type of repair assay can be used in 
epidemiological studies using short-term cultured lymphocytes and X-ray or bleomycin, a 
radio-mimetic drug (Benhamou & Sarasin, 2000). 
DNA repair capacity, measured in different studies in cancer patients ranges from 60 
to 80% of the population mean. In comparison XP patients have NER capacity of 1-2% of 
normal. The majority of epidemiological studies on breast and lung cancer and recently skin 
cancer report reduced DNA repair capacity as a risk factor for cancer, with OR values 
ranging from 1.6 to 10.0 (Mohrenweiser & Jones, 1998) 
There are several studies looking at the epidemiology of UV induced DNA damage 
repair capacity and risk of non-melanoma skin cancer. The majority of these studies use 
HCR to measure NER capacity, but also UV-induced unscheduled DNA synthesis, Comet 
and cytogenetic assays are used in others. DNA repair capacity (DRC) measurement reported 
in all HCR usually corresponds to the percentage of CAT activity expressed from a 700J/m 2 
UVC-irradiated plasmid relative to the non-irradiated plasmid. 
A report from the US on 88 BCC patients and 135 controls shows lower DRC values 
between cases and controls. Individuals who had a DNA repair level below the 30th 
percentile of the controls had a greater than 2-fold increased risk for BCC (OR=2.3, 95% Cl 
1.24.5 adjusted for age). Reduced repair levels were seen in the control subjects with BCC 
family history, similar to those of the cases. Their study showed an age-related reduction in 
DRC in both cases and controls. although it only reached significant decline in the controls 
where a 25% decrease in cumulative DRC over a 40-year period was observed. A direct 
correlation between lower DRC and increased number of tumours was reported in this study. 
Individuals with DRC below 30th percentile of controls were associated with 2.3-fold (95% 
CI 1.17 to 4.54-fold) increased risk for the occurrence of BCCs. A low DRC level was 
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correlated with great number of tumours in individuals after adjusting for age (p<O.OS) 
(Grossman, 1997). The same research group, using the same patients and controls previously 
reported association between low DRC and light skin (type I, II, OR=3.2), six or more severe 
sunburns (OR=4.2) and sun-related skin lesions (OR=4.4) (Wei et al., 1994). Both studies 
correlate low DRC with increased BCC risk. 
The same conclusion comes from a report in Denmark, on 80 persons divided in 4 
groups of 20 of psoriasis patients with and without BCC and non-psoriatics with and without 
BCC. Their HCR assay shows that psoriasis patients with BCC have lower DRC than 
patients without BCC (P0.015). Psoriasis patients without BCC had slightly higher repair 
than controls and non-psoriatics with BCC have the same levels of DRC as the healthy 
controls. The psoriasis patients were divided into groups of high and low repair by the 
median (cutoff value) of the healthy control group. As a result low repair was associated 
with 6.4 fold increase (0R6.42, P=0.008) in skin cancer risk compared with individuals 
with high repair (Dybdahi et al., 1999a). The same case and control groups analysed by 
Comet and UDS assays give consistent results, which support the HCR findings. Psoriatics 
with BCC had a lower level of UDS compared to psoriatics without BCC (P<0.007) and 
healthy persons (P<0.08). All cancer patients had lower UDS compared to non-cancer 
patients (P=0.07) (Moller et al., 1998). 
In opposition with these results are two studies, one from Italy and one from 
Australia. The study in Italy. on 49 BCC cases and 68 controls used HCR assay to determine 
the repair rates. In this study the level of DRC decreased as a function of UV dose in both 
cases and controls, independently of age. Younger cases had slightly lower but not 
statistically significant DRC. Over 40 years of age BCC patients had higher repair rates than 
controls at 350 and 700J/m 2 . Age related DRC decline is seen only in controls and not in 
cases (DErrico et al., 1999). An Australian population-based case-control study on 87 cases 
and 87 controls did not find low DRC in cases compared with controls. Although not 
significant, DNA repair capacity per 350J/m 2 increment was 1.07 greater in BCC cases than 
in controls and 1.04 times greater in SCC cases than in controls. DRC did decrease with age 
in both cases or controls (Hall et al., 1994). Despite the existence of these two reports and 
their negative results, the majority of reports sustain positive association between reduced 
repair and risk cancer. This is a more plausible result, from a biological and epidemiological 
point of view, as all positive studies looked at different subjects sampled from different 
populations. 
There are less studies on the epidemiology of the NER capacity and melanoma risk. 
HCR assay has not been applied to lymphocytes isolated from CMM patients. Melanoma 
cell lines, isolated from metastatic tumours display UV resistance due to increased repair of 
the photoproduct (Xu el al., 2000). One study measured DRC in Japanese XP patients of 
different ages with cutaneous malignant melanomas on sun-exposed areas. DRC was 
measured using UDS in fibroblasts grown from biopsies. Their results show that low repair 
rates, 5-30% tJDS are associated with early age of melanoma development (Takebe et al., 
1989). Another study investigated the repair kinetics of UV-induced DNA repair in skin in 
situ, on 17 melanoma patients and 13 controls. In this study patients and controls received a 
dose of 40mJ/cm 2 on unexposed buttock skin. Skin biopsies were taken at three sampling 
time points after ITV exposure and CPDs and 6-4PPs levels were measured using 32 P-
postlabeling HPLC method. Their results suggest a normal repair rate in CMM patients. At 
any time point CMM patients had the same levels of photoproducts as the controls. Also the 
faster repair of CPD TT=C compared to TT=T has been seen in both groups (Xu et al.. 
2000). Potential bias on these data is introduced by the use of whole epidermis, reflecting 
photoproduct levels in keratinocytes rather than in melanocytes. Also, this study measured 
global repair on these types of photoproducts and it is possible, that the TCR or the repair of 
other types of DNA lesion, such as DNA strand breaks and cross-links may be affected. 
1.3.3. Correlation between XPD po1vmohisms, repair capacity and cancer susceptibility 
There are six studies published on XPD polymorphisms and correlation with DNA 
repair capacity. The results are inconsistent, in the case of Asp3 1 2Asn, Lys75 1 Gin, which 
were found to have either no effect or low or high risk of sub-optimal DRC in various types 
of cancer. Argl56Arg showed a slightly higher repair rate in only one study, which might 
correlate with the slight protective effect reported in a study on association with risk of BCC. 
Asp3l2Asn, Lvs751Gln and Argl56Arg polymorphisms have been investigated for 
correlation with DRC levels measured by HCR assay, in a case-control study on 80 Danish 
individuals, divided in 4 groups of 20 psoriasis patients with and without BCC and non-
psoriatics with and without BCC. Their results showed no correlation between Asp3 I2Asn 
and Lys75 iGIn polymorphisms and DRC levels. 156ArgIArg variant genotype had slightly 
higher DRC rates 7.83% CAT activity at 700J/m 2 compared to 7.76% for heterozygotes and 
7.46% for 156Arg/Arg non-variant genotype but these figures are not statistically significant 
(Vogel et al., 2001; Dvbdahl et al.. 1999b). 
Another study investigated Lys75lGin and Asp3l2Asn polymorphisms and DRC 
levels in 341 lung cancer cases and 360 age-, sex-, ethnicity- and smoking-matched controls. 
In this study DRC levels, measured by HCR assay were statistically significantly lower in 
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cases than in controls (7.8 versus 9.55%, P<0.001). representing an average reduction of 
18%. Association between XPD genotypes and risk for sub-optimal repair was stronger in 
cases than in controls. 751Gm/Gin showed OR=1.57 risk for sub-optimal repair, 
3 i2AsnJAsn showed OR=3.50 risk and the strongest association. Presence of either of the 
two variant alleles has OR=l .23 risk for sub-optimal repair and cases homozygous at either 
locus (two or more variant alleles) have OR2.29. This study suggests association between 
less optimal DRC and XPD polymorphisms in lung cancer patients (Spitz et al., 200 1) 
In another study XRCCI Arg399Gin and XPD Lys75 I GIn relation to host damage, 
expressed as sister chromatid exchange (SCE) frequencies and number of polyphenol 
adducts has been investigated in 76 healthy subjects. SCE and DNA or protein adducts are 
markers of genotoxicity, which in some studies correlate with inherited predisposition to 
cancer and defective DNA repair. It has been found that XRCC I 399GlnlGln was associated 
with higher SCE frequencies in smokers and more adducts. XPD Lys/75lGln polymorphism 
was not associated with SCE frequencies, (0R1.2, P=0.09) or number of polvphenoi 
adducts (OR= 1.2, P0.6) (Dueli etal., 2000) 
Lvs75 1/Gin, lIe l99Met and Asp3l2Asn polymorphisms have been compared with 
repair proficiency of X-ray induced chromatid breaks and gaps in 31 women. In this 
cytogenetic assay the X-ray induced chromatid aberrations have been used to assess DNA 
repair proficiency. This study showed that the 75 iLys/Lys genotype was associated a higher 
number of chromatid aberrations and sub-optimal repair (0R7.2, P=0.035). lie l99Met was 
not present in this group. Asp3 l2Asn polymorphism did not affect DNA repair proficiency 
in this study group (ORl.8, P=:0.47) (Lunn et al., 2000). The relevance of this study can be 
questioned, because of the small sample of subjects, already categorised at risk for breast 
cancer and NER measurement in an assay involving ionising radiation. However, 
cvtogenetic assays have been used to detect reduced repair activity in XP heterozygotes in 
situations where conventional assays for NER have failed (Parshad et al., 1990). 
A recent study on 44 Finnish volunteers investigated the effects of Asp3 l2Asn and 
Lys75 I GIn on the rate of repair of two specific CPDs (TT=C and TT=T). In this study the 
DNA repair test was based on quantification of UV induced photoproducts in human skin 
biopsies by the 32P post-labelling technique. The subjects included 17 melanoma and 10 
BCC patients and 17 controls. This study showed that in all subjects exon 23 genotypes had 
the same rate of CPD repair. Exon 10 31 2AsnIAsn (6 individuals) had reduced rate of repair 
of TT=C CPD compared to Asp/Asn or Asp/Asp genotypes. The double homozygotes, 
Asn/Asn+GlnIGln (4 individuals) had subnormal TTC CPD repair and the mean rate was 
50% of the rates of other genotypes. Of the double homozygotes, two were below 50 years 
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of age (mean repair rate 46.1%) and two were older (mean repair rate 8.5%). Similar results 
were obtained for the repair rates of TTT CPD. Stratification by age only showed that exon 
23 C-allele (Gin) was associated with reduced repair in subjects older than 50 years. The 
relevance of this study in terms of statistics is minor, due to the extremely small number of 
subjects. Biologically, the association of exon 23 C allele with reduced repair in older 
subjects is in line with the study where C-allele was associated with risk of SCCI-IN in older 
subjects (Hemminki etal., 2001). 
In summary and despite the inconsistent data, the studies on XPD polymorphisms 
show that Lys75 I allele is associated with reduced repair and increased risk of cancer 
development. Next in line is XPD Asp312ASn. Also studies on XRCCI, which is involved 
in another excision repair pathway appear to indicate it as a potential susceptibility gene for 
cancer development. 
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It is known that a complete lack of NER leads to the XP, an inherited disease where 
there is a 1000 fold increased risk of cancer. Little is known about the functionality and risk 
for cancer development of the subtle alterations, single nucleotide po1morphisms (SNPs) in 
the NER genes. Increasing number of studies are reporting silent and non-silent SNPs in NER 
and BER genes. Genetic polymorphisms are usually less penetrant than loss of function 
mutations but have higher prevalence hence, higher attributable risk. Therefore, polymorphic 
variation in these genes can be a biomarker for cancer susceptibility in the population. 
In this context, this thesis was set out to find out how much polymorphism occurs at 
specific sites in two NER genes and if these sequence variations may be contributing risk 
factors of skin cancer development. Also a current research topic is to investigate these 
polymorphisms and association with various types of cancer, which in some cases showed 
positive results. A possible explanation for the positive association between NER SNPs and 
cancer risk is based on the reduced repair capacity. Alternatively NER gene polymorphisms 
might predispose to skin cancer because of altered interactions with cell cycle control 
machinery: a weaker p53-mediated cell cycle arrest after LTV-induced DNA damage, could 
increase the likelihood of DNA replication proceeding on a still damaged template with a 
resulting increased likelihood of skin cancer. Two NER genes have been chosen in this study, 
XPB and XPD. Both XPB and XPD proteins are essential for the NER pathway and in 
transcription, because they are components of the TFIIH. SNPs in both genes have been 
reported with relative high frequencies in the general population. Both proteins interact 
physically and functionally with each other and with p53 protein and both are required for the 
p53-mediated apoptosis. Therefore it is possible that polymorphisms in these two genes might 
result in an altered p53 response to UV induced DNA damage. 
This study investigated XPB and XPD possible sequence variation in melanoma 
patients and healthy population. Blood samples have been collected from cases and controls 
and DNAs have been extracted. In order to look for sequence variation each individual exon 
after PCR amplification is analysed by SSCP and/or RFLP and, if variation is observed, also 
by sequencing. Once the variants have been confirmed, all samples are genotyped and the data 
are statistically analysed for association with melanoma. 




Primary antibody. Oncogene research: Ab-7, 1/2500 dilution, 0.5% milk, Sheep polyclonal 
raised against human p53 (expressed in E.coli) 
Secondary anti bodv.Scottish Diagnostics: antisheep IgG- HRP 1/5000 dilution, 0.5% milk 
Actin antibodies 
Primary antibody, Santa Cruz Biotechnology: Actin 1-19. 1/300,1/400,1/1000 dilution 0.5% 
milk, goat polyclonal IgG 
Secondary antibody Scottish Diagnostics: antisheep IgG-HRP, 115000 dilution, 0.5% milk 
11.1.2. Buffers 
Ix buffer Cl -cell lysis buffer [320mM Saccharose, 5mM MgCl 2 , 10mM Tris/HC1, 1% Triton 
X-100, pH 7.5] 
Buffer G2-general lysis buffer [800mM Gu.HCI, 30mM EDTA, 30mM Tris/HC1, 5% Tween-
20, 0.5% Triton X-100. pH8.01 
Q BT-equilib ration buffer [750mM NaCl. 50mm MOPS, 15% Ethanol, 0.15% Triton X-100, 
pH7.0] 
QC-wash buffer [1 M NaCl. 50mM MOPS, 15% Ethanol, pH7.01 
QF-elution buffer [1.25M NaCl, 50mM Tris/HCI, 15% Ethanol, pH7.0] 
Ix PCR buffer [5mM KC1, 0.15mM MgCl,, 1mM Tris/HC1, 0.045% Triton X-100, 0.045% 
Tween-20, 0.00 1% gelatin] 
QlAquick buffers PB, PE, EB [elution buffer 10mM Tris/HC1, pH8.5], Qiagen 
Sample buffer [100mM EDTA pH 8. 0, 0.1% BromPhenol Blue, 20% Ficoll] filter sterilized 
lOx TBE: 0.9M Tris/HC1, 0.9M boric acid, 20 mM EDTA, pH 8.0 
lx TBE, running buffer for DNA eletrophoresis 
Loading buffer [95% Formamide, 20mM EDTA, 0.25% Bromophenol Blue, 0.25% Xylene 
Cyanol] 
3x SDS Red loading buffer [187.5mM Tris/HCI, 6% (w/v) SDS, 30% glycerol, 0.03% (w/v) 
phenol red], 1.25 M DTF, NEB 
lx protein Electrophoresis buffer [50mM Tris base, 192mM Glycine, 0.1% SDS, pH 8.3] 
Transfer buffer [25mM Tris base, 384m.M Glycine] 
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TBS buffer [12.5mM Tris/HC1, pH7.6, 150mM NaCl] 
TBS-T buffer [12.5mM Tris/HC1, pH7.6, 150mM NaCl, 0.01-0.5% Tween-20] 
Phosphate Buffered Saline [8mM K 2HPO4, 1.5mM KH2 PO4, 150mM NaCI] 
Lvsis buffer [125mM Tris/HC1, 32mM DTT, 2% SDS, 2mM PMSF, 2mM EDTA] 
11.1.3. Cell culture 
cRPMI: 88% RPMI-1640, 10% heat-inactivated FCS, 1% Sodium Pyruvate, 1% non-
essential amino acid, 0.5% penicillin/streptomycin 
I 0.ig/ml Concanavalin A 
lx RPMI-1640 medium with L-glutamine, liquid 
Fetal Calf serum-heat inactivated 
MEM I OOX nbnessential aminoacids without glutamine 
MEM 100mM Sodium pvruvate, liquid 
Penicillin G. Streptomycin sulfate, Sigma 
11.1.4. Enzymes 
Taq polvmerase, Promega UK 
Restriction enzymes: 
PstI. HpaII, TaqI, BRL; 
Acil, MwoI, Hinfi. Sau3AI, SphI, Fold. DrdI.NspI. BsrDl, NcoI. NEB 
Terminator ready mix, ABI 
2mg/nil Rnase A. Sigma 
20mg/mi Proteinase K. Sigma 
II. 1 .5. Molecular weight markers 
Pre-stained protein marker broad range [0.1-0.2 mg/nil of each protein in 70mM TrisHCl, pH 
6.8, 33mM NaCl, 1mM Na2EDTA. 2% w/v SDS, 1mM NaN 3, 40mM DTT, 0.01 % phenol 
red. 10% glycerol], NEB 
DNA hvperladder 1, Bioline 
1g441 100 bp DNA ladder, 0.54.t1 lambda DNA Hind III, BRL 
11.1.6. Staining solutions 
Coomassie stain [0.025% Coomassie Blue R-250, 40% Methanol, 7% Acetic acid] 
Coomassie Destain: 40% Methanol, 7% Acetic acid 
10mg/mi Ethidium bromide solution 
11.1.7. Primers 
Oligonucleotides used are listed in the table below and all are produced by Oswel, UK. 
Table 2a. XPB and XPD primers 
Gene Exon Primers Primers sequence 
XPB exon 3 A5580 (F)TCTGCAACTCATGTTTCCTTGTC  
A5581 (R)GCAGTTT'AlTAAGGCAAGTGACAGC 
exon 8 C 8558 (F)CAGTGTGAATGCTCCCATTGTTTCC 
C8559 (R)GGACAAGCCCATCGGCTGCTCCGTT 
exon 8 D 1319 (F)AGTGACAGTGTGAATGCTCCCATTG  
D1320 (R)CACACCATACCAGGTAAGCAGGCTG 
exon 9 A5582 (F)GGAGGGATTGCACTCTTGTTTC 
A5583 (R)CAGTGTGCTGAGGTAGCTGGGC 
C8556 (F)GGATTGCACTCTTGTTTCTTGTAGC 
C 8557 (R)CGCCAAAGTCCAGTGTGCTGAGGTA 
XPD exon 2 F2242 (F)AGAGGGGCTGAGGGGACGGGAACTG 
F2243 (R)CACGCCTGGGCCTAAGACAGATTGC 
exon 3-4 D8219 (F)CCAAGGTTCTGAGACCCTGTGTGTTGCC 
D8220 (R)GTGAGCACCTGTTCCYT'CTCCTTGCCCT 
exon 5 F 10252 (F)GTGCCTCCAATGAGCACAAGCTCC 
F10253 (R)CGTCCAACCACAAGTCCTGGATCC 
exon 6 F8736 (F)TGTCCAAAACCCCAGCCAGCTG 
F8737 (R)CAGGCAGCCTCCCTGACCCCTG 
exon 7 F27237 (F)CGATTCTATGAGGTTACTGGAGGGC  
F272 -38 (R)CTGCCCGCCCGTCTCCTGTCTGCC 
exon 8 Z5932 (F)TGGCAGGGCCCTGGTAACCCTGCTC  
C1110 (R)TGCCAGCCCCTCTGAGTGAGGCCC 
exon 10 Cliii (F)GTCTGACTTGTCCCCAGGGTTGCCAG 
Z 1602 (R)GCTGCCCGACGAAGTGCTGCAGGGTGA 
exon 11 F27239 (F)CCTCCCCGTCGCCGCTGATAGCGTC 
F27240 (R)CAGAGCCGTGTCCTCCACGCCTGTAGC 
exon 12 F27241 (F)CTGCTGGTCCTGCTCATGCTTCC 
F27242 (R)CAGCAGGGTCTAGAGGGTTGTTGGC 
exon 13 C8560 (F)GTAATCTCACCCCTCCTTGCCTGCC  
C8561 (R)CGGTGAGGGTGTGAATGCTCTGTGG 
exon 14 D8221 (F)CTCACTGCCCTCATCTCTCTCCAGCT 
D8222 (R)CTCCTAGTCCCTGACCTCCCTCCATG 




Gene Exon Primers Primers sequence 
exon 16 F10256 (F)CAGGTGGTCAGCACTCACGCTGGAGC  
F10257 (R)CTGAGTCATGCTGCTGTAACAAATATC 
exon 17 F2244 (F)CTCCTAGYT'CTAAGACAGAGAAGG 
F2245 (R)CTCAGTCCCTGGCACTGCACCGCT 
exon 18 F8738 (F)CTGTGCCCTGAACCCACCCTGACCTC  
F8739 (R)CTGAGGAGTGACCTAACTFGCGTCTC 
exon 19 F8740 (F )CTGAGGAGTGACCTAACTI'GCGTCTCG  
F8741 (R)GCTCTCTGGAACACCTGCCCGCTCTGC 
exon 20 F8742 (F)CTCAGACACAGCATCCTGGGTCG 
F8743 (R)CCACAGTGTTAGGATCAAGGGAG 
exon 21 F2240 (F)GAGTCCCACAGTGTTAGGATCAAG 
F2241 (R)GTGCCCCTGTGCTCCCATCCCAG 
exon 22 C8562 (F) AATGACCYTCTGTCCCTGGCCTGCG  
C8563 (R)TC CCGGCACCCTCCCAGGCTGAGCTTCT 
exon 23 D7895 (F)TCAAACATCCTGTCCCTACTGGCCAT 
D7896 (R)GTCACGTCCACAGCCTYFAATCGCAG 
Table 2.b. Primers for ERCC1 and CKMM 
ERCCI exon 3 F20475 (F)CTCAGATGTCCTCTGCTCACCCCAAC 
F20476 (R)CGGAGAAGTGAGGCCTTGAGGTFTTCAG 
exon 4 F320 -10 (F)TCATCCCTATTGATGGCTTCTGCCC 
F32031 (R)GACCATGCCCAGAGGCTTCTCATAG 
exon S F20477 (F )CTTGAAGAGACTGAGACCTCTCAACTC 
F20478 (R)CATCTGAGATGACATGGGTCACCAAG 
CKMM exon8 and 3' F32028 (F)TGATCGGCTGGGCTCGTCCGAAGTAG  
F32029 	I (R)CAGCTTGGTCAAAGACATTGAGGTGG 
11.1.8. Solutions & others 
1OmMEDTApH 8.0 
5mM dNTPs mix 
Regular Agarose or Low Melting Point Agarose, Sigma 
Acrylogel 3 pre-mix, BDH 
Acrvlamide/Bisacrvlaniide solution 30%, ratio 37.5: l-Bisacrv!aniide, Severn Biotech Ltd 
3M Sodium Acetate pH 5, Sigma 
95% and 70% Ethanol, Fisher 
Mineral oil, Sigma 
10% Ethanol, 1% Nitric acid, lmg/ml Silver nitrate, 30mg/mi Anhydrous sodium carbonate. 
40% Formaldehyde, 10% Glacial acetic acid 
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BCA-200 protein assay kit, Pierce 
1mg/mi Bovine Serum Albumin standard solution, NEB 
Immobilon-P (Millipore) transfer membrane (PVDF), with nominal pore size of 0.45micron, 
useful for blotting proteins over 1 OkDa, 
Methanol 
Non-fat dried milk powder, Marvel 
Hyperfi1m ECL Amersham Pharmacia Biotech UK, or Cronex medical X-ray film, 
Sterling Diagnostic Imaging 
ECL Plus Kit, Amersham Pharmacia Biotech, UK 
Stripping  solution [100mM 2-mercaptoethanol. 2% SDS, 62.5 mM Tns/HC1. pH6.7] 
Histopaque-1077 solution [polvsucrose 5 .7g/dL, sodium diatnzoate 9.0gJdL] Sigma 
Diagnostics 
11.2.1. Collection of blood samples for study of disease susceptibility 
Blood samples have been collected from normal donors and melanoma patients. 33 
control blood samples were randomly taken over a period of 2 years from donors to the 
Scottish Blood Transfusion Service (BTS), Royal Infirmary of Edinburgh. 28 melanoma 
blood samples were collected from individuals attending the melanoma clinic at the 
Dermatology Dept, Royal Infirmary of Edinburgh. Melanoma cases were chosen based on 
age, melanoma size and skin type. Therefore melanoma samples were collected from 
individuals under 50 years of age, with malignant melanoma (Breslow thickness of melanoma 
between 1 and 2 mm), skin type II or III, with no history of excessive sun exposure. The 
majority of patients are sporadic melanoma cases, except for four patients (D16, D18, D19, 
D20) with familial melanoma. Of the 28 melanoma cases, 4 (D13, D16. D17, D25) are 
nodular melanoma and the rest are superficial spreading melanoma. One case, D12 had 
multiple melanoma. The majority of the tumours were located on the back and leg (lower leg 
and thigh). One case had melanoma on the chest and another on the breast. Of the 28 cases, 9 
cases had preceding moles, 14 did not have and for 5 cases this is not known. Patients chosen 
were either attending the clinic for the first time or were on follow-up visits after surgery to 
remove melanoma and were regarded as incident cases. All patients consented to donating 
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lOmI of blood being previously informed about this ongoing  study. All blood samples were 
handled similarly and analysed contemporaneously. 
Table 3a. Details of control samples (in total 33) 
Sample ID Blood type Sex Age 
2336499 0+ M 29 
2344882 0+ M 42 
2353881 0± M 51 
2364352 0+ M 44 
2370972 0+ F 56 
238  
2392828 0+ F 52 
2477645 0+ NI 47 
2485699 0+ M 53 
7920040 0+ F 26 
2528681 0+ F 54 
Ql  
Q2  F47 
Q3 (2543788) 0+ M 53 
20:08  
915029E3/DC1 A+ F 40 
915030E7/DC2 A+ F 29 
915031E51DC3 0+ M 52 
915032E3/DC4 A+ F 41 
915033E1/DC5 0± M 25 
906754EXiDC6 0- F 39 
906755E8/DC8 0± M 26 
906753E1/DC7 0+ F 58 
028473Y4/DC13 0+ M 49 
028472Y6/DCI5 0+ F 43 
028471Y8/DC16 A+ F 33 
028469Y6/DC1I A+ M 49 
028470YX/DC1O A+ M 50 
028467YX!DCI2 A± M 44 
028466Y1/DC9 0+ M 57 
927204E6/DCI7 0+ F 52 
927205E4/DCI4 0+ F 41 
927203E8/DC18 	I A+ F 61 
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Sample ID Skin type Age 
Dli III 33 
D12 II EF 33 
D13 II 51 
D14 II M 50 
Dli II F 49 
D16 I M 30 
D17 Ill F 29 
D18 II M 58 
D19 I F 44 
D20 11 M 59 
D23 III F 29 
D24 II F 49 
D25 II M 42 
D26 II F 50 
D27 III F 53 
D28 I F 41 
D29 II F 36 
D30 II F 38 
D3l I M 47 
D32 II M 38 
D34 II F 42 
D35 I F 28 
D36 HI F 52 
D37 I F 49 
D38 II F 45 
D 3 9 [I M 43 
D40 II F 30 
D41 II F 36 
Table 3c. Details of the blood samples from patients with skin lesions other than melanoma (in 
total 12). 













Table 3b. Details of blood samples from melanoma patients (in total 28) 
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11.2.2. DNA extraction and concentration estimation 
11.2.2.1. DNA extraction 
Blood samples (lOml whole blood/EDTA) were obtained from all subjects. DNA was 
isolated using Qiagen genomic-tip 100 and Qiagen protocol. Whole blood was mixed with I 
volume lx ice-cold cell lysis buffer and 3 volumes ice-cold dl-1 20 by inverting until the 
suspension becomes translucent. After sitting on ice for 10 minutes, the lysed blood was 
centrifuged at 400g. 4 °C for 15 minutes. The nuclear pellet was resuspended again in 3m1 ice-
cold dl-120 and lml ice-cold lysis buffer and centrifuged at the same conditions as before. The 
pellet was then resuspended in 5m1 general lysis buffer by vortexing 10-30 seconds. 95p.l 
Protease K 20mg/mi. was added and the whole solution was incubated at 50°C for 30-60 
minutes. This solution was applied on a Qiagen Genomic-tip 100 equilibrated with 
equilibration buffer. The Qiagen Genomic-tip 100 was washed two times with 7.5m1 of wash 
buffer. Genomic DNA was eluted with Sml of elution buffer and precipitated by adding 3 .5m1 
isopropanol and then centrifuged at 4500rpm for 30 minutes. DNA pellet was resuspended in 
200.tl dH2 O and reprecipitated by adding 20.iJ 3M Sodium Acetate, pH 5 and 5001.tl Absolute 
Ethanol and centrifuged in a microfuge at fill speed for 10 minutes. DNA pellet was finally 
washed in 70% Ethanol, dried out and redissolved in 200p1 d.H20. DNA concentration was 
determined by reading the absorbance at 260nm and 280nm on an UV-Vis spectrophotometer 
(CECIL CE-2020, Cecil Instruments). 
11.2.2.2. Estimation of DNA concentration 
Optical density of a sample DNA, RNA or protein can be used to calculate its 
concentration. For DNA samples. 241 of DNA solution was added to 998p1 sterile dH20 and 
the absorbance at 260nm and 280nm was read on a spectrophotometer (Cecil CE 2020, Cecil 
Instruments Ltd). Since it is known that double stranded DNA of concentration 50.tg/m1 has 
an 0D260nm1.0, the concentration of the original sample will be given by its OD260nn  value 
multiplied by 50 and by 500 (dilution factor) and divided by 1000 to obtain the concentration 
in .ig4tl. The ratio OD260ninJOD280nm gives an estimate of DNA prep purity. A value >1.8 
indicates a good DNA prep. 
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11.2.3. PCR 
PCR assay was used to amplify 23 exons of XPD gene and 3 XPB exons. Primer 
pairs were designed using Genbank sequence entries: L47234 for XPD, M31899 for XPB, 
AC00578 1 for CKMM and M63796 for ERCC 1. Each PCR primer pair was selected -50-
60bp away from exon/intron boundaries. Genomic DNA (-100ng) was amplified in a 50pA 
reaction volume containing 1xPCR buffer, IOmMEDTA. 20-25mM dNTPs. 0.25units Taq 
polymerase and —300ng of each primer. The reactions were placed into a Techne Unit Genius 
thermocycler and subjected to different cycling condition, according to each primer pair. The 
cycling conditions are specified in the text of Chapter III. 5-10 pi of each PCR product was 
checked on 1% regular agarose gel before any further analysis. 
11.2.4. Single Stranded Conformational Polymorphism analysis 
Single Stranded Conformational Polymorphism (SSCP) analysis was used as a rapid 
and efficient screening method to detect a single nucleotide change. All XPD exons for each 
sample were individually amplified. 8.ii of each amplified fragment was mixed with Spi 
loading buffer, denatured by heating at 98 °C for 5 minutes and placed on ice 5 minutes prior 
loading on a native acrylamide gel. 30% acrylamide gel had the following composition: 1 2m1 
Acrvlogel 3 pre-mix, 1 .5m1 I OxTBE, 1 6.5m1 sterile dH20, 500p1 10% Ammonium persulfate. 
5pJ Temed. The entire sample volume of 13t1 was loaded on the gel and run in 1XTBE buffer 
under water-cooling in the cold room for 12-15 hours, depending on the size of the PCR 
product to be run. The electrophoresis apparatus used was a Hoefer S600 for small gels, size 
18cmxl6cmxlmm cast with square-tooth comb. Gels were run at 200V, 50-7OmA, for 2 gels 
back to back. DNA bands were visualised using the silver staining detection protocol. Once 
the electrophoresis was finished, i.e. both dyes were not longer visible, the gel was transferred 
to a dish for silver staining. The gel was washed in 500m1 Ethanol 10% for 5 minutes, then in 
500m1 nitric acid 1% for 3 minutes, then rinsed in 500m] distilled water. After rinsing, the gel 
was immersed in 250m1 silver nitrate 1mg/nil solution for at least 30 minutes with gentle 
shaking. Once the gel was in silver nitrate. 500m1 anhydrous sodium carbonate 30mg/mi 
solution was prepared and 25 041 formaldehyde 40% was added. The gel was rinsed in distilled 
water to remove the silver nitrate solution, then I OOml of the sodium carbonate solution was 
added. The gel was gently shaken until solution turns brown. This solution was discarded and 
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the remaining sodium carbonate solution was added, when the DNA bands started to become 
visible on the gel. Once the DNA bands were intense enough the staining solution was 
discarded. The gel was rinsed twice in distilled water and the reaction was stopped by 
immersion in 10% glacial acetic acid for 2 minutes. To have a permanent record, the gel was 
subsequently dried on filter paper on a gel drier for 2 hours. 
11.2.5. RFLP 
Between 5-1741 of each PC R products corresponding to each exon were digested with 
4-30 units of specific restriction enzymes for at least 4 hours or over night. Restriction 
reactions were usually carried on in 20.il final volume, except for XPD exon 6 and exon 8, 
where the digests were done in 300 and 5041. respectively. Restriction reactions were stopped-
either by incubating at 65 ° C for 10 minutes or by adding sample buffer. The restriction 
products were analysed by electrophoresis on regular or 1-2% low melting agarose gels made 
in 1xTBE solution (BRL model H5 electrophoresis apparatus, gel tray size 1 lcmxl4cm). 
DNA was visualised by staining with ethidium bromide. 
11.2.6. Sequencing 
11.2.6. 1. OlAquick PCR purification protocol 
QiAquick PCR purification protocol was designed to purify single- or double-
stranded PCR products ranging from lOObp to 10kb from primers, nucleotides, polymerases 
and salts using QlAquick spin columns in a microcentrifuge. 1 volume of the PCR reaction 
was mixed with 5 volumes of buffer PB and the mixture was applied to the QlAquick spin 
column, which was previously placed into a collection tube. The columns were centrifuged for 
30-60 seconds. The flow-through was discarded and the QL&quick column was placed back 
into the same collection tube. To wash bound DNA, 0.75ml buffer PE was added to the 
column. Again the flow-through was discarded and the column was centrifuged for an 
additional 1 rmin at maximum speed. To elute DNA, 30 .tl buffer EB were added to the center 
of the QiAquick column, which previously placed in a clean 1 .5m1 microfuge tube. The 
column was centrifuged for one minute and 28tl DNA solution was recovered. 
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11.2.6.2. Protocol for cycle sequencing 
Each sequencing reaction contained 81.tl  terminator ready mix, 6 p.! PCR product, 
3.2pmole primer and dH 20 up to 20p.1. The reaction mixture was overlayed with 3-4 drops of 
mineral oil and placed in a DNA thermal cycler (Hvbaid, Omnigene). The cycling conditions 
were the same for all exons: 25 cycles at 96 °C for 30 seconds, 50 °C for 15 seconds, 60 °C for 
4 minutes. After cycling, each extension product was purified before the automated 
sequencing reaction. 
11.2.6.3. Puring extension products 
Extension products were purified using an ethanol precipitation based protocol. For 
each reaction to a 0.5m1 tube was added 241 3M Sodium acetate and 50p.1 95% Ethanol. The 
entire 20p.l content of the cycling reaction tubes was added to the microfuge tubes containing 
the ethanol solution. The mix was vortexed and placed on ice for 10 minutes, then centrifuged 
in a microfuge at maximum speed for 15-30 minutes. The ethanol solution was removed and 
the pellet was rinsed with 25041 70% Ethanol. Finally, the ethanol solution was aspirated and 
the pellet was dried out. DNA pellet was now ready for automated sequencing. 
11.2.7. Statistical analysis 
Expected genotype distributions at each locus under study were calculated for both 
melanoma and controls and compared to the observed distributions in order to check their 
consistency with the Hardy-Weinberg equilibrium. Further analysis was based on the 
assumption that alleles are independent at each locus and their frequencies were compared in 
melanoma cases and controls. The tests were performed using a chi-squared test with Yates 
correction. Testing for association between several genetic markers and a disease locus or 
between genetic markers was done using the EH-extended haplotype program, available at 
http://linkage.rockefeller.edu/.  
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II 2.8. Lymphocyte preparation, culture, protein lysates 
11.2.8.1. Lymphocyte preparation 
Lymphocytes were isolated using the Density Gradient Isolation procedure. Whole 
blood (l0-20m1 fresh blood/EDTA) was diluted 1:1 with PBS. Histopaque 1077 solution was 
aliquoted 3m1 into 15m1 conical tubes. lOml of diluted blood were carefully layered over 
Histopaque 1077 solution and centrifuged at 400g for 20 minutes. Cells from the interface 
were transferred to 50ml Falcon tube and diluted 2:1 with PBS. Cells were then centrifuged 
again at 400g for lOminutes. Cell pellet was resuspended by gentle tapping in SmI PBS and 
transferred to a lSml conical tube. SOmI Falcon tube was washed once with 5m1 PBS and 
transferred to 45m] conical tube. Cell suspension was centrifuged at 400g for lOmmutes. Cell 
pellet was resuspended by gentle tapping in culture medium cRPMI with 1 0gIm1 
Concanavalin A. Lymphocyte suspension was aliquoted Sinl cell suspension per dish into 
60mm dishes. 
11.2.8.2. Lymphocyte culture 
Lymphocytes were grown for 2-3 days, after which they were irradiated at 20 JIm2 . 
For UV irradiation a short wave gennicidal lamp was used, suspended by clamps at 
approximately 30cm height. Cells to be irradiated were placed underneath the lamp and kept 
under LTV exposure for certain periods of time. After irradiation each dish received 0.5 ml of 
fresh cRPMI. Protein lysates were made 6-8hours after irradiation. 
11.2.8.3. Protein Mates 
6-8 hours after irradiation cells were collected from Petri dishes into Falcon tubes. 
Each culture dish was rinsed in PBS and added to the cell suspension, which was centrifuged 
10 minutes at 400g. Cell pellet was resuspended in 50.tl lysis buffer. Cell lysates were placed 
in a waterbath at 100 °C for 10 minutes and centrifuged in a microfuge top speed for 15 
minutes. Cell lysates were stored at -20°C. 
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11.2.8.4. Estimation of protein concentration 
Estimation of protein concentration was based on the absorbance of the samples at 
562nm using the BCA-200 protein assay kit. BCA mix was made of 50:1 v/v reagent A and 
reagent B. Samples to be checked for their protein concentration were diluted 1:100 with 
sterile dH20. 2m1 BCA mix was added to the diluted samples and the mixture was then 
incubated at 37 °C for 15 minutes. Absorbance at 562nm was read on a spectrophotometer 
(Cecil CE 2020, Cecil Instruments Ltd). OD readings were multiplied by 100 (dilution factor) 
and protein concentrations were expressed in g/n -d. This method was used to provide an 
indication of the protein content in the lymphocytes lysates. BSA solution 1mg/mi was used as 
a standard solution in calculating the protein concentrations of the samples. 
11.2.9. Protein assays 
11.2.9.1. Electrophoresis 
Protein samples were analysed by electrophoresis using Hoefer, Mighty small SE245 
for small gels, size lOx 10.5cm with square-tooth comb. Between 20-40 tg protein were mixed 
with 3xSDS loading buffer, denatured by heating at 99 °C for 5 minutes, centrifuged for 3 
minutes and loaded onto a 12% acrylamide minigel. Two gels were run simultaneously at 
maximum voltage, 30mAmp/gel until the dye moved to the bottom of the gel, usually after 2 
hours. To visualise protein bands and assess quality of the electrophoresis, one gel was stained 
with Coomassie brilliant blue R stain. The other gel was used to transfer the protein samples 
to a PVDF membrane. 
11.2.9.2. Blotting 
The proteins were transferred using a semi-dry apparatus (BioRad, Trans-blot SD) at 
constant voltage, usually 12 volts, for 1-2 hours. Prior to the transfer, the membrane was 
soaked in methanol and in transfer buffer. The transfer stack was assembled starting from the 
anode electrode plate with wet filter paper, followed by the membrane, the gel, wet filter paper 
and last the cathode electrode plate. Blots were used immediately but they can also be air-
dried and stored at 4°C. 
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11.2.9 3. Immunodetection 
Detection of specific protein bands was done by Western procedure. Firstly, blots 
were immersed in 5% non-fat dried miLk, 0.1%(v/v) Tween-20 in TBS at room temperature 
for 1 hour on an orbital shaker. The membrane was then washed once in a large volume of 
TBST for 10 minutes and incubated with diluted primary antibody for 1 hour at room 
temperature on an orbital shaker. The primary antibody was then removed by washing twice 
in a large volume of TBST, 10 minutes each time. The membrane was incubated with the 
diluted secondary antibody for 1 hour at room temperature on an orbital shaker. The 
secondary antibody was removed by washing three times in large volumes of TBST, 15 
minutes each time. The membrane was finally incubated with the ECL mix, detection 
solutions A and B, at room temperature for 5 minutes. The membrane was then placed protein 
side up in an X-ray film cassette, with a sheet of autoradiography film on top of the 
membrane. The film was exposed for 15 seconds and depending on the intensity of the bands, 
then other films were exposed for various periods of time. 
Once the protein of interest was detected, the blot can be stripped and reprobed for 
another protein. The primary and secondary antibodies were removed by submerging the 
membrane in stripping solution and incubating at 50 °C for 30 minutes with occasional 
agitation. Then the membrane was washed twice in large volumes of TBS-T buffer. Now the 
membrane can be used for another immunodetection. Alternatively, the membrane can be 
stored wet wrapped at 4 °C after each immunodetection. 
III. RESULTS 
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111.1 Molecular analysis of polymorphisms in XPB and XPD, two human NER genes 
Two DNA repair genes, XPB and XPD, have been chosen to be investigated for 
sequence variation. In choosing these two genes it was taken into account that the proteins 
they encode play important roles in nucleotide excision repair and transcription, interact 
both physically and functionally with each other and with p53 protein and are both required 
for p53-mediated apoptosis (Wang et al., 1996). Additionally, frequent polymorphisms have 
been reported in these two genes with associations reported between genetic polymorphism, 
reduced repair capacity and increased cancer susceptibility(Cheng et al., 2000; Dybdahl et 
al., 1999a; Dybdahi et al., 1999b). 
In order to look for sequence variation in the XPB and XPD genes the strategy was 
to amplify each individual exon by PCR, followed by SSCP and/or RFLP analysis and DNA 
sequencing. 
The Single Strand Conformational Polymorphism assay can be used to 
screen small DNA fragments for sequence changes or point mutations. SSCP analysis is 
used to screen for mutations in a specified DNA region by choosing PCR primers spanning 
that region. It is a simple and rapid technique that can be used on relatively large numbers of 
samples. Double stranded DNA is heat and formamide denatured into single stranded DNA 
and electrophoresed on a non-denaturing polyacrylamide gel. The sequence variations alter 
DNA mobility in gel electrophoresis, which is seen as a shift in the position of bands, when 
compared to the wild-type sequence. SSCP analysis only shows that a sequence change 
exists, subsequent sequencing has to be done in order to determine the precise nature of the 
electrophoretic mobility shift. SSCP analysis is limited by its resolving power to fragments 
less than 250bp, therefore PCR primers should be chosen accordingly and by the fact that 
some sequence changes might not cause a detectable shift in electrophoretic mobility. The 
main condition for SSCP analysis was small PCR products, ideally under 300bases. 
Therefore in designing the PCR primers, the size of the PCR product was the first priority. 
Also, for the purpose of the whole analysis the entire coding region had to be contained 
within the PCR product. In designing the PCR primers several general parameters were 
taken into account, such as primer sequence and concentration, denaturation time and 
temperature, annealing temperature, extension temperature and time, reaction components 
and number of cycles. It is known that primers of 18 or more nucleotides long should, on a 
random expectation be unique in a complex eukaryotic genome. Also, a typical G±C 
composition would be 50-60% (McPherson et al., 1995). Thus, the length of the individual 
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primers used in this thesis was on average 25 bases and primers within the same pair had the 
same length. For each primer pair the purine:pyrimidine content was maintained around 1:1 
(maybe 40-60%). Where possible, primer sequence ended with 1-2 GC bases. Also each 
potential primer pair was tested for hair-loops and primer-primer interactions and changed 
accordingly. For each PCR reaction, the concentration of the two primers should be the 
same. 300ng of each primer was used in 50pi  reaction mixture, which is rather different 
from the recommended 16.25ng of a 20-mer in a 25p1 reaction mixture (McPherson etal., 
1995). The denaturation step is an important cause of PCR failure, due to incomplete 
denaturation of template and/or PCR product. For targets 1kb or less, 94 0C for 1 min is 
commonly used (McPherson et al., 1995) and it was used in the amplifying reactions of 
individual XPB and XPD exons. The annealing temperature is another important factor for a 
successful PCR reaction. It depends upon the base composition, length and concentration of 
the amplification primers. A recommended annealing temperature is 5 0C below the true 
melting temperature (T m) of the amplification primers and generally annealing 
temperatures in the range of 55 to 72 0C produce best results (Innis et al., 1990). The 
melting temperature can be calculated using the formula T m=4(G+C) + 2(A±T), where A, 
C, G and T are the numbers of each base in the primer sequence. In this thesis, the annealing 
temperatures used were 67 or 69 0C as part of the standardised PCR profile used in our 
laboratory (35 cycles at 94 0C 1 minute, 67 0C 1 minute, 72 0C 30 seconds). Taq DNA 
polymerase is highly processive and extends at 2-4kb per mm (McPherson et al., 1995). 
Thus, at the commonly indicated extension temperature of 72 0C 1 minute is considered 
sufficient for products up to 2kb in length (Innis et al., 1990). Because the PCR products 
expected in this thesis were below 2kb, the indicated extension temperature and shorter time 
were used. In the case of 20-mer primers with a GC content of 60% or more, where the 
calculated melting temperature —5 0C is equivalent to the extension temperature, the 
annealing and extension steps can be combined into one step, for 1-2 minutes. This was 
applied in the case of one XPD exon. Of the reaction components, Mg2+  concentration is of 
importance for both specificity and yield, as it can affect the PCR reaction differently at 
high and low concentrations (McPherson et al., 1995). High Mg2+  might prevent strand 
dissociation of both template and PCR product, thus leading to a reduced yield. High 
magnesium concentrations also affect product specificity, due to stabilisation of annealing 
of the primer to incorrect template sites, resulting in undesired products. Low magnesium 
concentrations impair the extension reaction, as all of the common thermostable 
polymerases require free Mg2+  for enzymatic activity and fidelity. The optimum 
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magnesium concentration should be established in correlation with the concentrations of 
other reaction components such as EDTA and dNTP, which are Mg2+chelating factors. In 
addition, the ionic environment and the pH of the reaction buffer are critical for successful 
PCR reactions. KCI buffers are widely used and are adequate for most of the PCR reactions. 
Up to 50mM KCI can be included in the PCR reaction mix to facilitate primer annealing 
(Innis et al., 1990). Most reactions are buffered by 10-50mM Tris/HCI at pH8.3, at 20 0C 
(McPherson et a!, 1995). Also, buffers may contain enzyme stabilisers, such as gelatin, 
BSA (100tgIml) and non-ionic detergents (Tween20). The buffer of the PCR reactions used 
to amplify XPB and XPD exons was a Tris/HCI, KCI buffer which contained gelatin. 
Tween-20, Triton X-100 and MgC12  at balanced concentrations. dNTP concentration is also 
important for yield, specificity and fidelity of a PCR assay. The four dNTPs should be used 
at equivalent concentrations to minimise misincorporation errors (Innis el al., 1990). In the 
PCR assays in this thesis, all 4 dNTPs were used at equivalent concentrations, to give the 
excess required even at a 50% degradation rate during the thermal cycling. The Taq DNA 
polymerase concentration is important for specificity and yield of the PCR reaction. A high 
concentration results in the accumulation of non-specific products, whilst low concentration 
results in an insufficient amount of product. A recommended concentration would be 1-
2units per 100.tl reaction mix (McPherson et al., 1995), which was used in the PCR assays 
for XPB and XPD exons. The recommended number of cycles for most amplification 
reactions is 30 cycles (McPherson et al., 1995). The optimum number depends on the 
starting concentration of template DNA and on the primer to template ratio. A high number 
of cycles can increase the amount of non-specific background products, whilst too few 
cycles give low product yield. In this thesis 30 to 35 cycles were used to amplify template 
DNA. The template DNA concentration used depended on the yield of DNA extracted from 
each blood sample and was --bOng, in agreement with the indicated 125ng per 25i11 
reaction (McPherson et al., 1995). 
Where possible, PCR primers were chosen - 50-60bp away from the exonlintron 
boundaries in order to obtain PCR products suitable for sequencing. For the exons where 
these requirements could not be met the size of the PCR product was increased (e.g. XPD 
exon 23) by choosing primers —lOObp away from the exonlintron boundaries. Alternatively, 
the analysis of variants within exons was prioritised, e.g. due to the sequence composition 
and product size constraints around XPD exon 7, the reverse primer contained the intron 
variant 22812. Thus, only the exon variant 22637, which mapped within the PCR product 
was chosen to be analysed. 
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The Restriction Fragment Length Polymorphism assay can be used to detect 
published sequence variants, which alter restriction sites in a specific DNA fragment. RFLP 
is used in conjunction with PCR, which amplifies the DNA fragment carrying the sequence 
change. PCR products are digested with restriction enzymes specific to a sequence change. 
Restriction products are electrophoresed on agarose gels and the resultant fragments are 
used to genotype the variants. RFLP is another simple and rapid technique useful in 
screening samples for known variants. It has no limitation in terms of PCR product size, 
although the quality of the PCR product might affect the restriction reaction leading to 
inaccurate results. 
Sequencing is an accurate but laborious assay to identify a sequence change. The 
automated dye-terminator sequencing procedure is a laborious assay, which involves 
amplifying a DNA fragment by PCR, purifying the PCR product (removing dNTPs and 
primers), separately reamplifying and dye-labelling each strand (cycle sequencing with 
dRhodamine terminator ready mix), purifying and air-drying extension products before 
loading a sequencing gel on ABI Prism 3 10 Genetic Analyzer. The quality of the sequencing 
outcome depends on the quality and quantity of the PCR product to be sequenced and also 
on the size of the template, up to 800bp template DNA will give good sequences. Because it 
involves so many steps in preparation of template DNA sequencing it is not a rapid method 
readily applicable to a large number of samples. 
The total number of samples, cases and controls was 73. All these samples were 
analysed for sequence variation in XPB and XPD genes. However, only the 28 melanoma 
samples and 33 controls, i.e. 61 samples, were statistically analysed. The rest of the 
samples, BCC, AK and SCC were not included in the statistical analysis due to their low 
number. 
111.1.1 Molecular analysis of three exons in XPB gene 
The XPB gene is composed of 14 exons, ranging in size from 50 to 439bp, spread 
over a region of —50kb (Weeda etal., 1991). It encodes a 89.2 kDa ATP-dependent 3' to 5' 
DNA helicase essential for both transcription and repair functions of the TFIII-I protein 
complex. 
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Structurally, the 782 amino acid XPB protein is composed of the nuclear 
localisation signal (amino acid 9-19), four acidic domains (amino acid 20-28, 256-265, 697-
701, 721-728), the ATP binding domain (amino acid 340-347), the DEVH box (amino acid 
441-444), the DNA binding domain (amino acid 121-142) and seven helicase motifs (amino 
acid 333-349, 362-381, 432-447, 464-477, 545-566, 597-618 and 630-647) (Ellis, 1997). 
Mutations in XPB gene can lead to XP/CS and lTD and it was shown that mutations in 
helicase domains I to VI and in the potential DNA-binding domain abolish repair activity 
(Ma el al., 1994). XPB protein makes a functional heterodimer with XPD-NER component, 
interacts with p34, p44, p62-all TFIIH subunits and with XPG-another NER component, 
(Iyer el al., 1996). XPB helicase motif III interacts with C-terminus domain of p53 (Wang el 
al., 1995). All these protein-protein interactions are summarised in fig.6, from de Laat el al., 
(1999) 
XPGRD 	 needed for 
5 'incision 
XPD, 1234-BD 	p64' p44-BD 
198 305 	387 	 742 	782 
782aa 
I la 	II III 	IVV VI 
DNA unwinding domains 
Fig.6. Schematic representation of the identified functional domains in the XPB 
protein. The yellow boxes represent protein-protein-binding domains. The putative functional 
domains based on the primary amino acid sequence are indicated below each schematic 
representation (hatched boxes). 
Exons 3, 8 and 9 were selected to be analysed for sequence variation. The selection 
of these exons was based on structural and functional considerations. Exon 3 encodes the 
DNA binding domain, exon 8 encodes the DNA helicase motifs I, la and 11 and exon 9 
encodes the DNA helicase motif III. There are also two variants published, LysIl7Arg in 
exon 3 and Gly402Cys in exon8 (Butkiewicz el al., 2000). Specific PCR primers, 
corresponding to each exon were designed using XPB Gen-Bank sequence M31899 (Weeda 
elaL, 1991; Weedaetal., 1990). 
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XPB exon 3 
Exon 3 is 237bp long and PCR primers were chosen so that the exon sequence will be 
entirely contained within the 298bp PCR product, amplified using primer pair forward A5580 
and reverse A5581 (coding sequence shown in bold) One variant has been reported within this 
DNA region at nt 445, a A->G transition (Butkiewicz etal., 2000). 
TCTGCAACTC ATG1T7CCT7 GTCTGr I 11 G TCCAT17GGT ATCTCTCAGGC 
TCCCGATGGC CATATCTTCT TGGAAGCCTT CTCTCCAGTT TACAAATATC 
CCAAGACTT CTTGGTGGCT ATTGCAGAGC CAGTGTGCCG ACCAACCCAT 
GTGCATGAGT ACAA 45ACTAAC TGCCTACTCC TTGTATGCAG CTGTCAGCGT 
TGGGCTGCAA ACCAGTGACA TCACCGAGTA CCTCAGGAAG CTCAGCAAGA 
CTGGAGTCCC TGATGGAATT ATGCAGTTTA TTAAGGC4 AG TGACAGC 
Exon 3 gave a strong PCR product under the following thermal cycling conditions: 
940C Iminute, 67 °C 1 minute, 720 C 30 seconds for 35cycles. The same PCR reaction was 
performed for all DNA samples. Subsequently, each PCR product was run on a SSCP gel. 
SSCP analysis showed good separation between ds and ssDNA and the same migration 
pattern in all samples analysed (fig.7). All DNA samples screened for XPB exon 3 showed no 
sequence variation by SSCP analysis. 
ssDNA  
dsDNA  
Fig.7. SSCP analysis of XPB exon 3 PCR products in three samples. No sequence variation 
was detected. The dsDNA appears on some gels due to partial renaturation. 
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XPB exon 8 
Exon 8 is 31 5bp long and two pairs of primers were tried (coding sequence shown in 
bold). One variant has been reported within this region, a G->T transversion at nt 1299. 
(Butkiewicz el al., 2000). The first pair (1 forward C8558 and reverse C8559) should give a 
216bp product but all PCR conditions tried resulted in no product at all. The second pair tried 
( forward D1319 and reverse D1320) gave a very poor 360bp product, which proved to be 
of no use for the SSCP analysis. Therefore, no SSCP analysis was possible for this exon. 
AAAATAAGAA AGAAAA GTGA C' AGTGTGAAT GCTCCCATTG TTTCC TCAGG 
TGCTGGAAAG TCCCTGGTTG GTGTGACTGC TGCATGCACT GTCAGAAAAC 
GCTGTCTGGT GCTGGGCAAC TCAGCTGTTT CTGTGGAGCA GTGGAAAGCC 
CAGTTCAAGA TGTGGTCCAC CATTGACGAC AGCCAGATCT GCCGGTTCAC 
CTCCGATGCC AAG' GACAAGC CCATCGGCTG CTCCGTF' GCC ATTAGCACCT 
ACTCCATGCT GGGCCACACC ACCAAAAGGT CCTGGGAGGC CGAGCGAGTC 
ATGGAGTGGC TCAAGACCCA GGAGTGGGGC CTCATGATCC TGGATGAAGT 
GC ACACCATA CCAGGTAAGC ACiCiCIG 
XPB exon 9 
For exon 9, which is 1 85bp long, three pairs of primers and combinations of these 
were tried (coding sequence shown in bold). Pair A5583/A5582 would give a 223bp product 
and pair C8556/C8557 would give a 21 lbp product. None of these pairs did work nor did 
combinations of them. One more pair was tried, D132l-D1322, again the 230bp product was 
unobtainable. 
CAACCJ 3GTCC TTGG'GAGG GA TTG 3CACTCTT GTTFC'TTGTA GCCAAGATGT 
TCCGAAGGGT GCTCACCATC GTGCAGGCCC ACTGTAAGCT GGGTFTGACT 
GCGACCCTCG TCCGCGAAGA TGACAAAAT GTGGATTAA ATFTTCTGAT 
TGGGCCTAAG CTCTACGAAG CCAACTGGAT GGAGCTGCAG AATAATGGCT 
ACATC GCCAA A GTCC 'AGTGT GCTGAGGTA ci CIKK1C 'CT 
6Oaa 
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111. 1.2. Molecular analysis of XPD gene 
The XPD gene is situated on chromosome 19, q arm, region 13.2 and it is composed 
of 23 exons, spanning approximately 20kb. It encodes the 86.9 kDa 5' to 3' DNA helicase 
component of the nine-subunit TFIIH complex involved in the initiation of RNA polymerase 
11 transcription, nucleotide excision repair and possibly in cell cycle regulation (de Laat et al., 
1999). 
The main structural features of the 760 amino acid XPD protein are: ATP binding 
motif(aa 35-52), DEAH box (an 234-237), putative nuclear localisation signal (an 682-695) 
seven helicase motifs (an 35-51, 69-88, 225-240, 464-478, 539-560, 587-611, 654-67 1) and 
DNA binding domain localised within helicase motif V (Ellis, 1997; Hoeijmakers, 1993a; 
Hoeijmakers, 1993b). Helicase motifs have an important functional role and it was shown 
that the majority of mutations leading to XP, XP+CS and 'lTD phenotypes map within 
helicase motifs I, II, III, V, VI (Ellis, 1997, Hoeijmakers, 1993a and Hoeijmakers, 1993b) 
XPD protein is involved in several protein-protein interactions summarised in fig.8 
(Shen et al., 1998). Specifically, the XPD protein makes a heterodimer with XPB and has 
interaction domains for p34, p44, p62 and XPG. The XPD N-terminal 300 an interacts with 
the C-terminus domain of p53 (Leveillard ci al., 1996). 
04-1313 	 p62-BD 
p44, XPB, XPG-BD 	 XPG-BD 
I 	la 	 II 	 Ill 	IV V VI 
DNA unwinding domains 
Fig. 8. Schematic representation of the identified functional domains of the XPD protein. The 
yellow boxes represent the protein-binding domains. The putative functional domains based 
on the primary amino acid sequence are indicated below each schematic representation 
(hatched boxes). 
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Almost all 23 exons of the XPD gene were analysed for sequence variation. XPD 
GenBank sequence L47234 was used to design primer pairs specific to each individual exon. 
Since a number of papers have reported polymorphisms at various positions within the XPD 
gene this was taken into account when choosing the screening method. 
Exon 2 
Exon 2 encodes part of helicase motif I and the nucleotide triphosphate-binding motif 
(fig.8). XPD exon 2 begins at nt 17361 on database sequence L47234 and is lOObp long 
(coding sequence shown in bold). The PCR primer pair forward F2242 and reverse F2243 
was designed between nt 17313 and nt 17531 to give a PCR product of 222bp. No variants 
have been reported within this region. Reported polymorphisms in the XPD gene begin in 
intron4atnt 18814. 
AGAGGGGCTG AGGGGACGGG AACTGACCCA GCAGCCCCTG CCGCCAGG" 361 CT 
CAACGTGGAC GGGCTCCTGG TCTACTTCCC GTACGACTAC ATCTACCCCG 
AGCAGTTCTC CTACATGCGG GAGCTCAAAC GCACGCTGGA CGCCAAG'7460 GTG 
GGTGGCCGGT GGGCCCGACC CGCCCACTCG ACCGGTGGGG CTGCCACGCC 
TGGGCCTAAG ACAGAUGC 
Exon 2 amplified well at 94 °C Iminute, 69 0C iminute, 72 °C 30 seconds for 30 cycles. 
Once the PCR conditions were established, the exon was amplified in all DNA samples. PCR 
products were run on a SSCP gel under the standard conditions. SSCP analysis resolved the 
ssDNA well. The same migration pattern was seen, therefore there no sequence variation was 
detected in all 73 samples analysed (fig.9). 
Fig.9. SSCP analysis of exon 2 PCR products does not detect any variations. 
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Three samples, 236, Dl 6, D 19 were randomly chosen to be sequenced. The sequences 
obtained were aligned against the database sequence and the alignment showed no sequence 
modifications in these three samples. 
Exon 3-4 
Exon 3 starts at nt 18447 on database sequence L47234 and is 78bp long. XPD exon 
4 starts at nt 18601 on database sequence L47234 and is 63bp long (coding sequence shown 
in bold). Part of helicase motif I is encoded by exon 3 Helicase motif la is unique to the 
helicases and is encoded by exon 4 and exon 5. 
PCR primers, forward D8219, reverse D8220 were designed between nt 18397 and 
18719 to give a PCR product of 322bp overlapping both exons. No variants have been 
reported within this region. 
CCAAGGUCT GAGACCCTGT GTGTTGCCCC TCTGGTCCCC AACATGCAGG' 8447 
GTCATGGAGT CCTGGAGATG CCCTCAGGCA CCGGGAAGAC AGTATCCCTG 
TTGGCCCTGA TCATGGCATA CCAGAGA 1 8524GTG AGTGATGCGC TGAACCCGTA 
AAGGCAGACA AAGGAAGGGG CGGGACAGGG ACTGAGTCCG CYGTATCG GCAG 
G' 8601 CATAT CCGCTGGAGG TGACCAAACT CATCTACTGC TCAAGAACTG 
TGCCAGAGAT TGAGAAG 1 8663GTA AGCTGGGACT CATCCTGGTG CTCCAGCCCC 
ACTGTrCCCTAGGCCCTATTGGTC 
The PCR conditions, used to amplify exon 3 and 4 were 94 °C Iminute. 67°C Iminute, 
72°C 35 seconds for 35 cycles. This PCR reaction was performed on all DNA samples. The 
PCR product was good but slightly too big for an optimal SSCP analysis. The SSCP gels had 
to be n.m for 20-36 his and although ssDNA was separated on the gel, clear results cannot be 
taken from this analysis. 
Six samples (235, D20, D9, 239, Dl 1, 20:08) were chosen randomly to be sequenced. 
The sequencing outcome was good, the forward and reverse sequences were readable and they 




Exon 5 spans a 114bp region between nt 18850 and 18962 on Gen-Bank sequence 
L47234 (coding  sequence shown in bold). It partly codes for helicase motif Ia. PCR primer 
pair, forward F10252 and reverse F10253 amplifies a 239bp PCR product, spanning nt 18801 
to 19040. 
GTGCCTCCAA TGAACACAAG CTCCCCCTGC CCCCCAACTt TGGAGTAGG' 
GATTGAAGAG CTTCGAAAGT TGCTCAACTT CTATGAGAAG CAGGAGGGCG 
AGAAGCTGCC GTTTCTGGGA CTGGCTCTGA GCTCCCGCAA AAACTTGTGT 
ATTCACCCTG AG' 8962GTGAGCAC CTGTTCCTTC TCCTTGCCCT TAGCCCAGAG 
GTAGAGAAAA CTC1TFCGTC CAACCACAAG TCCTGGATCC 
The region spanning nt 18801 to 19040 contains two published variants : an A->G 
transition at nt 18814 in intron 4 and a C->T transition at nt 18980 in intron 5 (Shen et al.. 
1998). The allele frequency for the variant 18814 0.21 and for variant 18980 is 0.04. The 
restriction map of the exon 5 PCR product is modified only by variant 18814, which 
introduces a third Bsp1286 Land BsiKHA I site (both atnt 18816). 
Variants: 
GTGCCTCCAA TGAG'8814CA3 bsi3  CAAG CTCCCCCTGC CCCCCAAC1T TGGAGTAGGT 
GATTGAAGAG CTTCGAAAGT TGCTCAACTT CTATGAGAAG CAGGAGGGCG 
AGAAGCTGCC GTTTCTGGGA CTGGCTCTGA 	 bspl,bsil  CCCGCAA AAACTFGTGT 
AYrCACCCTG AGGTGAGCA bspl,bs,2  C CTGT7CCTI'T'8980 TCCTTGCCCT TAGCCCAGAG 
GTAGAGAAAA CTC1T]TCGTC CAACCACAAG TCCTGGATCC 
bspl, bsp2, bsil. bsi 2 are the original Bsp1286 I and BsiHIKA I sites 
bsp3, bs13 are the new Bsp 1286 land BsiFIKA I sites introduced by 18814 variant 
The screening assay for the exon 5 involved finding appropriate PCR conditions then 
running the PCR products on SSCP native acrylamide gels. XPD exon 5 amplified well at 
940C iminute, 670C lminute, 72 0C 30 seconds for 30 cycles in all DNA samples. All PCR 
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products were run on SSCP gels. SSCP analysis showed good separation, but there was no 
sequence variation in the DNA samples analysed. 
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Fig. 10. SSCP analysis of exon 5 PCR products. The ssDNA separated as two bands at the 
top of the gel. The same migration pattern indicates no sequence variation. 
Variant 18814, although having a reported relatively high frequency of 0.21, was not 
seen in the DNA samples because it maps within the first 15bp of the forward primer and it is 
not detectable by SSCP or RFLP. Variant 18980, located within the last 70bp of the PCR 
product sequence, has a low frequency of 0.04, perhaps explaining why it was not present in 
the 73 DNA samples analysed. Based on this and on the fact that SSCP analysis did not show 
any sequence variation, exon 5 was not analysed by RFLP or sequencing. 
Exon 6 
Exon 6 is 117 bp long and spans nt 22435-22551 on Gen-Bank sequence L47234 
There is no particular functional domain encoded by exon 6. PCR primers, forward F8736 
and reverse F8737 were chosen between nt 22335 and 22622 to give a 287bp PCR product 
(coding sequence shown in bold). 
TGTCCAAAAC CCCAGCCAGC TGGGAGGTGT GGAGACCAGG GTTTGAAGAG 
TGGTFGGGU TCCACCCTGT CTGGGTGCTA AGATGCCCCA CACCCCCAGG2435 
TGACACCCCT GCGCTTTGGG AAGGACGTCG ATGGGAAATG CCACAGCCTC 
ACAGCCTCUCT ATGTGCCGGGC GCAGTACrnWOCAG CATGACACCA GCCTGCCCCA 
CTGCCGthATTC TATGAG 2551 GTTA CTGGAGGGCA GGGCTGAGGG AGpmGGAGGCAG 
GACAGGTAGC CTGGGGCAGG CthUAGCCTCCCT GACCCCTG 
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Two variants have been reported within this region (Shen et al., 1998). One in exon 6, 
a silent A->C transversion nt 22541 and the other is in intron 6, an A->C transversion nt 
22559. The allele frequency for variant 22541 is 0.25 and for variant 22559 is 0.04. Both 
variants introduce new restriction sites, therefore they can be easily analysed by RFLP assay. 
Variant 22541 introduces a Taul site, a second Acil site and a Fnu4H I site, all at position 
22538. Variant 22559 introduces a second site for: MwoI (nt 22564), Acil (nt 22558). Faul 
(nt 22550) and Sth132 I(nt 22549). Also Hinfi and TfiI (both at nt 22539) and BpmI (nt 
22573) can be used for RFLP assay. Hinfl and TfiI cut database sequence and variant 22559 
but not 22541. Bpnil cuts database sequence and variant 22541. 
Variant 22541 
TGTCCAAAAC CCCAGCCAGC TGGGAGGTGT GGAGACCAGG GGAAGAG 
TGGTTGGGU TCCACCCTGT CTGGGTGCTA AGATGCCCCA CACCCCCAGG 
TGACACCCCT GCGCTfl'GGG AAGGACGTCG ATGGGAAATG CCACAGCCTC 
ACAGCCTCCT ATGTGaCLCGGGC GCAGTACrnWOCAG CATGACACCA GCCTGCCCCA 
CTGCaCLhinffnu 	TATGAGGTA 	CTGGAGGGCA 	GGGCTGAGGG 
AGbPmGGAGGCAGGACAGGTAGC CTGGGGCAGG  CthUAGCCTCCCT  GACCCCTG 
Restriction sites for variant 22541: aci (AciT), mwo (MwoI), hinf (Hinf I). thu (Fnu4FH) 
Variant 22559 
TGTCCAAAAC CCCAGCCAGC TGGGAGGTGT GGAGACCAGG G17FGAAGAG 
TGGTTGGGTT TCCACCCTGT CTGGGTGCTA AGATGCCCCA CACCCCCAGG 
TGACACCCCT GCGC1TT'GGG AAGGACGTCG ATGGGAAATG CCACAGCCTC 
ACAGCCTCfaUCT ATGTG'cGGGc GCAGTACrnWOCAG CATGACACCA GCCTGCCCCA 
CTGCCG 	AYTC 	TATGAGGf3Y7ACTGGaCIC229GGGCAmWOGGGCTGAGGG 
AGGGAGGCAG GACAGGTAGC CTGGGGCAGG CAGCCTCCCT GACCCCTG 
Restriction sites by variant 22559: aci (Acil), mwo (MwoI). hinf (Hinfi). tfi (TfiI.) thu 
(Fnu4HI), fau (Faul) 
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XPD exon 6 was amplified in all DNA samples using the following PCR conditions: 
35 cycles at 940C iminute, 690C Iminute, 720C 30 seconds. Particularly for exon 6, PCR 
reactions used undiluted DNAs, if the PCR product was to be used for PULP assay and 
diluted DNAs, if the PCR product was to be used for SSCP analysis, because acylamide gels 
have better resolving power than agarose gels. 
PCR products corresponding to all DNA samples were run on SSCP gels. SSCP 
analysis showed good separation and a mobility shift was seen in the upper part of the gel, 
where the ssDNA was separated (fig. 11). 
AA AC AC 	CC 
ssDNA 	 ?u.ø 
ssDNA  
Fig. 11. SSCP analysis of exon 6 PCR products; variation was detected in the ssDNA region. 
The genotypes are marked at the top of the lanes. 
The SSCP analysis detected the existence of sequence variation within samples, 
which can be attributed to either of the two reported polymorphisms or to a new one. Two 
samples of each of the three migration patterns, up (genotype AA), two bands (genotype AC) 
and down (genotype CC) on the SSCP gels were sequenced. The sequencing data show that 
the SSCP variations were due to the A22541C variant, the other 22559 variant was not 
observed (fig.! 1 a). 
exon6ATGTGCGGGC GCAGTACCAG CATGACACCA GCCTGCCCCA CTGCCGATFC 
CC ATGTGCGGGC GCAGTACCAG CATGACACCA GCCTGCCCCA CTGCCGCTT'C 
AA ATGTGCGGGC GCAGTACCAG CATGACACCA GCCTGCCCCA CTGCCGATTC 
AC ATGTGCGGGC GCAGTACCAG CATGACACCA GCCTGCCCCA CTGCCG TFC 
Fig.!la. Sequence alignment of exon 6 showing A22541C variant; in bold the normal 
sequence, in green the homozygote and red the heterozygote (marked with N due to the 
presence of the A and C peaks at the same nt position on the electrophoregram). 
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In order to confirm this change all exon 6 PCR products have also been assayed by 
RFLP assay. Based on the restriction maps for database and variant sequences and the 
commercial availability of restriction enzymes three enzymes were chosen Acil, MwoI, 1-linfi. 
Acil and MwoI cut all three possible sequences giving different fragment sizes. Hinfi cuts 
only database and variant 22559 sequences. In this way, samples can be simultaneously 
analysed for both reported variants. The expected fragments, resulting from independent 
digestions with the three enzymes are listed in table 4 
Table 4. XPD Exon 6 Aci I, Mwo I, Hini I expected restriction fragments (bp) 
XPD Exon 6 PCR product 288bp Aci I (bp) Hinf I (bp) Mwo I (bp) 
database sequence 165+123 206+82 177+111 
variant 22541 . 165+84+39 288, no cut 177+111 
variant 22559 165+59+64 	1 206+82 177+53+58 
In three separate reactions each of the PCR products corresponding to all 71 DNA 
samples was digested with 15-30 units of each restriction enzyme in a 30 .tl total reaction 
volume. Restriction products were run on 2% LMP agarose gels, stained with EtBr and 
photographed (fig. 12, 13 and 14). 
Acil. MwoI and Hinfl restriction fragments expected of variant 22541 were seen on 
agarose gels. The RFLP assay confirmed that the sequence variation seen on the SSCP gels is 
due to variant A2254 IC. MwoI restriction fragments indicate that all samples have database 
sequence at position 22559, i.e. all samples have AA genotype and variant 22559 was not 
present. 




Fig. 12. Hinfi restriction fragments of exon 6 PC  products indicate variant 22541. The 
fragment sizes and genotypes are marked. 
Fig. 13. Acil restriction fragments of exon 6 PCR products indicate variant 22541 The 
fragment sizes and genotypes are marked 
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Fig.14. MwoI restriction fragments of exon 6 PCR product indicate that the variant 22559 
was not present 
Exon 7 
Exon 7 is 1 l7bp and starts at nt 22637 on Gen.Bank sequence L 47234 (coding 
sequence shown in bold). PCR primers fonvard F27237 and reverse F27238 were chosen 
between nt 22539-22826 to give a 288bp PCR product. 
CGATTCTATG AGGTTACTGG AGGGCAGGGC TGAGGGAGGG AGGCAGGACA 
GGTAGCCTGG GGCAGGCAGC CTCCCTGACC CCTGGCACTC T7GTCCCAGG 2263 
AATTTGATGC CCATGGGCGT GAGGTGCCCC TCCCCGCTGG CATCTACAAC 
CTGGATGACC TGAAGGCCCT GGGGCGGCGC CAGGGCTGGT GCCCATACTT 
CCTTGCTCGA TACTCA 2254 GTGA GGAGGCTGGT GGGATGGGCA GAGGGGCGAG 
TGTGAGGGTG TGGGCTGCCC GCCC 228 ' 2GTCTCC TGTCTGCC 
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The exon 7 PCR product overlaps with the exon 6 PCR product, so that variants 
22541 and 22559 map in the first 20bp of exon 7 PCR product. There is one other variant 
reported within intron 7, a C->T transition at nt 22812. The frequency of this variant is 0.33 
(Shen et al., 1998). Variant 22812 modifies the restriction map of the exon 7 PCR product by 
removing sites for BscGI, Esp3I and BsmBI. 
Exon 7 amplified well at 94 ° C lminute, 69° C iminute, 72 °C 30 seconds for 30 
cycles in all DNA samples. PCR products were run on SSCP gels under the standard 
conditions. SSCP gels separated ssDNA well in the upper part of the gel and dsDNA in the 
lower part of the gel. All samples displayed the same migration pattern (fig. 15). SSCP 
analysis did not detect any sequence variation, therefore no RFLP analysis was performed on 
this exon. 
The PCR primers used in this assay were chosen based on the size and composition of 
the DNA sequence to analyse, which was exon 7 coding sequence. Exon 7 is a relatively big 
exon (for the SSCP analysis) and had to be contained within the PCR product. Exon 7 
flanking introns are short and unsuitable for primer design; intron 6 is only 85bp and the first 
200bp of the intron 7 were not suitable for primer design. This led to the overlapping with 
variants 2254 land 22559, in trying to obtain a PCR product below 300bp, which contains the 
entire exon sequence. Variants 22541, 22559 and 22812 were not detected by SSCP due to 
their location within the primer sequences. Variant 22812 is potentially detectable by RFLP, 
where there are no constraints in terms of size of the PCR product. No RFLP analysis was 
performed on exon 7 due to the location of the variant 22812 in intron sequences. 
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Exon 8 
XPD exon 8 is 124bp long and starts at nt 23039 (coding sequence shown in bold). 
Helicase motif II is partly encoded by exon 8. Also DEAH (Asp-Glu-Ala-His) box is encoded 
by exon 8 (nt 23145-23156) and it is a typical signature for an ATP-dependent helicase. 
Primers used, forward Z5932 and reverse C 1190 gave a product of 214bp PCR product, 
which spans nt 23007 to 23 163. 
TGGCAGGGCC CTGGTAACCC TGCTCCCCGG CCCCCCAGA 22039T CCTGCATGCC 
AATGTGGTGG TTTATAGCTA CCACTACCTC CTGGACCCCA AGATTGCAGA 
CCTGGTGTCC AAGGAACTGG CCCGCAAGGC CGTCGTGGTC TTCGACGAGG 
CCCACAACAT TG 2363GTGAGGGG GGCGCCAGGG GCCAAAGGGA TGCCAGCCCC 
Two variants have been reported within this region (Shen et al., 1998). A C->G 
transversion at nt 23047 which results in an amino acid change 11el99->Met. Variant 23047 
has allele frequency of 0.04. The second change is a C->T transition at nt 23051, which 
results in amino acid substitution, His 201->Tvr. Variant 23051 has allele frequency of 0.04. 
Both variants modify restriction sites within this region. Variant 23047 eliminates a Sau3Al 
site (nt 23043) and introduces sites for: Fnu4I-ll (nt 23048) and Tse I (nt 23047). Variant 
23051 eliminates a Sphl site (nt 23054), a MslI site (nt 23055) and one site for: NspI, NlaIII 
(nt 23054). Cac8I (nt 23052) and CviRI (nt 23050). 
Variant 23047 
TGGCAGGGCC CTGGTAACCC TGCTCCCCGG CCCCCC4 GAl G23°47t 3eCrIIUTGCATGIPhCC 
AATGTGGTGG 1TFATAGCTA CCACTACCTC CTGGACCCCA AGATFGCAGA 
CCTGGTGTCC AAGGAACTGG CCCGCAAGGC CGTCGTGGTC TFCGACGAGG 




TGGCAGGGCC CTGGTAACCC TGCTCCCCGG CCCCCC4 SaUGAT  C CTGT23051 ATGCC 
AATGTGGTGG 177ATAGCTA CCACTACCTC CTGGACCCCA AGTFGCAGA 
CCTGGTGTCC AAGGAACTGG CCCGCAAGGC CGTCGTGGTC 1TCGACGAGG 
CCCACAACAT TGGTGAGGGG GGCGCCAGGG GCCAAAGGGA TDCCAGCCCC 
TCTGAGTGAG GCCC 
Exon 8 amplified relatively well at 94 °C iminute, 72°C 35 seconds for 35 cycles in all 
DNA samples. The PCR reactions were performed with 1 .tl of undiluted DNA. SSCP gels 
showed too many bands and their pattern was very difficult to interpret in terms of changes at 
the DNA level. 
The reported variants can be assayed by RLFP, using SphI for variant 23047 and 
Sau3AI for variant 23051. The expected restriction fragments are listed in table 5. 
Table 5 XPD exon 8 Sau 3A I and Sph I expected restriction fragments (bp) 
XPD exon 8 PCR product 214bp Sau3A I Sph I 
database sequence 37+ 177 48+166 
variant 23047 no cut 48+166 
variant 23051 37+ 177 no cut 
SphI digests were performed under the standard conditions arid Sau3A I digests were 
performed in a final volume of 50.tl. Restriction fragments were analysed on 1.8% agarose 











Fig. 17. SpH I restriction fragments indicate no sequence variation. 
All samples were cut with SphI and Sau3Al and the expected restriction fragments 
were seen on the agarose gels, indicating that neither of the two published variants was present 
in these samples. RFLP assay of 73 DNA samples could not detect any of the two published 
variants, possibly due to their low frequency. 
Four samples Q3, D5, D7 were sequenced. Their sequences did not show any of the 
reported variants or other changes. 
Exon 10 
XPD exon 10 is 134bp long and starts on GenBank L 47234 sequence at nt 23474. 
PCR primers, forward Cl 111 and reverse Z1602 span the region 23415-23612 and were used 
to obtain a 1 95bp PCR product (coding  sequence shown in bold). 
GTCTGACUG TCCCCAGGGT TGCCAGCCCC CTCCCAGCCC CAGCTCATCT 
CTCCGCAGG 234 ' 4A TCAAAGAGAC AGACGAGCAG CGCCTGCGGG ACGAGTACCG 
GCGTCTGGTG GAGGGGCTGC GGGAGGCCAG CGCCGCCCGG GAGACGGACG 
CCCACCTGGC CAACCCCGTG C'TGCCCGACG AAGTGCTGCA GG2360 GTGA 
One variant has been reported between nt 23415-23610 (Shen et al., 1998). At nt 
23591 there is a G->A transition, which results in an amino acid change, Asp3 1 2->Asn. This 
change does not affect the restriction map of this region and its allele frequency is 0.42. 
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Variant 23591 
GTCTGACUG TCCCCAGGGT TGCCAGCCCC CTCCCAGCCC CAGCTCATCT 
CTCCGCAGGA TCAAAGAGAC AGACGAGCAG CGCCTGCGGG ACGAGTACCGG 
CGTCTGGTGG AGGGGCTGCG GGAGGCCAGC GCCGCCCGGG AGACGGACGC 
CCACCTGGCC AACCCCGTGC TGCCCA 23591 ACGA AGTGCTGCAG GGTGA 
Amplifying the exon 10 PC R product proved to be a difficult task. 5 primers and 
combinations of these under different PCR conditions were tried. 2 forward primers were 
used: one shown underlined (-50bp away from the exon boundary) and one only 10bp away 
from exon boundary. Three reverse primers were tried, one showed above double underlined 
and two others (not shown) 50-80bp inside intron 11. Only the pair shown above, single and 
double underlined produced a PCR product of poor quality under the following PCR 
conditions: 94 0C iminute, 72 0C 30 seconds for 40 cycles. SSCP analysis of these PCR 
products gave very poor results. SSCP gels were of extremely poor resolution, only the 
dsDNA can be seen. The region of the gel, where the ssDNA should be, displayed faint bands, 
impossible to be assessed. 
As variant 23591 does not change the restriction map and the corresponding PCR 
product was of very poor quality to be used in SSCP analysis, it was analysed by sequencing. 
Samples Dli, Dl, 20:08, 233, 239 were chosen at random to be sequenced. Samples Dl, 
20:08 7  233, 239 produced readable sequences, which showed no changes when aligned against 
the database sequence. 
Exon 11 
XPD exon 11 starts at nt 23686 on Gen-Bank sequence L 47234 and is 163bp long. 
PCR primers used to amplify this exon are forward F27239 and reverse F27240. The PCR 
product is 282bp and spans nt 23645 to 23927 (coding sequence shown in bold). There are no 
variants reported between nt 23645-23927. 
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CCTCCCCGTC GCCGCTGATA GCGTCTCCTC GCAGAGGCAG T2366GCCTGGCTC 
CATCCGCACG GCCGAGCATT TCCTGGGCTT CCTGAGGCGG CTGCTGGAGT 
ACGTGAAGTG GCGGCTGCGT GTGCAGCATG TGGTGCAGGA GAGCCCGCCC 
GCCTTCCTGA GCGGCCTGGC CCAGCGCGTG TGCATCCAGC GCAAGCCCCT 
CAG23850GTGCGGC CCCAGACAGC GCGCGGGGTG GGGGCCCGGC AGGTCCCGGT 
TATGCAGAGC CGTGTCCTCC ACGCCTGTAG C 
XPD exon 11 could not be amplified using the primer pair mentioned above, although 
three different PCR reactions were tried. PCR conditions tried were: I) 94 °C Iminute, 67°C 
Iminute, 72°C 30 seconds for 30 cycles, 11) at 94 °C iminute, 69°C Irninute, 72 °C 30 seconds 
for 35 cycles, III) 94 ° C Iminute, 72 °C 30 seconds for 35 cycles. All three sets ended up with 
no product at all. These different PCR sets worked well on most other XPD exons. 
Exon 12 
XPD exon 12 starts at nt 25949 on GenBank sequence L 47234 and is 119 bp long 
(coding sequence shown in bold) PCR primers, forward F 27241 and reverse F27242 were 
used to amplify the region between nt 25892 and nt 26149 and to obtain a 257bp PCR 
product. There are no variants reported between nt 25892 and nt 26149 
CTGCTGGTCC TGCTCATGCT TCCGTCTGCC CCCCGACCCCG TCTCTCCTCC 
CCGCCAGA 5949TT CTGTGCTGAA CGCCTCCGGT CCCTGCTGCA TACTCTGGAG 
ATCACCGACC TTGCTGACTT CTCCCCGCTC ACCCTCCTTG CTAACTTTGC 
CACCCTTGTC AGCACCTACG CCAAAG26068GTAA GCTCACC1TF TTCTGTCCCT 
GCTGGGCCTC CTAGCAGCTG GAATCAGGGT CCCAGCAGGG TCTAGAGGGT TGTI'GGC 
XPD exon 12 amplified well in all DNA samples at 94 °C iminute, 69°C Iminute, 
720C 30 seconds for 30 cycles. PCR products were clean and of good yield, suitable for SSCP 
analysis. Each PCR product was loaded onto SSCP gels and electrophoresed under the 
standard conditions. SSCP analysis showed good separation in both ds and ssDNA regions 
but no sequence variation in all samples analysed (fig. 18). 
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Fig. 17. SSCP analysis of exon 12 PCR products, separated ssDNA showed the same 
migration pattern and no sequence variation was detected. 
Exon 13 
Exon 13 maps between nt 29894 and 29964 on GenBank XPD sequence L 47234 and 
it is 70bp long (coding sequence shown in bold). PCR primers, forward C8560 and reverse 
C8561 were used to amplify the region between nt 29860 and 30000, giving a 140 bp PCR 
product. There are no variants reported within this region. 
GTAATCTCAC CCCTCCT['GC CTGCCCTCTG CAGG 29894 CTTCAC CATCATCATC 
GAGCCCTTTG ACGACAGAAC CCCGACCATT GCCAACCCCA TCCTGCACTT 
CAG °°64 GTGGGAC CCTGCCCGGT GAGGGTGTGA ATGCTCTGTG G 
XPD exon 13 amplified well in all DNA samples at 940  C iminute, 72°C 35 seconds 
for 35 cycles. All PCR products corresponding to the 73 DNA samples were run on SSCP 
gels, under the standard conditions. SSCP gels showed good separation and the same 
migration pattern in all samples, indicating no sequence variation (fig. 19). 
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Fig. 19 SSCP analysis of exon 13; separated ssDNA had the same migration pattern and no 
sequence variation was detected. 
Exon 14 
XPD exon 14 begins at nt 30049 on GenBank XPD sequence L 47234 and is 70 bp 
long (coding sequence shown in bold). PCR primers used to amplify this exon were forward 
D8221; reverse D8222. The resulting PCR product is 140bp and spans the region 30025- 
30 165. No sequence variation has been reported within this region. 
CTCACTGCCC TCATCTCTCTC CAGCTGCATG GACGCCTCGC TGGCCATCAA 
ACCCGTATTT GAGCGTTTCC AGTCTGTCAT CATCACATCT GGGGTAAGGA 
CCCTTCCCCG TCCCCTCCTA GTCCCTGACC TCCCTCCATG 
XPD .exon 14 amplified well in all DNA samples at 94 °C lminute, 67°C lminute, 
72°C 35 seconds for 35 cycles. Each PCR product was run onto SSCP gels under the standard 
condition. All PCR products were resolved well by SSCP analysis. The SSCP analysis 
showed the same migration pattern in the ssDNA region in all DNA samples analysed, 




Fig.20. SSCP analysis of the exon 14 showed the same migration pattern and no sequence 
variation was detected. 
Exon 15 
XPD exon 15 maps betweennt 30220 and 30322 on GenBank XPD sequence L47234 
and is 102 bp (coding sequence shown in bold). It codes for helicase motif Ill, which like 
motif la and motif VI, is a unique feature of a helicase. PCR primers used to amplify this exon 
were forward F10254 and reverse F10255. The resulting PCR product is 267bp and spans nt 
30139 to 30406. No variants have been reported within or adjacent to this region. 
102 
CTCCTAGTCC CTGACCTCCC TCCATGGGCC TCCTGGTCCC TGCCCAGTCC 
TGCTGAGATC CCTCCCACTG TCCCGCCACA GA 30220CACTGTCC CCGCTGGACA 
TCTACCCCAA GATCCTGGAC TTCCACCCCG TCACCATGGC AACCTTCACC 
ATGACGCTGG CACGGGTCTG CCTCTGCCCT ATG3° GTGAGTG GGAGAGGCTA 
GGGCTGGGGC CGGGAGGGGA GATGGGGGCA AGGGGCCGCC CTCCTCCT 
Three sets of PCR reactions were tried in order to amplify XPD exon 15. PCR 
conditions tried are I) 94 °C iminute, 67°C lminute, 72 °C 30 seconds for 30 cycles, II) 94 0C 
Iminute, 69 0C lminute, 72°C 30 seconds for 30 cycles, III) 94 0 C Iminute, 72 °C 30 seconds 
for 35 cycles. Set I and III gave no product at all, whereas set II gave a very weak product. 37 
(15 controls and 22 cases) PCR products, obtained from set II were tried on SSCP gels. As 
expected, SSCP analysis showed extremely faint bands in the upper part of the gel, which 
could not be analysed. 
Exon 16 
XPD exon 16 begins at nt 31864 on GenBank XPD sequence L 47234 and is 64 bp 
long. PCR primers used to amplify this exon were forward F10256 and reverse F 10257. The 
PCR product is 222bp and spans the region 31795-32017 (the coding sequence shown in 
bold). No variants have been reported in this region. 
CAGGTGGTCA GCACTCACGC TGGAGCAGTT GCTGCTGCCT CGCYI'ATCGT 
GACCTCTGU GCTCTCCAGA 3 ' TCATCGGCCG TGGCAATGAC CAGGTGGCCA 
TCAGCTCCAA ATTTGAGACC CGGGAGGATA TTG 3198GTATGCT GCCAGTGGGG 
CTGG11CTG TGGGTCCAA GAGGGGAGGT GTATCAGTCA GGTGGGCTGA 
XPD exon 16 amplified well in all DNA samples at 94 °C Iminute, 67 0C Iminute, 
72°C 30 seconds for 30 cycles. The PCR products were clean and of good yield, suitable for 
SSCP analysis, which was performed under the standard conditions. SSCP gels resolved all 
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PCR products well. The SSCP migration pattern showed no mobility shift in the ssDNA 
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Fig.2 1. SSCP analysis of exon 16 indicates same migration pattern and no sequence variation 
was detected. 
Exon 17 
Helicase motif IV spans exons 17 and 18. XPD exon 17 begins at nt 32742 on 
GenBank XPD sequence L 47234 and is 122 bp long. PCR primers used to amplify this exon 
were forward F2244 and reverse F2245. The resulting PCR product is 252bp and spans nt 
32670 to 32921 (coding sequence shown in bold). No variants have been reported between nt 
32670 and 32921. 
CTCCTAGITC TAAGACAGAG AAGGGAGGAG GACCTGGGCC AGGAGAGGGC 
CCAACCTCTG ACCCC'ITGCA GC 32742TGTGATCC GGAACTATGG GAACCTCCTG 
CTGGAGATGT CCGCTGTGGT CCCTGATGGC ATCGTGGCCT TCTTCACCAG 
CTACCAGTAC ATGGAGAGCA CCGTGGCCTC CTGGTATGAG CAG 32864GTACGCC 
TGGCCACCCC CTCCCTGCAC CTGCTCTCCT CAGTCCCTGG CACTGCACCG CT 
Exon 17 amplified well in all DNA samples at 94 °C Iminute, 69°C iminute, 720C 30 
seconds for 30 cycles. The PCR products were clean and of good yield, suitable for SSCP 
analysis. SSCP analysis produced well resolved bands in the ssDNA region. All DNA samples 





Fig.22. SSCP analysis of exon 17; separated ssDNA showed the same migration pattern and 
no sequence variation was detected. 
Exon 18 
Helicase motif IV is partly encoded by exon 18. XPD exon 18 begins at nt 34259 on 
GenBank XPD sequence L 47234 and is 93 bp long. PCR primers used to amplify this exon 
were forward F8738, reverse F8739. The PCR product is 205bp and spans nt 34215 to 34420 
(coding sequence shown in bold). 
CTGTGCCCTG AACCCACCCT GACCTCCCTG GGTCCTTCCC CAGG 3459GGATCC 
TTGAGAACAT CCAGAGGAAC AAGCTGCTCT TTATTGAGAC CCAGGATGGT 
GCCGAAACCA GTGTCGCCCT GGAGAAGTAC CAGGAG'4352 GTGG GTGTGCGAGG 
CCAGCGTGGA GAGGGGTGGG GGAGGTGGCT CTGAGGAGTG ACCTAACUG 
A G->C transversion nt 34382 in intron 18 has been published (Shen et al.. 1998). 
The allele frequency for this change is 0.29 and the restriction map of this region is not 
modified by this change. 
Variant 34382 
CTGTGCCCTG AACCCACCCT GACCTCCCTG GGTCCTTCCC CAGGGGATCC 
TTGAGAACAT CCAGAGGAAC AAGCTGCTCT UATT'GAGAC CCAGGATGGT 
GCCGAAACCA GTGTCGCCCT GGAGAAGTAC CAGGAGGTGG GTGTGCGAGG 
CCAGCGTGGA GAGGGGTC3 GG GGAGGTGGCT CTGAGGAGTG ACCTAACYI'G 
CGTCTC 
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XPD exon 18 amplified well at 30 cycles at 94 °C iminute, 67°C iminute, 72 °C 30 
seconds and gave a clean, strong PCR product. Exon 18 was amplified in all DNA samples 
and analysed by SSCP. The SSCP gel showed good separation and the samples analysed 
displayed a mobility shift in the ssDNA region, seen as I band for both homozygotes and 2 
bands for the heterozygote (fig.23). 
Fig.23. SSCP analysis of the exon 18 PCR product. Sequence variation is detected, seen in the 
ssDNA region as the common 1-2-1 migration pattern. 
SSCP analysis indicated a sequence variation in exon 18 PCR product in the samples 
analysed. All samples were run on SSCP gels, but only 47 (28 melanoma and 19 controls) 
showed a good clear migration pattern. For the rest of the samples, although the same 
conditions were used, the SSCP patterns could not be analysed, due to poor migration or 
resolution of the samples. Samples (D 12, 239, 234, 233, DC7- all CC genotype), (236, DC 14, 
DC17, Dl, D7, 247-all GC genotype), (D17, Qi, 792-all GG genotype) corresponding to 
each migration pattern were sequenced. Only samples listed in bold produced good sequencing 
data, in which variant 34382 was present: 239-homozygote CC, 236 and 247-heterozygotes 
CG and Q1-homozvgote GG. These genotypes correlate with the SSCP pattern, supporting 
the designation of genotype for the 47 samples analysed. 
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Fig.23a. The electrophoregrams of the exon 18 (top) normal sequence and (bottom) variant 
34382. The nt position is indicated by the arrow; heterozygote CG is shown in the bottom 
electrophoregram as N, because G and C peaks appear at the same nt position, 34382. 
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Exon 19 
XPD exon 19 begins at nt 34438 on GenBank XPD sequence L 47234 and is 73 bp 
long. It encodes the helicase motif V and DNA-binding motif. PCR primers used to amplify 
this exon were forward F8740 and reverse F8741. The PCR product spans the region 34395-
34577 and is 182bp (coding sequence shown in bold). No variants have been reported within 
this region. 
CTGAGGAGTG ACCTAACT7G CGTCTCGGTC TCCCCACCTC AGG 34438 CCTG CGA 
GAATGGCCGC GGGGCCATCC TGCTGTCAGT GGCCCGGGGC AAAGTGTCCG 
AGGGAATCGA CTTTG3451' GTGAG TGGACTGGGC TCTI'CCTCCC CAGGTGTCYF 
CCCAGAGCTC TCTGGAACAC CTGCCCGCTC TGC 
XPD exon 19 amplified well at 94 °C Iminute, 67°C Iminute, 72 °C 30 seconds for 30 
cycles. All PCR products were clean and of good yield, suitable for SSCP analysis. SSCP 
gels resolved all PCR products well, with ssDNA separated in two strong bands at the upper 
part of the gel (fig.24). SSCP analysis indicated no sequence variation for exon 19 in all 
samples analysed. 
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Fig.24. SSCP analysis of XPD exon 19 showed the same migration pattern and no sequence 
variation was detected. 
Exon 20 
XPD exon 20 begins at nt 34777 on GenBank XPD sequence L 47234 and is 71bp 
long. PCR primers used to amplify this exon were forward F8742 and reverse E8743. The 
21 lbp PCR product spans the region 34685-34896 (coding sequence shown in bold). 
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CTCAGACACA GCATCCTGGGICCGTGAGG CTGTCCCTGT CCCACCAGCC 
ACACUGTAA CCCCCCTCGC CCCCTCTCCT CTGCCCACCA GT34777 GCACCACT 
ACGGGCGGGC CGTCATCATG TTTGGCGTCC CCTACGTCTA CACACAGAGC 
CGCATTCTCA AG34 S 48GTGAGTAG CTCTGTCTCC CAGGGAGTCC CACAGTGTI'A 
GGATCAAGGG AG 
Three variants within this region have been published (Shen et al., 1998) all located in 
intron 19. Variant 34706 is a C->T transition. which results in loss of BstUT site (nt 34708). 
The allele frequency for this change is 0.25. Two C->T transitions are located at nt 34750 and 
nt 34770 respectively. Both changes have allele frequencies of 0.04 and no effect on the 
restriction map of the region. 
Variants: 
CTCAGACACAG CATCCTGGGT T34706GCGTGAGGC TGTCCCTGTC CCACCAGCCA 
CACYrGTAAC CCCCT34750TCGCC CCCTCTCCTC TGCCT34770ACCAG TGCACCACTA 
CGGGCGGGCC GTCATCATGT UGGCGTCCC CTACGTCTAC ACACAGAGCC 
GCATrCTCAA GGTGAGTAGC TCTGTCTCCC AGGGAGTCCC ACAGTGTTAG 
GATCAAGGGA G 
XPD exon 20 amplified well at 30 cycles at 94 0C iminute, 67°C lminute, 72 0C 30 
seconds. SSCP gel showed good separation between dsDNA and ssDNA. Of the 73 samples 
analysed, 13 samples, D14, 239 and D25, 233, Qi, Q2, D2, DC 12, D31, D40, D39, DI. D2 
display a mobility shift seen as an additional band in the ssDNA region (fig.25). 
CT 
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Fig.25. SSCP analysis of the exon 20. The sequence variation is seen in the ssDNA region. 
The additional band in one sample indicates a potential heterozygote, subsequently shown to 
be CT genotype due to variant 34750. 
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Exon 20 had a different SSCP migration pattern in comparison to the other 4 exons 
with sequence variation. Exon 6 and 18 and 22 and 23 had a common pattern in the ssDNA 
region, where a heterozygote was seen as 2 bands and the homozygotes as one upper or lower 
band only. 
Of the three published variants, a candidate responsible for the SSCP migration 
pattern would be either variant 34750 or variant 34770. Variant 34706, although it has a 
higher allele frequency than the other two variants is undetectable, due to its position inside 
the primer sequence. 
Eleven samples showing the additional SSCP band (D14, 239. D25, 233, Qi, Q2, 
D2, DC12, D40, D31. D39) and 6 samples with the normal pattern (Dl, 1)18. 234, D20, 
D28, D32) were sequenced. Sequencing data indicate that variant 34750 is detected by the 
SSCP analysis. Of the 73 samples analysed only 13 are heterozygous for the C-> T change. 
Homozvgote YT variant was undetectable probably due to the low frequency of T variant 
allele. 
TA A C C C C C C T CS C C C C C 
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Fig.25a. Sequence data of exon 20 database sequence (top) and variant 34750 (bottom). The 
nucleotide position change is indicated by arrow; the heterozygote is indicated in the bottom 




XPD exon 21 codes for helicase motif VI. The potential nuclear localisation signal 
spans exons 21 and 22. Exon 21 begins with nt 34944 on GenBank XPD sequence L 47234 
and is 144 bp long. PCR primers used to amplify this exon were forward F2240 and reverse 
F2241, designed between nt 34869 and nt 35123 to give a 254bp PCR product (coding 
sequence shown in bold). No variants have been reported within this region. 
GAGTCCCACA GTGTI'AGGAT CAAGGGAGGA GTGGCTCCCC CACCTCCCCA 
GCTTCTCATC CTCCGTATCT GCAGG 34944CGCGG CTGGAATACC TGCGGGACCA 
GTTCCAGATT CGTGAGAATG ACTTTCTTAC CTTCGATGCC ATGCGCCACG 
CGGCCCAGTG TGTGGGTCGG GCCATCAGGG GCAAGACGGA CTACGGCCTC 
ATGGTCTTTG CCGACAAG 35088GT GCAGCTI'CAG GGGTGCCCCT GTGCTCCCAT 
CCCAG 
XPD exon 21 amplified well in all DNA samples at 94 °C iminute, 69 0C iminute, 
72°C 30 seconds for 30 cycles. The PCR products were strong and clean, suitable for SSCP 
analysis. On the SSCP gels there is a good separation between ss and dsDNA, but no 
sequence variation was detected in all samples analysed (fig.26). 
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Fig.26. SSCP analysis of exon 21 showed the same migration samples in all samples analysed 
and no sequence variation was detected. 
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Exon 22 
XPD exon 22 begins with nt 35241on Gen-Bank XPD sequence L47234 and is 144bp. 
PCR primers used to amplify this exon were forward C8562 and reverse C8563. The resulting 
228 bp PCR product spans the region 35202-35429 (coding sequence shown in bold). 
AATGACCTTC TGTCCCTGGC CTGCGCUCT GCCCACAGC 35241 G GTTTGCCCGT 
GGGGACAAGC GGGGGAAGCT GCCCCGCTGG ATCCAGGAGC ACCTCACAGA 
TGCCAACCTC AACCTGACCG TGGACGAGGG TGTCCAGGTG GCCAAGTACT 
TCCTGCGGCA GATGGCACAG CCCTTCCACC GG 3535 GTGAGGCC TGCGTCCCCC 
A silent C->T transition has been reported within exon 22 at nt 35326 (Shen et al., 
1998). The allele frequency for this change is 0.25. Variant 35326 introduces one site for 
BstF51 site (nt 35329) and Fold site (nt 35336) and removes one DrdI site (nt 35330). 
Variant 35326 
AATGACCTTC TGTCCCTGGC CTGCGCTI'CT GCCCACAGCG GTTrGCCCGT 
GGGGACAAGC GGGGGAAGCT GCCCCGCTGG ATCCAGGAGC ACCTCACAGA 
TGCCAACCTC AACCTGACCG TGGAT326  GAG  b3t  GG  TGTCC'0AGGTG GCCAAGTACT 
TCCTGCGGCA GATGGCACAG CCCYtCCACC GGGTGAGGCC TGCGTCCCCC 
TCCCGGCACC CTCCCAGGCT GAGCUCT 
XPD exon 22 amplified well at 94°C 1 minute, 72 °C 30 seconds for 35 cycles in all 
DNA samples. The PCR product was clean, strong and suitable for SSCP analysis. The 
SSCP gels resolved well between ds and ssDNA. A mobility shift in the ssDNA region was 
detected (fig.26). 
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Fig.27. SSCP analysis of exon 22. The separated ssDNA indicates sequence variation, which 
was subsequently determined as being variant 35326. The genotypes corresponding to variant 
35326 are shown. 
Single-stranded DNA migration pattern showed the existence of sequence variation, 
seen as two bands for the heterozvgote and one band for each of the homozygotes. The 
potential sequence variation seen in samples analysed can be attributed either to the reported 
C35326T variant or to a new one. 
In order to further explore the variant 35326, all PCR products were assayed by 
RFLP. Fold and DrdI restriction enzymes were used in this RFLP assay, because they are 
commercially available and the restricted fragments differentiate easily between the published 
and variant sequences. The expected fragments resulting from independent digestions with 
Fold and DrdI enzymes are listed in table 6. 
Table 6. XPD exon 22 expected Drd I and Fok I restriction fragments (bp) 
XPD exon 22 PCR product 228 bp Drd I Fok I 
database sequence 128+ 100 no cut 
C->T Variant 35326 no cut 134+94 
In two separate reactions each PCR product corresponding to all 73 DNA samples 
was digested with each restriction enzyme using the standard restriction conditions. Digestion 
reactions were run on 2% regular agarose gels, which were stained with EtBr and 
photographed (fig.28 and 29). 
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Fig.28. Fok I restriction fragments of exon 22 indicate variant 35326. The fragment sizes and 
corresponding genotypes are marked. 
Fig.29. Drd I restriction fragments of exon 22 indicate variant 35326. The fragment sizes and 
the corresponding genotypes are marked. 
The expected DrdI and FokJ restriction fragments were seen on agarose gels, therefore 
the RFLP assay confirmed that the sequence variation seen on the SSCP gels was due to the 
C35326T variant. 
For each SSCP migration pattern two PCR products were sequenced. Six samples, 
Q3 and D4-potential heterozygotes, Qi and 20:08-potential IT hornozygotes, D8 and 235-
potential CC homozygotes were sequenced and their assumed genotypes were confirmed. The 
alignment for sequences Q3, 20:08 and 235 is shown below. 
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exon 22 TGCCAACCTC AACCTGACCG TGGACGAGGQ TGTCCAGGTG GCCAAGTACT 
CC/252 TGCCAACCTC AACCTGACCG TGGACGAGQG TGTCCAGGTG GCCAAGTACT 
TGCCAACCTC AACCTGACCG TGGAGAGGG TGTCCAGGTG GCCAAGTACT 
TT/20:08TGCCAACCTC AACCTGACCG TGGATGAGGG TGTCCAGGTG GCCAAGTACT 
Fig.27a. Sequence alignment of exon 22 data shows the C35326T variant (bold the normal 
sequence, in green the homozygote variant, in red the heterozygote-shown as N due to the 
presence of a C and T peaks at the same position, nt 35326) 
Based on the results obtained from all screening methods all 73 samples were 
genotyped. Five samples (1319, D20, Dl0, 252, Q3) present one more band than expected 
when digested with FokI. This band cannot be explained, as D19 and 252 were sequenced 
and their sequences are identical with the database sequence. 
Exon 23 
XPD exon 23 starts at nt 35872 on GenBank XPD sequence L 47234 and is 93 bp 
long. Primers used to amplify this exon were forward D7895 and reverse D7896. The PCR 
product spans the region between nt 35760 and 36103 and is 344bp long (coding sequence 
shown in bold). 
TCAAACATCC TGTCCCTACT GGCCATTCGG GGGGGTGGTT GGGGAAGTGC 
AGCAGCTGCC TGGGCCCCTG CCCAACAGTG CCCCCCTCTC CCTTTCCTCT 
GTTCTCTGCA GG3572AGGATCAG CTGGGCCTGT CCCTGCTCAG CCTGGAGCAG 
CTAGAATCAG AGGAGACGCT GAAGAGGATA GAGCAGATTG CTCAGCAGCT 
CTGA35965GTGGQG CGQGTGGGGC CATAAACGQT TCCTGGTGAC TCCTGAGTCT 
TGCCTGQCCC TGGTTCCCAG CGGCGGTGGT GCTAGAAGGT CTTATGAAGT 
CAGGTGACAT TTCTCACTGT CACGTCCACA GCCTTTAATC GCAG 
There is an A->C transversion reported within exon 23 at nt 35931 (Shen et al., 
1998). Variant 35931 results in an amino acid change Lys75lGln. The allele frequency for 
this change is 0.29. Variant 35931 modifies the restriction map by introducing a second Pstl 
site at nt 35932. Two other variants have been found within iniron 22. The G insertion at nt 
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35788 has the allele frequency 0.04 and does not affect the restriction map. The second 
change, a G->C transversion at nt 35790, has allele frequency 0.29. This change introduces a 
second Faul site at nt 35782 and a forth Acil site t nt 35789. 
Variants 
TCAAACATCC TGTCCCTACT GGCCATTCG35788GG C3790GGGGTGGTI' GGGGAAGTGC 
AGCAGCTGCC TGGGCCCCTG CCCAACAGTG CCCCCCTCTC CCTTCCTCT 
GTTCTCTGCA GGAGGATCAG CTGGGCCTGT CCCTGCTCAG CCTGGAGCAG 
CTAGAATCAG AGGAGACGCT GC35931A'tGAGGATA GAGCAGATTG CTCAGCAGCT 
CTGAGTGGGG CGGGTGGGGC CATAAACGGT TCCTGGTGAC TCCTGAGTCT 
TGCCTGGCCC TGGTTCCCAG CGGCGGTGGT GCTAGAAGGT CTTATGAAGT 
CAGGTGACAT YI'CTCACTGT CACGTCCACA GCCTTTAATC GCAG 
XPD exon 23 amplified well at 94 °C 1 minute, 67 °C 1 minute, 72°C 30 seconds for 
35 cycles in all DNA samples. Although the PCR products were 344bp long, slightly bigger 
than optimal for the SSCP resolving power, they were used on SSCP gels and produced a 
good migration pattern. SSCP gels were run for 32 hours, longer than usual and at this length 
of time only ssDNA was seen on the gels. SSCP analysis detected a mobility shift in the 
ssDNA region. indicating a change in the DNA sequence (flg.30). 





Fig.30. SSCP analysis of exon 23 detected sequence variation. Variant 35391 was 
subsequently identified and the three genotypes are marked. 
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In order to determine the nucleotide change responsible for the SSCP pattern, RFLP 
assay was performed on all PCR products. As variant 35391 may be seen on SSCP gels, each 
PCR product was digested with PstI. The PstI restriction fragments, listed in table 7 indicate 
the three possible genotypes, AA (110 and 234bp fragments), AC (172, 110, 62, 71 and 
234bp fragments) and CC (172, 110 and 62bp fragments). 
Table 7. XPD exon 23 expected Pst I restriction fragments (bp) 
XPD exon 23 PCR product 3 44b Pst I 
Database sequence 110+234 
A->CVariant 35931 110+62+172 
The restriction reactions were performed for all DNA samples under the usual 
conditions and the restriction fragments analysed on 2% regular agarose gels. The expected 
PstI restriction fragments corresponding to the variant 35391 were seen on the agarose gels, 
(flg.3 I). The RFLP assay confirmed that A3593 1C variant was responsible for the mobility 
shift seen on SSCP gels. 





Fig. 311. Pst I restriction fragments of .xon 2 3 P C R proiuct indicate variant 35391. The 
fragment sizes and the corresponding genotypes are marked. 
Two samples of each migration pattern and corresponding genotype (D1 5, D4 -AC 
genotype), (D2, 238-CC genotype), D20, 252-AA genotype) were chosen to be sequenced in 
order to confirm the sequence change as being the variant 35391.These samples produced 
good, readable sequences, which confirmed the variant 35391 (flg.30a). Based on the results 
obtained from all screening methods all 73 samples were genotyped. The changes at nt 35788 
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or nt 35790 were not detected by SSCP or RFLP either due to their low frequency or location 
within the primer sequence. 
exon 23 CTAGAATCAG AGGAGACGCT GAAGAGGATA GAGCAGA1TG CTCAGCAGCT 
I CNNGAATCAG AGGAGACGCT G AGAGGATA GAGCAGATFG CTCAGCAGCT 
D2 CNAGAATCAG AGGAGACGCT GCAGAGGATA GAGCAGATTG NTCAGCAGNT 
238 CCCGAATCAG AGGAGACGCT GCAGAGGATA GAGCAGAYFG CTCAGCAGCT 
D20 CTAGAATCAG AGGAGACGCT GAAGAGGATA GAGCAGATG CTCAGCAGCT 
252 CTAGAATCAG AGGAGACGCT GAAGAGGATA GAGCAGATFG CTCAGCAGCT 
Fig.30a. Sequence alignment of exon 23 A35931C variant. In bold is the database sequence, 
in green the variant homozygote and in red the heterozygote (marked with N due to the 
presence of A and C peaks at the same nt position). 
Summary of the molecular analysis of the polymorphisms in the XPB and XPD genes 
Gene PCR SSCP RFL 
p 
Sequencing Variants 
XPB Exon 3 Yes Yes  No 
Exon 8 Poor No No 
Exon 9 No No  No 
XPD Exon 2 Yes Yes  Yes No 
Exon 3-4 Yes No  Yes No 
Exon 5 Yes Yes  No 
Exon 6 Yes Yes Yes Yes Yes 
Exon 7 Yes Yes  No 
Exon 8 Yes No Yes Yes No 
Exon 9 ND  
Exon 10 Poor No  No 
Exonli No No  No 
Exon 12 Yes Yes  No 
Exon 13 Yes Yes  No 
Exon 14 Yes Yes  No 
Exon 15 No No  No 
Exon 16 Yes Yes  No 
Exon 17 Yes Yes  No 
Exon 18 Yes Yes  Yes Yes 
Exon 19 Yes Yes  No 
Exon 20 Yes Yes  Yes Yes 
Exon 21 Yes Yes  No 
Exon 22 Yes Yes Yes Yes Yes 
Exon 23 Yes Yes Yes Yes Yes 
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Fig.32. Map of a 1Mb region of human chromosome 19q13.2—q113. The direction of 
transcription (where known) is indicated by an arrowhead. APO, apolipoprotein gene 
complex; ASE-1, antisense ERCC1 (CD3-associated protein); C, unknown function; CKM 
muscle creatine kinase; CLPTM1, cleft lip and palate-associated transmembrane protein 1; 
ERCC1. NER gene; FOSB, transcriptional activator; KLC2, kinesin light chain 2; VASP, 
vasodilator-stimulated phosphoprotein. 
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Additional markers to either side of the XPD locus were analysed in order to determine if 
any associations observed between melanoma and XPD also extend to the 5' and 3' flanking genes. 
The XPD flanking markers, CKMM and ERCC 1 genes were chosen based on the chromosome 19 
map and the published polymorphisms in the genes located closest to XPD. 
111.2.1. Map of chromosome 19, band g13 
A detailed map and extensive sequence information is available for human chromosome 
19q13.2-q13.3 (Lamerdin et al.. 1996), which contains two other DNA repair genes, nucleotide 
excision repair gene ERCC1 and single strand break repair gene. XRCC1, in addition to XPD. 
CKMM. XPD and ERCC19enes are physically linked within a segment of approximately 250kb. 
The order of the genes is: cen- 3 CKMM 5 -3 'XPD 5 -3 'ERCC1 5 -ter, with transcription start sites for 
the three genes on their telomeric side (Smects et al., 1990). The closest flanking markers to XPD, 
for which RFLPs are available are muscle creatine kinase (CKMM), located 50Kb 3' and ERCC 1, 







Fig.32. Map of a 1Mb region of human chromosome 19ql3.2—q13.3. containing XPD gene. 
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111.2.2. Molecular analysis of two CKMM pohosms 
The human CKMM gene contains 8 exons interrupted by 7 introns spanning 17.5 kilobase 
pairs of DNA. The intron-exon splice sites were identified and conform to the GT-AG consensus 
rule. The TATA and CAAT boxes are located at positions -31 and -56 upstream of the 
transcription start site (Trask et al., 1988) 
It codes for the cvtosolic protein creatine kinase. M chain, SWISS-PROT P06732. 
Creatine kinase (EC2.7.3.2) reversibly catalyses the phosphate transfer between ATP and various 
phosphogens (e.g. creatine phosphate). Its isoenz mes play a central role in energy transduction in 
tissues with large fluctuating energy demands such as muscle, heart, brain and spermatozoa. It is 
localised in the cytoplasm and the active form is a dimer of identical or non-identical chains, of 
which the MM isozyme is the major form, found in skeletal muscle and myocardium: MB is found 
in myocardium and BB is found in many tissues, especially in the brain. The expression of the 
creatine kinase isozvmes is tissue-specific and developmentally regulated (Rivera et al.. 1997) 
CKMM gene sequence is available from GenBank AC 005781. Based on the database 
sequence and the reported po1morphisms in CKMM gene, a DNA fragment containing two 
restriction site polymorphisms was chosen to be analysed in all 73 samples. The CKMM fragment 
spans nt 23 877-24975 and starts 5 1 b inside exon 8 and ends in the 3' end of the gene. Primers 
used to amplify this fragment were forward F32028 and reverse F32029, adapted from Lavedan et 
al., (1990) (coding sequences shown in bold). 
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ATCGGCTGGG CTCGTCCGAA GTAGAACAGG TGCAGCTGGT GGTGGATGGT 
GTGAAGCTCA TGGTGGAAAT GGAGAAGAAG TTGGAGAAAG GCCAGTCCAT 
TC.TGACGACATG ATCCCCGCCC AGAAG TA GGC GCCTGCCCAC CTGCCACCGA 
CTGCTGGAAC CCAGCCAGTG GGAGGGCCTG GCCCACCAGA GTCCTGCTCC 
CTCACTCCTC GCCCCGCCCC CTGTCCCAGA GTCCCACCTG GGGGCTCTCT 
CCACCCTTCT CAGAGTTCCA GCAACCA GAGTTCCAAC CAATGGGCTC 
CATCCTCTGG ATTCTGGCCA ATGAAATATC TCCCTGGCAG GGTCCTCTC 
1TTTCCCAGA GCTCCACCCC AACCAGGAGC TCTAG1TAAT GGAGAGCTCC 
CAGCACACTC GGAGCTTGTG C1TGTCTCC ACGCAAAGCG ATAAATAAAA 
GCATTGGTGG CCTTAGC GTGCGATAGT TAUGAGGGA GGACGTGCAA 
TfGGCCACTG TGTGGTCTCA GAGTGG1TTG TCCTGTCTAG GCATGTACTA 
AACATGTCTT ATCCCGGGTC TAAAATGAGG CAAAGTAGG TCACAGAATC 
TAGTCCAAAA ATT'AGAAGGC TCTATGGGGA ATCTGAGACC CAGAGAGACA 
CTGAGCCCAG TGTCACTCAC CCAAAGCATG GGCCCTTTCC AACTATGGCT 
TTGAATTAGT CATGCTCAGA TCTCAAACAC GAGGTCCACG CTGGGGAGGA 
ATGCAGCCAA ACGAAATGTC TGAAACTTGA A1TFAGCCCA ACGGTCTCCA 
GTr1I GAGAC CTCCCATGCA GCTCGTCACA TCTACCTATA TTCTGCTTCT 
CAGTGGCCTC CTTCTGTCCC GTCTGACTTC ATCCCTCTGT AGCTGCTGCC 
AGTCCCTTAC TITCTCAAGA ACCTGCNCOICATG  GCTCCCCA1T TCTCCTAGAA 
AGC1TVICTG rrAITFIGCA ACTCAAGGCC ACACTGAAAT GCATACCATT 
TGCTGGAGGC TCACC1TTCC AGUC1T7CC CCA'ITACTCC TCTGATTC1T 
TCACACCTGA CACCCTCCAA UCCCACCTC AATGTCTTTG ACCAAGCTG 
CKMM fragment spans nt 23877-24975 and has a polymorphic TaqI site at nt 23977 and 
a polymorphic NcoI site at nt 24800 (Coerwinkel-Driessen et aL, 1988), (Perryman et al., 1988). 
Another NcoI polymorphism in the 3 'end of CKMM gene has been described in (Differ et al., 
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1992). This additional NcoI site is located 5' to the original sitein the CKMM fragment and 
generates two restriction fragments of 675bp and 260bp respectively. This is a very rare variant. 
Two other silent polymorphisms have been reported, a C->T transition in exon 4 and a A-
>C transversion in exon 5 (Bally et al., 1991). The C->T polymorphism has C allele frequency of 
0.57 and T allele frequency of 0.43. The A->C polymorphism affects a BstUT restriction site and 
the frequencies of BstUl (+) and Bstt.JI (-) alleles are 0.89 and 0. 11, respectively. 
The CKMM fragment amplified well at 94 ° C 1 minute; 67 0 C 1 minute; 72 ° lminute for 
35 cycles and gave a strong 1 098bp product, which was analysed by RFLP assay using Taqi and 
NcoI restriction enzymes. TaqI restriction fragments, listed in table 8, indicate the three possible 
genotypes TT (109%p-no cut), TC (1099bp+999bp+100bp) and CC (100bp+999bp). NcoI 
restriction fragments, listed in table 8 indicate the three possible genotypes CC (926bp+173bp). 
CX (1099bp+926bp+173bp) and XX (lO99bp-no cut). 
Table 8. CKMIvI expected Taqi and NcoI restricted fragments (bp) 
CKMM PCR product 1098bp TaqI Ncol 
database sequence 1099 no cut 926+173 
variant exon 8 999+100 
variant 3'end 1099 no cut 
CKMM amplified fragments corresponding to all DNA samples were separately restricted 
with TaqI and NcoI. The restriction reactions were performed under the usual conditions and the 
resulting fragments were separated on 1.5% regular agarose gels, EtBr stained  and photographed 
(fig.33 and 34). 
TT 	TC 	CC 
Fig.3 3. CKMM Taqi restriction fragments, which indicate sequence variation. The genotypes and 




Fig.34. CKMM Ncol restriction fragments indicate sequence variations. The genotypes and 
fragment sizes are shown. 
The expected TaqI and NcoI restriction fragments were seen on the agarose gels. 
Therefore, both variants were present and all samples were genotyped. 
111.2.3. Molecular analysis ofERCC1 exons 3. 4 and 5 
ERCC1 gene is composed of 10 exons ranging in size from 60 to 216bp. The promoter is 
located 1 7Obp upstream of the transcription initiation site and it does not contain the classical 
elements such as CAAT, TATA, GC boxes (van Duin et al., 1987). The major transcript is a 
1.1kb rnRNA. The 3' region contains a CAYTG box and a T-rich element and there are also 
multiple adenylation sites in the 3' UTR. ERCCI gene encodes a 297 amino acid endonuclease 
involved specifically in nucleotide excision repair pathway. 
93 	126 	224 	 297 
236 	289 
2xHhH motif 
Fig.35. Schematic representation of the ERCC1 protein identified functional domains. 
The yellow boxes represent the protein-binding domains. The putative nuclear localisation signal 
spans an 17-23 and the DNA-binding domain spans an 134-156. The putative functional domain 
based on the primary amino acid sequence is indicated below each schematic representation 
(hatched boxes). 2xHhHdouble helix-turn-helix motif. Adapted from de Laat et al., (1999). 
125 
Exons 3, 4 and 5 of the ERCC1 gene were analysed for sequence variation. These exons 
wee chosen based on the variants reported in these exons and on the gene orientation on the 
chromosome. ERCC1 GenBank sequence M63796 and (Shen et al., 1998) was used to design 
primer pairs, specific to each individual exon and to set up RFLP assays. 
Exon 3 
Exon 3 spans nt 19982-19766 on M63796 GenBank sequence and is 216bp long. Primer 
pair, forward F20475 and reverse F20476 amplified exon 3 and gave a 31 7bp PCR product, 
spanning nt 20026-19126 (coding sequences shown in bold) 
CTGAAAAC CTCAAGGCCT CACTFCTCCG TCTCCCTCCT CACCTGCCGA 
GGGCTCACAA TGATGCTGTT GGATTTTGCC CCGGGTTTCA GGGCCTGGTT 
GGGCGTCTCT CCTGCCAGGG GCTCTGACCC TGTGGGGCAC' 9 GTGGCCCCAG 
CCCCTTCCAG AGGCTGTGAG ATGGCATATT CGGCGTAGGT CTGAGGGGCC 
GCCTGGGCCG AGGTGTCCAC AGTGGGAAGG CTCTGTGTAG ATCGGAATAA 
GGGCTTGGCC TGTGGGGAGA AAGGGAGTTI' GCAGGGGACT GGTTGGGGTG 
AGCAGAGGAC ATCTGAG 
There is a C->T silent transition at nt 19886, reported with a frequency of 0.04 (Shen et 
al., 1998). Variant 19886 modifies the restriction map of the region by introducing sites for NspI 
and Nialil. 
Exon 3 amplified well in all DNA samples under the following thermal cycling conditions: 
940 C iminute. 67° C iminute, 720 30 seconds for 30 cycles. Each individual PCR product was 
digested with Nspl under the standard conditions. The possible three genotypes are: CC (31 7bp, no 
cut), CT (317+180±137bp) and IT (180+137bp). The restricted fragments were analysed on a 2% 
regular agarose gel, which was stained with EtBr and photographed (fig.36). All samples were 
restricted with NspI and none of them were cut. Therefore variant 19886 is not present in the 
samples analysed, possibly due its low frequency. 
Fig.36. NspI restriction analysis ofERCC1 exon 3 PCR products. All the samples did not cut with 
NspI, indicating that there was no sequence variation amongst samples; uncut fragment size is 
shown. 
Exon 4 
ERCC1 exon 4 spans nt 19071-18975 on Genbank sequence M 63796 and is I06bp long. 
Primer pair forward F 32030 and reverse F32031 amplified exon 4 and gave a 252bp PCR 
product, spaning nt 19 177-18935 (coding sequences shown in bold). 
GACCATGCCC AGAGGC1TCT CATAGAACAG TCCAGAACAC TGGGACATGA CCCTCCCAGG 
CCAGTGGGGT GCCCTI'CCTG AAGTCTGGGG TGGCGCCGCA GAGCTCACCT 
GAGGAACAGG GCACAGGTGC TCTGGCCCAG CACATAGTCG GGAATTACGT 
CGCCAAATTC CCAGGGCACG 900 ' TTGCGCACGA ACTTCAGTAC GGGATTGCCC 
CTCTGGGGAG GGACGAAGGG CAGAAGCCAT CAATAGGGAT GA 
A G->A transition is reported within the exon at nt 19007, with allele frequency of 0.46 
(Shen et al., 1998). Variant 19007 introduces second sites for Tail and MaeII and removes the 
BsrDI site. 
Exon 4 amplified well in all DNA samples under the following thermal cycling conditions: 
940 C Iminute. 69 0 C lminute, 720 30 seconds for 35 cycles. Each individual PCR product was 
digested with BsrDI under the usual restriction conditions. The BsrDl restriction fragments 
expected of variant 19007 indicate the three possible genotypes, GG (252bp-no cut), GA 
(252bp+179bp±73bp) and AA (179bp+73bp). Restricted fragments were analysed on a 2% 
regular agarose gel, stained with EtBr and photographed (fig. 37). 
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GG GA AA 
252bp  
179bp 
Fig.37. BsrDI restriction fragments of exon4 PCR products indicate sequence variation; 
The genotypes and fragment sizes are shown. 
The expected BsrDl restriction fragments for the variant 19007 were present on the 
agarose gels, therefore all samples were genotyped for the BsrDl polymorphic site, grouped by 
genotype and statistically analysed. 
Exon 5 
ERCC1 exon 5 spans nt 17810-17910 on GenBank sequence M 637967 and is lOObp 
long. Primer pair. forward F 20477 and reverse F 20478 amplified exon 5. The 287bp PCR 
product spans nt 18048 to nt 17693 (coding sequences shown in bold). 
CTGGTGACC CATGTCATCT CAGATGTGAA AAACG17CCT CGCTGAGGT 
TTAGCTGCAT TTCCTCTTGG AAGGGATTCA ACAGCCCACT GCACAACCTC 
AAAGCCCG1 GT GAGGCTGGCT AGGGAGCAGC CCCTGCTTAC CACATCCACC 
TGGACAAGCA GGACCCGCAA GGCGAAGTTC TTCCCCAGGC TCTGCAGCCG 
CCCA" 3TGGATG TAGTCTGGGT GCAGGTTGTG GTAGCGGAGG CTGGTGGGGG 
CAGGGAGCGG GAGYFGAGAG GTCTCAGTCT CTCAAG 
In this region two polymorphisms have been reported: an A->G silent transition in exon 5, 
at nt 17773 and a G->T transversion in intron 5, at nt 17677 (Shen et al., 1998). Variant 17773 
has a frequency of 0.04 and removes the NcoI site. Variant 17677 has a 0.33 frequency and 
removes sites for: HphI, Ncil, ScrFI, HpaII, BssKl. 
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The PCR reaction worked well iii all DNA samples, under the following thermal cycling 
conditions: 940  C 1 minute, 67° C 1 minute, 72 ° 30 seconds for 30 cycles. Each PCR product was 
digested with NcoI under the standard restriction conditions. NcoI restriction fragments expected of 
variant 17773 indicate the three possible genotypes AA (80bp+207bp), AG (287bp+80bp+207bp), 
GG (287bp, no cut). NcoI restriction fragments were run on 2% regular agarose gels, EtBr stained 
and photographed (fig. 38). The NcoI restriction analysis showed that all samples were cut by NcoI. 
Therefore, variant 17773 was not present in all samples analysed. 
207bp 
Fig.38. NcoI restriction fragments of ERCC 1 exon5 PCR products. The 207bp fragment shown 
indicates that all samples were cut and therefore no sequence variation was present in the samples 
analysed. 
The two CKMM polymorphisms (exon 8 and 3'UTR) and the ERCC1 exon 4 
polymorphism were used to investigate whether the association seen between XPD and melanoma 
also extended to these two flanking markers. 
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Tot Me- 110911POR111031113. 
In order to carry out the association study of NER gene polymorphisms and 
melanoma, blood samples were obtained from 40 patients, attending the Dermatology 
Department at the Royal Infirmary of Edinburgh.  comprising 8 basal cell carcinoma, 4 actinic 
keratose. 28 melanoma patients and 33 normal donors at the Scottish Blood Transfusion 
Service in the same hospital. The criteria for suitability were chosen to maximise the chance 
of there being a strong genetic component to the disease. These criteria were age under 50 and 
no history of extreme sun exposure. The mean age of the patients was 42 +1- 10, compared 
with a mean age of 45+1-10 for the controls. 
XPB exon 3 SSCP analysis did not show any variation in control and melanoma 
samples, whilst the other two XPB exons 8 and 9 have not been analysed due to poor 
amplification reactions. 
XPD polymorphism study on healthy individuals and melanoma patients showed 
sequence variation in the XPD gene in exons 6, 22 and 23 and introns 18 and 19. All these 
variants are in concordance with a previous report, where these polymorphisms were observed 
in a study of 12 presumed healthy individuals (Shen et al., 1998). 
The data obtained for G34382C variant in intron 18 were incomplete. The SSCP 
analysis was not sufficiently indicative and it would have had to be supported by extensive 
sequencing analysis. For intron 18, only 47 of 73 samples were analysed by SSCP and only 
few produced good sequencing data. For intron 19, the SSCP and sequencing analyses showed 
that the C34750T variant is present amongst the 73 samples analysed, of which 13 were CT 
and the rest homozygote (CC and iT). Therefore, the data on these two variants are 
incomplete and have not been included in the statistical analysis. 
111.3.1. Statistical analysis of XPD polvmorohisms 
Molecular analysis of XPD variants within coding sequences shows that 156Arg 
(exon6), 71lAsp (exon22) and Lvs75 1Gm (exon23) are present and the genotypes were 
determined for control and melanoma samples. The 156Arg genotype distribution, shown in 
table 9 gives C-allele frequency of 0.636 in controls and 0.464 in melanoma cases. It can also 
be seen that the distribution of normal and variant homozygous genotypes is approximately 
the same in melanoma cases (9 AA versus 7 CC). Similar distribution is seen in controls, 
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where 3 were AA and 12 CC. In all 61 samples (28 cases and 33 controls) 12 were AA and 
19 CC. 
Table 9. XPD 156Arg genotyping (A22541C, exon6) 
sample total AA (%) AC (%) CC (%) 
description  
all samples 61 12 (19.67) 30 (49.18) 19 (31.14) 
controls 33 3(9.09) 18 (54.54) 12 (36.36) 
234.DC 1 5.DCI 6 233,235,236,237,239,252, 238,248.20:08.Q1 
247,DC 1.DC2.DC4.DC5. 7 Q2.Q3,792,DC3, 
DC6,DC8,DC1O.DC12, DC7.DC9.DC1 1. 
DC13.DC17. DCI8 DCI4 
melanoma 28 9 (32.14) 12 (42.85) 7 (25) 
D16,D17,D18.D19. D12.D25,D26,D28,D29, Dl 1,D13,D14, 
D23,D24,D27.D3() D3 1,D34,D36,D37,D38. Dl 5,D20,D32. 
D41 D39, D40. D35 
71 IAsp is present in the group studied, with T-allele frequency of 0.363 in control 
and 0.178 in melanoma cases. From table 10 it can be seen that in melanoma cases the T 
allele is under-represented, only one case is homozygous IT (sample D34), whilst the C-allele 
is over-represented with 19 cases homozygous CC. In the control group 6 individuals are 
homozygous TT and 15 are homozygous CC. In the whole group, T-allele is under-
represented with 7 individuals TT versus 34 CC. 
Table 10. XPD 71 lAsp genotyping (C35326T, exon 22) 
sample total CC (%) CT (%) TI' (%) 
description  
all samples 61 34 (55.73) 20 (32.78) 7(11.47) 
controls 33 15 (45.45) 12 (36.36) 6(18.18) 
233,234.235.236.237, 247,Q2.Q3DC2,DC1, 20:08,248, 
239,792,252,DC4,DC7, DC 14,DC 11 ,DC 12, 238,Q1 .DC3 
DC 16,DC 1 5.DC6.DC13, DC 10,DC 17,DC 18, .DC9 
DCS DCS  
melanoma 28 19(67.85%) 8(28.57%) 1 (3.57%) 
Dl8,Dl7,Dl6.D14.D12, 1311,1313,D15,1320, D34 
D19,1323,1324.1325,D27, D26, D28,D32,D35 
D29.D30,D3 I .D36,D37, 
D38.1339.1340.134 I  
131 
Lys75lGln is present in the group studied, with C-allele frequency of 0.409 in control 
and 0.196 in melanoma cases, Genotype distribution by cases and controls shows that similar 
to 71 lAsp variant, the C-allele is under-represented in melanoma cases where only one case 
(D34) is homozygous CC, whilst the A allele is over-represented, 18 cases are homozygous 
AA. Again similar to the 71 lAsp distribution, in the control group 8 individuals are 
homozygous CC and 14 homozygous AA. In the whole group, C-allele is under-represented 
with 9 CC individuals versus 32 AA (table 11). 
Table 11. XPD Lys75lGln genotvping (A35391C, exon 23) 
sample total AA (%) AC (%) CC (%) 
description  
all samples 61 32 (52.45) 20 (32.78) 9(14.75) 
controls 33 14(42.42%) 11(33.33%) 8(24.24%) 
234,235,236,237,239,792, 247,Q3,233,DC l,DC2, Ql,Q2,20:08, 
252.DC4.DC5.DC7,DC6, DC8,DC 1O,DC 12, 248.238,DC3. 
DC13.DC 15,DC16 DCI4.DC17,DC18 DC9,DC 11 
melanoma 28 18(64.28%) 9(32.14%) 1(3.57%) 
D12,D14.D16.D17.D 18. Dl 1,Dl3.D15,D25, D34 
Dl 9.D20,D23.D24.D27. 1326,1328,D32,D35, 
D29.D30,D3 l.D37.D38. D36 
D39.1340.D4 1  
The 71lAsp and Lvs751Gln genotype distributions indicate that for both 
polymorphisms cases and controls show under-represented variant allele and over-represented 
non-variant allele. In the melanoma group one individual, sample D34 is homozygous for both 
variant alleles. Also, of the 10 individuals heterozygous for either polymorphism, 7 are 
heterozygous for nucleotide variations in both exon 22 and 23. Similarly,  in control group, of 
the 8 individuals homozygous for either polymorphism, 6 are homozygous for both variant 
alleles. And of 13 individuals heterozygous for either polymorphism, 10 were heterozygous for 
both polymorphisms. A large proportion of individuals was homozygous for both normal 
alleles in cases and controls. A similar but weaker trend is seen in exon 6. These data indicate 
strong linkage disequilibrium between exon 22 and 23, which becomes weaker towards exon 
6. This observation agrees with numerous previous reports, where exon 6. exon 10, exon22 
and 23 polymorphisms were strongly linked. In order to investigate the possible association 
between XPD genotypes and melanoma, the data for exon 6, 22 and 23 have been statistically 
analysed. The statistical analysis was done by Dr. Harry Campbell. 
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The expected genotype distributions for exons 6, 22 and 23 under Hardy-Weinberg 
equilibrium were derived for both melanoma cases and controls and compared to the observed 
distributions. This confirmed that the observed distributions were consistent with the Hardy-
Weinberg equilibrium. Therefore alleles at these exons were assumed independent. Then allele 
counts rather than genotypes were compared, in melanoma cases and controls because of the 
resulting increased power of the statistical analysis. The exon 23 (nt35931) A allele was 
significantly over-represented in melanoma patients (odds ratio 2.8, 95% confidence interval 
1.2-7.0, p0.02). The exon 22 (nt 35326) C allele was also significantly over-represented in 
the disease group (odds ratio 2.6, 95% confidence interval 1.1-6.7, p=0.04). For exon 6 (nt 
22541) A allele the odds ratio for over-representation in the disease group was 2.0 (95% 
confidence interval 0.94.5) but the effect was not statiscally significant, p=0.08 (table 12). 
This correlates with the idea that the association between XPD polymorphisms and melanoma 
is stronger for exons 23 and 22 and weakens towards exon 6. 
Table 12. Comparison of XPD exon 6, 22 and 23 allele counts in controls and melanoma 
Exon6 A C 
melanoma 30 26 odds ratio 2.0, 95% confidence interval 0.9-4.5, p0.08 
controls 24 42 
Exon22 C T 
melanoma 46 10 odds ratio 2.6, 95% confidence interval 1.1-6.7, p=O.04 
controls 42 24 
Exon23 A C 
melanoma 45 11 odds ratio 2.8. 95% confidence interval 1.2-7.0, p0.02 
controls 39 27 
* chi squared with Yates correction 
This analysis was extended by carrying out a haplotype analysis using the linkage 
utility programme EH. This programme tests for allelic association between loci by comparing 
the likelihoods of the data under the assumption of no association and of association. In the 
former case it is assumed that alleles at different loci occur independently so haplotype 
frequencies are formed as the product of constituent allele frequencies, while if association is 
allowed for haplotype frequencies are estimated from the data. The programme estimates the 
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haplotype frequencies under the assumption of no allelic association (HO), allelic association 
between markers but not with disease (H 1) and association between alleles and the disease as 
well as allelic association (1-12). Analyses by EH of allele counts for the following pairs of 
exons confirmed significant allele association and association between allele and disease 
status: exon 23/exon 22 (H2 chi squared 87.1, 3df, p<O.00l) ; exon 23/exon 6 (1-12 chi squared 
42.1, 3df. p<0.00 I) - exon 22/exon 6 (1-12 chi squared 37.2, 3df, p<0.00 1). 
Statistical analysis provided clear evidence of a statistically significant positive 
association between XPD exons 6, 22 and 23 polymorphisms and melanoma. Several 
explanations could account for this result. One possible explanation is that the alteration in 
XPD protein itself is responsible for this association, but there are a number of other possible 
alternative explanations: chance, artefact, linkage disequilibrium and population stratification. 
Whilst the first two explanations are considered in the discussion chapter, the last two 
competing explanations were addressed by analysing polymorphisms in genes flanking XPD in 
the control and melanoma groups. 
111.3.2. Statistical analysis of genotyping data for XPD flanking markers 
Although statistical analysis gives evidence for a positive association between XPD 
exon 6. 22 and 23 polymorphisms and melanoma, one possible explanation for the association 
is linkage disequilibrium. If linkage disequilibrium was responsible for the association 
observed between XPD and melanoma, a similar association would also occur between the 
markers flanking XPD and disease status. In order to investigate this, CKMM and ERCC 1 
genotvping data were used in statistical analysis. 
CKMM genotyping, shown in table 13a and table 13b indicated that Taqi T-allele and 
NcoI X-allele have similar frequencies of 0.26. Similar frequencies of 0.33 for NcoI and 0.27 
for Taqi are reported in other studies (Gennarelli et al., 1991), (Rivera et al., 1997) Unlike the 
XPD polymorphisms, the frequency of CKMM genotypes in control and melanoma groups 
appeared very similar. This indicates that Taqi and NcoI polymorphisms are not linked to 
XPD polymorphisms. Also, in my study group, CKMM TaqI and Nco I were not linked 
together, although this was reported in myotonic dystrophy families in Spain and Italy 
(Genriarelli et al., 1991) and in sedentary and athletic individuals in Canada (Rivera et al., 
1997). 
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Table 13a. CKMM Taqi genotyping 
sample total Ti' (%) TC (%) CC (%) 
description  
all samples 61 1 30 30 
controls 33 1(3.03) 17 (51.51) 15 (45.45) 
Q3 DCI .DC2,DC5.DC6,DC8 20:08.Ql ,236,237,238, 
,DC1O,DC1 l,DC12,DCI3 247,Q2.792,DC3,DC4, 
.DC1 5.DC 18,248.252,239 DC7,DC9,DC I 4.DC 16, 
234.235. 233, DC 17 
melanoma 28 0 13 (46.43) 15 (53.57) 
Dl2.D16.D18,D19.D23, Dl 1.1313,D14.D15,D17, 
D24,D25D27D29,D3 1, D20,1326,1328,D30,1332, 
D36.D40.D41 D34, D35,D37.D38.D39 
Table 13b. CKMM Ncol genotyping 
sample total CC (%) CX (%) XX (%) 
description  
all samples 61 31 26 4 
controls 33 16 (48.48) 15 (45.45) 2 (6.06) 
235,792,252,Q2,Q3 233,234.236,237, 247,DC3 
,DC1,DC4.DC5, 238,239.Ql,20:08, 
DC8,DC1O,DC11, 248,DC2,DC6, 
DC13.DCI4.DC15, DC7, DC9,DC12, 
DC16.DC18 DC17  
melanoma 28 15 (53.57) 11(39.28) 2(7.14) 
D14,D16,D18,D19. Dl 1,P12,1315,D17, D13,D32 
D20,D23,D24,D28, D25,D26,D27,D3 1, 
D29.D30,D34,D35, D38.D39,D40 
D36,D37.D4 1  
The genotype distributions of CKMM Taqi and NcoI were used in further statistical 
analysis to confirm that the association seen for melanoma and XPD gene does not extend to 
its 3' neighbour. CKMM. The CKMM genotype distributions were consistent with those 
expected under Hardy-Weinberg equilibrium. As before the allele counts found in melanoma 
cases and controls were compared (table 14). ORs below 1 and p values of 0.6 and 0.9 
indicated that there was no association between the two CKMM polymorphisms and 
melanoma. 
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Table 14. Comparison of CKMM allele counts in controls and melanoma 
CKMMexon8 T C 
melanoma 13 43 odds ratio 0.75, 95% confidence interval 0.3-1.8, p=0.6" 
controls 19 47 
CKMM3' C X 
melanoma 41 15 odds ratio 0.9, 95% confidence interval 0.4-2.2, p=0.97' 
controls 47 19 
* chi squared with Yates correction 
ERCC 111 8Asn genotype distribution is shown in table 15 In the study group in this 
thesis the A-allele frequency was 0.6; only one other study in 12 presumed healthy individuals 
reports ERCCI 118Asn with a frequency of 0.46. Unlike the XPD polymorphisms, the 
frequency of ERCC 1 genotypes in control and melanoma groups appeared very similar. This 
indicated that the ERCC I exon 4 polymorphism was not linked to XPD polymorphisms. 
Table 15. ERCC1 1 l8Asn genotvping (G19007A. exon 4) 
sample total TT/AA (%) TC/GA (%) CCIGG (%) 
description  no cut 
all samples 61 22 36 3 
controls 33 9(27,27) 22 (66.66) 2 (6.06) 
235,236.237,792, 233,234,238,239,252,247, 20:08, 248 
Q3.DC3,DC4,DC 13 Qi .Q2,DC l,DC2,DC5, 
,DC 16 DC6,DC7,DC8,DC9.DCIO 
,DC1 1,DC12,DC14,DC15, 
DC17. DC18  
melanoma 28 13 (46.42) 14 (50) 1 (3.57) 
D12,D14,D15,D16, Dl 1,D13,D17,D19,D20, D31 
D 18,D24,D26,D29, D23,D25,D27,D28,D32, 
D30,D34,D38,D40, D35, D36, D37,D39 
D41 
The ERCC I genotyping data were used in further statistical analysis to confirm that 
the association seen for melanoma and XPD gene does not extend to its 5' nearby gene. The 
ERCC 1 genotype distributions were consistent with those expected under Hardy-Weinberg 
equilibrium. Then the allele counts found in melanoma cases and controls were compared 
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(table 16). As for CKMM, there was no association between ERCC1 1 I8Asn polymorphism 
and melanoma, with p value of 0.3. 
Table 16. Comparison of ERCC1 allele counts in controls and melanoma 
ERRClexon4 G A 
melanoma 16 40 odds ratio 1.6, 95% confidence interval 0.7-3.7, p=0,3* 
controls 26 40 
* chi squared with Yates correction 
Statistical analysis of XPD flanking markers did not show an association with 
melanoma. Thus, it is possible that melanoma susceptibility is confined within the XPD gene. 
However. linkage disequilibrium between XPD and another gene, i.e. one more closely linked 
to XPD than CKMM or ERCC 1 (although none of these have an obvious correlation with 
cancer) might still account as a possible explanation for the association seen between XPD 
polvmorphisms and melanoma. 
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111.4. 1. p53 
p53 protein is almost undetectable in resting cells, whereas in transformed, or 
proliferating cells p53 is activated and can be easily immunodetected. In response to DNA 
damage, such as ionising radiation, ultra-violet light, hypoxia and ribonucleotide triphosphate 
depletion p53 also becomes activated (Albrechtsen et al., 1999). 
The main function of activated p53 protein is to transactivate p53-responsive genes, 
which can induce either cell cycle arrest or apoptosis depending on the cell type and the severity of 
DNA damage. Growth arrest takes place either before DNA replication in G  or before mitosis in 
G2 and allows DNA damage to be repaired (Albrechtsen et al., 1999). If the damage cannot be 
repaired then p53 can induce apoptosis. 
The NER pathway removes UV light-induced DNA damage. NER does not operate in 
isolation, it is closely linked with transcription, as some NER proteins are TFLIIH components and 
with DNA replication via the p53-pathway. p53 protein potentially has multiple roles in NER as it 
regulates p53-responsive downstream genes and it interacts with both damage and repair proteins 
(Wani etal., 1999). In NER p53 can be a trigger or a modulator. p53-dependent NER takes place 
after DNA damage activated p53 protein stops the cell cycle to allow damage to be repaired. p53 
can modulate NER activity through interaction with single-stranded DNA or association with 
repair proteins XPB, XPD, XPE, RPA, CSB which are required for transcription coupled repair 
or global genome repair (McKay et al., 1999). 
Since p53 protein is linked with NER it is interesting to see whether or not NER gene 
polymorphisms correlate with UV light induced p53 expression in fresh human cultured 
lymphocytes. It is possible that subtle changes in the XPB and XPD proteins might alter p53 
interactions, leading to a reduced p53 response to UV-induced DNA damage and as a result 
increased risk of cancer. If XPD polymorphisms correlate with p33 response to UV irradiation, 
then lymphocytes from individuals with genotype associated with increased cancer risk would 
have reduced p53 response. 
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111.4.2. p53  detection in cultured peripheral lymphocytes 
Peripheral blood lymphocytes represent a convenient surrogate tissue to experiment on, as 
they are accessible and easy to collect and grow in culture (Cheng et at., 1999). Cultured 
peripheral lymphocytes have been mainly used to study the hypothesis of low repair rates and 
association with high risk of cancer. To investigate this, DNA Repair Capacity (DRC) is 
measured in blood lymphocytes, using a host-cell reactivation assay to measures cellular 
activation of a reporter gene irradiated with UV light. Recently, a multiplex RT-PCR assay has 
been developed for measuring relative mRNA of NER genes in stimulated cultured lymphocytes 
isolated from normal individuals and from lung cancer patients (Cheng ci al.. 1999), (Cheng et 
at., 2000). The general tendency is now to investigate the link between NER polymorphisms and 
susceptibility to cancer in human cultured peripheral lymphocytes. To date there are no reports of 
correlation between p53 protein levels in cultured peripheral lymphocytes and XPD 
polymorphisms. 
In order to study a potential correlation between XPD exon 23 and exon 22 
polymorphisms and p53 protein levels, 8 blood samples from normal individuals (table 16) were 
collected and lymphocytes isolated. Smnl from each blood sample were used to isolate DNA and all 
8 DNA samples were genotyped for XPD exon 23 and 22. 
Table 16. Details of blood samples used in the lymphocyte assay 
BTS ref# blood type sex age 
235463E2 A+ F 38 
235465E9 0+ M 50 
235459E4 0+ F 44 
235464E0 0+ F 45 
235916E2 A+ F 48 
235918E9 0+ M 50 
235958E8 0+ F 27 
235960EX A- M 
:38
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The lymphocytes were stimulated with Concanavalin A, lOj.tg/ml and grown for 3 days in 
two 60mm dishes in liquid RPM! medium. After 3 days, one dish for each sample was irradiated 
with 20 JIm2 and the other kept as control. Protein Ivsates were made 6-8hours after irradiation. 
All 8 protein samples were analysed using the same conditions: -20404g protein/lane were 
loaded and run on 12% acrylaniide gel, then transferred to a membrane which was probed for p53 
and subsequently for actin. Actin signal was used as a loading control and to quantify the p53 
signal. 
Samples 463, 465. 459, 464 (control and UV-Irradiated) were run on the same gel. After 
Iminute exposure p53 signal was detectable in control samples. lanes 1,3,5,7 and showed a strong 
response in irradiated samples, lanes 2,4,6,8 (fig.39). Quantification of the p53 response by actin 
reprobing of the same membrane showed that the control and UV-Irradiated lanes for each sample 
were matched (fig.39). 
1 	34 	c 	( 	- 
PS3 
Actin 	 - 	iiMP 
Fig.39. p53 and actin detection. 
Samples 463 (lanes 1 and 2), 465 (lanes 3 and 4), 459 (lanes 5 and 6), 464 (lanes 7 and 8). 
Lanes 1, 3, 5. 7 protein lysates from non-irradiated cells; lanes 2, 4, 6, 8 protein Mates from 
irradiated cells. 
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Sample 916 and 918 (control and UV-irradiated) were run on the same gel. After 5 
minutes exposure p53 protein was detectable in control samples, lanes 1, 3 and showed a strong 
response in irradiated samples, lanes 2, 4 (fig.40). The p53 response was quantified by actin 
reprobing of the same membrane, which showed at 5 seconds exposure time, that the 2 lanes 
corresponding to each sample were matched (fig.40). 
1 	2 	3 	4 
P53 
_____...-...... Actin  
Fig40. p53 and actin detection. 
Sample 916 (lanes 1 and 2) and 918 (lanes 3 and 4). 
Lanes 1 and 3 protein lysates from irradiated cells; lanes 2 and 4 protein Mates from non- 
irradiated cells 
Samples 958 and 960, control and UV-irradiated were run on the same gel. After one 
minute exposure p53 protein was detectable in control samples, lanes 1 and 3. It appeared that, 
after irradiation sample 958 in lane 2 had a stronger p53 response than 960 in lane 4 (fig.41). 
Actin reprobing and 2 seconds film exposure showed that the apparently stronger p53 response 
seen in sample 958 was in fact due to an underload in lane 4 (fig.41). 
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Fig. 41. p53 and actin detection. 
Sample 958 (lanes 1 and 2) and 960 (lanes 3 and 4). 
Lanes 1 and 3 protein lysates from non-irradiated cells; lanes 2 and 4 protein lvsates from 
irradiated cells. 
111.4.3. p53 expression and XPD po1wnohisms 
All 8 lymphocyte cultures had detectable levels of p53, which increased following UV 
light exposure. Actin reprobing showed that the loading of the gel was reasonably well matched 
and the actin signal was used to quantify the p53 response. In order to quantify the p53 response, 
p53 and actin signals were scanned, analysed with Nil-I Image 1.62f software and the intensities 
were measured. Columns 3 and 4 of table 17 show the raw data for p53 and actin signals. From 
these, the p53/actin ratio was calculated. The p53 response for each culture was calculated by 
dividing the p53/actin band intensity ratio for the irradiated sample by that of the non-irradiated 
sample. Table 17 summarises the p53 response data for all 8 samples genotyped for XPD 
C35326T and A35391C. 
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Table 17. Summary of the p53 response in lymphocytes genotyped for XPD C35326T and 
A3 5391 C 
p53/actin band intensity ratio 












235463E2 CC AC 0.901 1.076 1.19 
235465E9 CT AC 0.104 0.880 8.46 
235459E4 CT AC 0.739 1.017 1.38 
235464E0 CT AC 1.035 1.031 1.00 
235916E2 •CC AC 0.467 0.791 1.70 
235918E9 CT AC 0.201 0.883 4.40 
235958E8 T1' CC 0.323 1.012 3.13 
235960EX CT AC 0.053 0.835 15.75 
Table 17 shows that XPD exon 22 and exon 23 genotypes correlate for all samples except 
for 463 and 916. For exon 22 and 23 polymorphisms a positive association with melanoma was 
found. If this predisposition is due to an altered interaction between the NER proteins and p53, 
this would be seen in reduced p53 response to UV induced DNA damage in lymphocytes carrying 
the predisposing alleles. Therefore, it would be expected that lymphocytes with exon 23 A-allele 
or exon 22 C-allele or both would show reduced p53 response. As can be seen from table 17 the 
p53 response varied widely in the 8 samples from ito 15. In this assay the highest (sample 960) 
and the lowest (sample 464) p53 response are seen in lymphocytes with exon 22 CT and exon 23 
AC genotype. Sample 958, homozygote for both variants does not have higher p53 response than 
the other 7 samples containing 1 or more C alleles. A better interpretation of the p53 values would 
be based on a gel where all control and/or irradiated protein samples would be loaded and 
migrated simultaneously. This would allow for a better quantification of the p53 response in all 
samples relative to the reference sample. 
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In conclusion, the p53 assay worked on fresh human lymphocytes. The 8 samples 
analysed showed that there was no correlation between the p53 response and the XPD exon 22 
and 23 genotypes. 
IV. DISCUSSION 
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The molecular analysis of the two NER genes, XPB and XPD produced good results, 
which show that the assays used in this study have been suitable and reliable. XPB has not 
been investigated as extensively as XPD, partly because of the not so detailed available 
sequence information. Of the three XPB exons analysed, only one produced a good PCR 
product, which when analysed by SSCP showed no variations. XPD has 23 exons and 21 have 
been analysed. Of these 17 exons were successfully amplified and analysed by SSCP and/or 
RFLP and sequencing. Of these, 5 exons showed variation. exon 6, 18, 20, 22 and 23; all 
variants found proved to have been already described. The main problem encountered was 
poor quality or lack of PCR product, as the quality of the PCR product was important in 
determining the outcome of the SSCP analysis and sequencing. This was the case for exon 10, 
11 and 15, where no PCR product could be obtained despite different primer pairs and/or 
PCR conditions tried. This is particularly important for exon 10, where a frequent 
polymorphism (Asp3 l2Asn) has been identified. Also, exon 18 analysis was incomplete, due 
to problems with SSCP and sequencing.  In general, both SSCP analysis and sequencing 
worked well for all exons, producing good PCR products. 
IV. 1.1 Frequency of XPD polymorphisms in the control group 
Control samples were taken at random from donations made to the Scottish Blood 
Transfusion Service, Royal Infirmary of Edinburgh. The mean age of the control group is 
45+/-10. Distribution by gender in control group is 15 males and 14 females. Most of the 
XPD exons have been analysed for sequence variation. Of these, variation has been found in 
exons 6, 22, 23, 18 and 20. The variants found match those reported by Shen et al. (1998). Of 
these, 156Arg, 71lAsp and Lys751Gln variants have been statistically analysed. All 
genotypes analysed in the control group were in Hardy-Weinberg equilibrium and this 
constitutes an acceptable control group for this exploratory study. The frequencies reported by 
Shen et al. (1998) have been taken as reference in the Results chapter, as this paper is the 
most comprehensive report on repair gene polymorphisms of importance for this thesis. 
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Exon 6 Argl56Arg has been reported in control populations with a frequency ranging 
from 0.25 to 0.60, table 18. In the control group in this thesis the exon 6 variant allele 
occurred with a frequency of 0.636, higher than any reported so far, although comparable to 
the 0.60 value reported by the UK study. 
Table 18. 156Arg frequencies in healthy Caucasians subjects 
Frequency No of individuals Reference/country 
0,60 211 cadaveric renal transplant donors (Winsev et al., 2000)/UK 
0.525 20 healthy individuals (Dybdahi et al.. 1999)/Denmark 
0.45 496 non-Hispanic whites (Sturgis et al., 2000)/USA 
0.41 111 controls (Vogel et al., 2001)/Denmark 
0.39 139 (Caggana et al., 2001)/USA 
0.25 12 presumed healthy individuals (Shen et al., 1998)/USA 
There are fewer studies on the exon 22 71 lAsp silent polymorphism. Two studies 
from the USA report frequencies of 0.25 and 0.33, respectively, table 19. In the control group 
in this study, 71 lAsp occurred with a frequency of 0.363. 
Table 19. 71 lAsp frequencies in healthy Caucasians subjects 
Frequency No of individuals Reference/Country 
0.33 140 (Caggana et al.. 2001)/USA 
0.25 12 presumed healthy individuals (Shen et al., 1998)/USA 
Exon23 Lvs751Gln has been more extensively studied in USA, Denmark. UK and 
Italy. Reported frequencies range from 0.26 to 0.42, table 20. In the control group of this 
study Lvs75 IGIn occurred with a frequency of 0.409, comparable to the values reported by 
one study in the UK and one in the USA. 
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Table 20. Lys75lGln frequencies in healthy subjects 
Frequency No of individuals Reference/Country 
0.42 85 hospital-based controls, patients with 
benign 	diseases 	(cystitis, 	hernias, 
vasculopathies, 	diabetes, 	heart 	failure, 
asthma) 
(Matullo et al., 2001)/Italy 
0.42 96 healthy men (Butkiewicz et al., 200 1)/Poland+USA 
0.41 148 (Caggana et al., 2001)/USA 
0.40 211 cadaveric renal transplant donors (Winsey et al., 2000)/UK 
0.39 76 	controls, 	friends 	or 	relatives 	of 
enrolled cases 
(Duell et al., 2000)/USA 
0.363 117 (Vogel et al., 2001)/Denmark 
0.35 20 healthy individuals (Dybdahi et al., 1999)/Denmark 
0.34 496 non-Hispanic whites (Sturgis et al.. 2000)1/USA 
0.33 360 (Spitz et al., 2001)/USA 
0.29 12 presumed healthy individuals (Shen et al., 1998)/USA 
0.26 31 women with relative risk for breast 
cancer 
(Lunn et al., 2000)/USA 
IV. 1.2 Frequency of XPD polymorphisms in melanoma 
Case samples were collected from patients attending the Dermatology Department at 
the Royal Infirmary of Edinburgh and consisted of 28 melanoma. 8 BCC and 4 AK cases. The 
study presented in this thesis refers only to the 28 persons in the melanoma group, the other 12 
non-melanoma cases were not included, mainly due to their small number and for one sample 
D21, lack of information. The melanoma group consisted of 8 males and 20 females. The 
mean age of the case group is 42+/-10. The criteria for suitability, under 50 years of age, no 
history of excessive sun exposure, Stage 1 melanoma at presentation and tumour thickness 1-
2mm were chosen to maximise the chance of a strong genetic component to their disease. The 
three XPD pohmorphisms investigated in the melanoma group, 156Arg, 71lAsp and 
Lys751GIn occurred with frequencies of 0.464, 0.178 and 0.196 respectively. A similar UK 
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study on 125 melanoma patients reported higher 156Arg and Lvs751Gln frequencies of 0.62 
and 0.40, respectively (Winsey etal., 2000). 
IV. 1.3 Association between three XPD polymorphisms and melanoma 
Association analysis of three XPD polymorphisms. I 56Arg, 711 Asp and Lys75 1 GIn 
and melanoma, presented in this thesis shows positive statistically significant evidence. The 
strongest association is seen for Lys75 IGIn with OR=2.8, 95% confidence interval (CI) 1.2-
2.7, P=0.02. The other two polymorphic sites, 71 lAsp and 156Arg also show association with 
0R2.6. 95% Cl 1.1-6.7, P0.04 and OR2.0, 95% Cl 0.9-4.5. P0.08 respectively. Allele 
association with disease status has been also confirmed. As Lys75 1Gb is a non-silent 
polymorphism and has the strongest association with melanoma, this might be an indication of 
a causal association, resulting in increased risk for melanoma. However, the positive 
association seen between XPD and melanoma could also be attributed to chance, artefact, or 
linkage disequilibrium. 
Chance is an unlikely explanation for the association observed, since three separate 
polymorphisms (although not completely independent) showed association with melanoma. 
Also significant association was to be considered only if P<0.05. In addition, this study 
followed a prior hypothesis, i.e. to investigate the link between predisposition to melanoma 
and the potential functional polymorphisms in repair genes, XPD and XPB. While this study 
was being carried out, similar studies reported association between XPD and predisposition to 
skin and non-skin cancer (Dvbdahl et al., 1999), (Matullo et al., 2001), (Caggana et al., 
2001) and (Spitz et al., 2001). An artifactual explanation for the association, such as the 
genotypes obtained being affected by problems in storage or analysis, is equally unlikely. 
Control and case blood samples were obtained and processed contemporaneously and all the 
genotypes from the control group were in Hardy-Weinberg equilibrium. In addition, the XPD 
exon 6, 22 and 23 allele frequencies in the control group agree well with those published by 
(Winsev et at.. 2000), (Caggana et at., 2001) and (Duell et at., 2000). The possibility of 
linkage disequilibrium, as an alternative explanation for the positive association between XPD 
and melanoma has been addressed by typing two XPD flanking markers, CKMM and 
ERCC1. 
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IV. 1.4 Lack of association between polymorphisms in XPD flanking genes and 
melanoma 
The strong association between XPD polymorphisms and melanoma did not extend to 
the closest available polymorphic markers, CKMM and ERCC 1 genes, flanking the XPD gene 
on the human chromosome 19q. In the study presented in this thesis CKMM and ERCC1 
typed markers showed no association with melanoma, P>0.3. This indicates that the gene 
responsible for the association is located within the segment flanked by CKMM and ERCC 1 
genes. In this region, XPD is a strong candidate and has been associated with cancer; as for 
the other genes in this region no link with cancer has been identified. This argues against the 
association being due to linkage disequilibrium or population stratification, although these 
competing explanations cannot be completely ruled out. However, it is plausible to consider 
XPD a strong candidate, as it has a clear role in UV-induced DNA damage repair pathway 
and it is known that the most important etiologic factor in melanoma development is UV 
radiation. Also inherited mutations in XPD lead to XP, a genodermatose with high risk of skin 
cancer. Therefore, XPD as a repair gene might be involved in melanoma development and any 
potential causative changes to the gene/protein are associated with increased risk. 
IV.2 XPD nolvmorohisms and mali2nancv 
IV.2. I XPD polymorphisms and non-melanoma skin cancer 
Several studies reported association between XPD polymorphisms and non-melanoma 
skin cancer (NMSC). Most of the association studies investigated 156Arg (in exon 6) and 
Lys75 1Gm (in exon 23). Fewer studies investigated Asp3 12Asn (in exon 10), whilst 71 lAsp 
in exon 22 has not been investigated at all. 
A Danish group studied 156Arg and Lys75 lGln in BCC patients with and without 
psoriasis. In their study group both polymorphisms were linked and occurred with relatively 
high frequencies. 75lLys/Lys was associated with increased risk of BCC and early age of 
onset, suggesting that the variant Gln might have a protective effect in BCC development. 
156Arg was associated with risk of BCC only in psoriasis patients and the variant allele had a 
protective effect (Dybdahl et al., 1999). The results of this study are comparable to those 
presented in this thesis, where Lys 751 had the strongest and 1 56Arg the lowest association 
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with melanoma. The same group repeated the study on these two polymorphisms and 
Asp3 l2Asn in American BCC patients. In this study 156Arg was associated with BCC risk, 
confirming that the variant allele has a protective effect. Lys75 I Gln and Asp3 12Asn did not 
show a statistically significant BCC effect; Asp3 l2Asn was found to be associated with BCC 
among subjects (6 cases and 9 controls) with a family history of NMSC, (0R5.25, CI 1.15-
23.93. P=0.027) (Vogel et al., 200 1) 
An American study investigated 156Arg and Lys751Gln and susceptibility to 
SCCHN in a hospital-based case control study. Both polymorphisms occurred with high 
frequencies, table 21. In this study 156Arg effects were non-significant, whilst 751GInJGln 
was more frequent in cases than controls and associated with a borderline increased risk 
(OR'1.65, 95% Cl 0.98-2.77) (Sturgis et al., 2000). This is the opposite association to that 
seen in this thesis where Lys75 1 was associated with increased risk. 
Table 21. Reported XPD polymorphism frequencies in NMSC 
Polymorphism Frequency No of patients/disease status Reference /Countr 
Argl56Arg 0.525 20/BCC (Dvbdahl et al.. 1999)/Denmark 
ArglS6Arg 0.485 66/BCC (Vogel et al.. 2001)/USA, Deiunark 
ArglSoArg 0.425 20/13CC and psoriasis (Dvbdahl et al.. 1999)/Denmark 
Arg156Arg 
0.42 I89ISCC of the 	head and 
neck 
(Sturgis et al., 2000)/USA 
Lvs751Gln 0.415 70/BCC (Vogel et al., 2001)/USA. Denmark 
Lvs751Gln 0.39 189 SCC of the head and 
neck 
(Sturgis etal., 2000)/USA 
Lvs75lGIn 0.275 20/13CC and psoriasis (Dybdahi et al., 1999)/Denmark 
Lvs75lGIn 0.250 20iBCC (Dybdahl et al., 1999)/Denmark 
Asp3l2Asn 0.390 68/13CC (Vogel et al., 2001)/USA. Denmark 
IV.2.2 XPD polymorphisms and melanoma 
In the study group in this thesis of 28 cases and 33 controls XPD polymorphisms 
were associated with melanoma. As it was a small pilot study, one would expect to see 
positive association if the effect is strong. The OR point estimate of 2.5 indicates that XPD 
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did have an effect in this particular study group. In contradiction with this comes one other 
UK study, which looked at ten polymorphisms in DNA repair genes XRCC 1, XPD, ERCC 1, 
XPF. XRCC3 and melanoma risk in 125 patients and 211 controls. The three XPD 
polsmorphisms they investigated, Arg 1 56Arg, Asp3 I 2Asn and Lys75 1 Gln occurred with 
similar frequencies in case and control groups and did not show significant association with 
melanoma risk. In their study the XRCC3 Thr241Met polymorphism occurred with 
significantly different frequencies in case and control groups and showed significant 
association with melanoma (Winsey et al., 2000). The fact that no association has been seen 
for XPD could be attributed to the differences in the design of the study groups. One 
difference is age of the subjects. The Oxford patients are older than the patients in this study, 
half of their subjects are over 52 years of age. If a genetic susceptibility factor exists this 
would be most evident in the patients with an early onset of the disease. Another difference is 
the stage of disease. In this thesis all patients were in Stage I, which, like Stage II is limited to 
the skin and presents no invasiveness, no lymph nodes involvement and no distant metastases. 
In the Oxford study, 86.4% of patients were in Stage III and IV, late stages in melanoma 
development. According to the AJCC Staging Stage III is characterised by regional nodes 
metastases or in-transit metastases and Stage IV includes distant skin or visceral metastases. 
with poor prognosis, mean survival about 6 months. There were no patients in Stage I. 
therefore no complete comparison to the study presented in this thesis can be made. Taking 
into account the percentage of patients in late stages of melanoma development, the XRCC3 
polymorphism might influence cutaneous melanoma prognosis, although the study did not 
show stratification of data by any prognostic features, like stage at presentation (I, II versus 
IILTIV) or tumour thickness. On the other hand, the biologic role of XRCC3 in 
recombinational repair would be compatible with it being a susceptibility and prognosis gene. 
Another difference lies in the control groups. The control group in this thesis was assembled 
from healthy blood donors, but is too small in number and it is age-matched with the case 
group, whereas it should be matched for sex and ethnicity, at least. In the Oxford study, the 
control group was assembled from cadaveric renal transplant donors and there is no indication 
on the degree of matching between cases and controls. Both control groups suffer from one 
aspect or the other, perhaps the Oxford controls are more representative because of the larger 
number. Despite all the differences and possible interpretations, between the study in this 
thesis and the Oxford study, the question still stands, why XPD did not show association with 
melanoma in the Oxford study, which can only be addressed in a larger study with better 
controls. 
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In addition, the Oxford paper reported an initial association between melanoma and 
two polymorphisms in the XPF gene, 5' UTR T2063A and exoni 1 T30028C, with OR= 1.65, 
P=0.038. As the study set out to investigate 10 polymorphisms, the P value had to be 
corrected by 10, therefore the association was no longer significant. P'0.38. 
The 28 melanoma samples used in the study presented iii this thesis have been further 
analysed in my supervisor's lab and the XPF exon 11 polymorphism did show association 
with melanoma, whilst XRCC1 exon17 polymorphism did not show association. XPF, like 
XPD is involved in nucleotide excision repair and the fact that the two genes showed 
association with melanoma in the same case control group, might support the hypothesis that 
variation in repair genes is a susceptibility factor for skin cancer. 
IV.2.3 XPD polmorphisms and other types of cancers 
The XPD polymorphisms have been investigated for association with other types of 
cancer. A study in the USA investigated ArgI56Arg. Lys75lGln, Asp7IlAsp and 
Asp3 1 2Asn polymorphisms and association with brain tumours. Their results are important, 
because some repair deficient patients (XP, XP/CS, TTD) have neurological abnormalities 
and some XP patients develop brain tumours. The four XPD polymorphisms occurred more 
often in controls than in cases, where frequencies varied from 0.274 to 0.504. In this study, 
despite the fact that cases were not in Hardy-Weinberg  equilibrium, all four polymorphisms 
were linked irrespective of the disease status; 156Arg appeared to be associated with gliomas, 
which is comparable to the study presented in this thesis, where it showed association with 
melanoma. Because 156Arg is a silent polymorphism, linkage disequilibrium with the nearby 
glia maturation factor-gamma (GMFG) gene has been advanced to explain the association 
with glioma (Caggana et at, 2001). This gene maps on chromosome 19 q13.2, upstream 
XRCC 1 proximal to the PSG cluster. It is involved in glial differentiation, neural regeneration 
and inhibition of tumour proliferation. Given the location of this gene and the fact that 1 9q 13 
is a region frequently deleted in gliomas, glioma patients have been screened for mutations in 
hGMF-gamma and none has been detected. Another possible gene is the glioma tumour 
suppressor gene, recently mapped on chromosome 19q band 13.3, between DM and LIGI 
genes (Smith et at., 2000). 
Asp3 l2Asn and LvS751GIn polymorphisms have been investigated for lung cancer 
susceptibility. The Asp312Asn polymorphism was found to be significantly associated with 
lung cancer (Butkiewicz et at., 2001). In their study the 312 Asp-allele was more common in 
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cases than in controls and associated with two-fold risk, whilst the variant allele was 
considered protective. Also linkage between 312 and 751 polymorphisms has been reported in 
this case-control group. Another study looked at these two polymorphisms and DNA repair 
capacity in lung cancer. This study found that cases had lower repair rates than controls and 
either variant allele in both polymorphisms was associated with suboptimal DNA repair 
capacity in cases and controls (Spitz et al., 2001). This is in agreement with Sturgis et al., 
(2000), where 751 GIn/Gin was associated with increased risk of SSCHN and in opposition 
with the study presented in this thesis, where 751 Lys/Lys showed increased risk of melanoma. 
Asp3 l2Asn and Lvs75lGln polymorphisms have been studied in correlation with 
repair proficiency in an X-ray-induced chromosome aberration assay. Lymphocytes with 
751Lvs allele showed reduced repair, 0R7.2, Cl 1.01-87.7. Asp3l2Asp showed more 
chromatid aberrations than the Mn carriers, but the difference was not statistically significant. 
Lys75 1 associated with reduced repair agrees with the studies on BCC mentioned above and 
with the study in this thesis, where Lys75 I had the strongest association with melanoma. 
However, their results should be regarded with caution. Firstly, because it extrapolates NER 
from X-irradiation-induced DNA damage and secondly, the subjects were 31 women (again, a 
very small number) of whom, one had breast cancer, 15 were at high risk due to the number of 
close relatives with breast cancer and 15 were at low risk. (Lunn et al., 2000). This 
cvtogenetic assay has been used to identify clinically normal carriers of the XP gene(s) within 
known XP families (Parshad et al., 1990). The basis for identification is given by the 
magnitude of the cytogenetic responses to G2 phase X-irradiation measured in lymphocytes 
and skin fibroblasts. The justification for identification of the carriers is given by the fact that 
they carr cancer-prone genes but show little incidence of skin cancer and developmental 
disabilities, common among homozygotes. The cvtogenetic responses of nine normal controls 
were compared to those of 8 XP heterozvgotes and six XP homozygotes at three time points 
(1.3. 2.3, 3 .3hrs) following X-irradiation. At 1 .3hrs post-irradiation all lymphocytes show the 
same response. At 2.3 and 3.3hrs post-irradiation lymphocytes from XP heterozygotes had 
two fold higher frequencies of chromatid breaks or gaps than cells from normal controls. 
Lymphocytes from XP homozygotes had aberration frequencies threefold higher than normal. 
Skin fibroblasts from the XP heterozygotes had two-fold higher frequency of chromatid breaks 
and fourfold higher frequency of gaps than cells from normal donors; these frequencies were 
half those seen in fibroblasts from XP homozvgotes. This study gives evidence of X-ray 
induced cytogenetical aberrations in cells from XP individuals, who are NER deficient and 
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have high risk for skin cancer. It also provides a base for following studies on NER gene 
polymorphisms and X-ray induced cytogenetic responses. 
Overall, the case-control studies on the XPD polymorphisms and cancer risk 
are small in size and, as a result, produce either non significant or less accurate results 
reflected by wide confidence intervals in their statistical analysis. Other epidemiological 
studies, although bigger in size, suffer from common confounding factors, generating 
inconsistent results. However, each study mentioned so far tries to correlate variation in repair 
genes and susceptibility to cancer which, biologically is a plausible hypothesis. All studies on 
XPD polymorphisms suggest that repair gene variants have a functional relevance. Of the 
three most analysed polymorphisms, one is silent and the other two affect the coding sequence. 
Lys75 lGln is located outside functional domains,  but close to the XP mutation site 683. It is 
also a conserved amino acid residue in human, mouse, hamster and fish. In some studies and 
in this thesis this region of the gene showed strong association with cancer risk and it is 
possible that the Lys to GIn change is causative. 156Arg is silent and unlikely to directly 
affect the helicase function of XPD. The association with risk of cancer seen in some studies 
can be explained by linkage with the 751 polymorphism, seen in almost all studies 
investigating exon 6, 10 and 23 polymorphisms and cancer risk. Also 711 Asp in exon 22 is in 
linkage with 751, as it has been seen in this thesis (similar under-representation of the variant 
allele in exon 23 and 22 in cases and controls and close OR values for association with 
melanoma) and in others. Another potential explanation for the association of silent 
polymorphisms and risk of cancer could be attributed to a dysfunctional protein, as a result of 
altered mRNA stability or reduced rate of translation, due to altered codon usage. The 
Asp3 12Asn could not be analysed in this thesis, due to poor PCR amplification. Asp3 l2Asn 
is a non-silent polymorphism and it could affect the function of the protein, although it again 
resides outside functional domains. Two epidemiological studies found association between 
Asp3 1 2Asn polymorphism and lung cancer. A potential explanation for the results of XPD 
epidemiological studies is that different polymorphic sites affect the protein differently, in 
terms of repair or apoptotic functions. Alternatively, XPD could be in linkage disequilibrium 
with another gene located inside/outside the region flanked by CKMM and ERCC 1, possibly a 
tumour suppressor gene, which might account for the association seen between the XPD 
polymorphisms and risk of cancer. It is also possible that the causative change within the XPD 
gene remains to be identified. 
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P1.3 1 Cutaneous malignancy and genetic susceptibili tV  
The majority of epidemiological studies investigated sequence variation in repair 
genes as potential susceptibility factors for cutaneous malignancy. Polymorphisms in 
nucleotide excision repair genes, ERCC1, XPD, XPF and base excision repair genes XRCCI 
and XRCC3 have been looked at in case control studies of melanoma and non-melanoma skin 
cancer. These genes have been chosen due to their essential function in repair pathways and 
their location, as XRCC1, XPD, ERCC1 map in a cluster on chromosome 19 band 13.2-13-3. 
with XPD less than 250kb from ERCC1. The study, that investigated five repair genes in 125 
melanoma patients is the Oxford study, already mentioned, where only XRCC3 showed 
significant association with melanoma. 
Of the five repair genes, XPD and XRCC 1 have been also investigated in non-
melanoma skin cancer. Two polymorphisms in the XRCCI gene, Arg194Trp and Arg399Gln 
have been investigated in SCCHN patients. The study shows association between 1 94Arg/Arg 
or 399GlnIGln genotypes and increased risk of SCCH, particularly in subgroups of current 
users of tobacco and alcohol. XRCC 1 is advanced as a susceptibility gene, based on several 
lines of evidence: I) risk genotypes are more frequent in cases than in controls and show 
additive effect; 2) some of the highest risk genotype frequencies were among cases under 50 
years of age; 3) both polymorphisms show higher risk in subgroups of smokers and drinkers 
reflecting a gene-environment interaction (Sturgis et al., 1999). This hypothesis is plausible, 
as the two polymorphisms are non-silent and could affect the function of the protein. The 
399Gln polymorphism could be particularly important as it resides in the BRCT domain, 
which is involved in protein-protein interactions and is homologous to the COOH-terminal 
region of BRCA I. the breast cancer susceptibility gene. Therefore, changes within this domain 
could contribute to increased risk of cancer. 
In addition polymorphisms in genes involved in specific pathways other than 
repair/recombination have also been taken into account as susceptibility factors in skin 
cancers. Detoxifying  enzyme genotypes have been associated with cutaneous malignancy, as 
the main etiologic factor for skin cancer. the 1.JV radiation comprises an oxidative stress. 
Polymorphisms in GST and CYP genes have been investigated for BCC risk. Molecular 
epidemiological studies show that detoxifying enzyme polymorphisms appear to have an effect 
on number of tumours, influencing the outcome within BCC patients rather than susceptibility 
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(Lear et al., 2000). Sequence variants Within the melanocortin-1 receptor gene (MCR- 1) and 
vitamin D receptor (VDR) have been associated with cutaneous malignancy. Melanocortin-1 
receptor gene variants influence skin pigmentation and have been previously associated with 
red hair and fair skin colour. Three variants Argl5lCys, Argl60Trp, Asp294His are 
associated with non-melanoma and sporadic melanoma development (Jones et al., 1999). 
Vitamin D receptor Fold and TaqI polymorphisms are correlated with tumour occurrence and 
behaviour of melanoma, suggesting a role for Vitamin D in melanoma development. In vitro 
studies show that normal and malignant melanocytes express VDR and their growth is 
inhibited by vitamin D. In a study on serum levels of [1,25(OH) 2 D 3] melanoma patients had 
lower levels than controls although the effect was not statistically significant (Hutchinson et 
al., 2000). 
Other • polymorphisms investigated for melanoma susceptibility are variants within 
matrix metalloproteinase I (MMPI) and HILA-DQB 1. Epidemiological studies indicate MMPE 
variant genotype as a prognosis genotype, influencing tumour invasion and metastasis through 
modulation of the expression of the matrix degrading enzyme (Ye et al., 2001). Human 
leukocyte antigen (HLA) DQB I genotypes were found to associate with melanoma in a study 
from USA, which has not been confirmed by an Italian study, suggesting an ethnic variation 
for HLA DQB 1 locus or more complex genetic and environmental factors responsible for 
melanoma development (Bateman et al., 1998). 
IV. 3.2 Repair gene polymorphisms and susceptibility to disease 
Variants of repair genes have been investigated for association not only with skin 
cancer but also with brain, lung and bladder cancers. Epidemiological studies on nucleotide 
excision repair genes XPF, XPD and ERCC1 did not find any association for XPF and apart 
from XPD, ERCC1 was associated with brain tumours. The ERCCI 3'UTR polymorphism 
was associated with brain tumours. In this study the variant genotype was more frequent in 
cases than in controls and associated with early onset. There are no other epidemiological or 
functional studies on ERCC 1 pol morphisms and their biological significance is complex, due 
to its overlap with the ASE-1 gene and the involvement of ERCC 1 in both excision and 
recombinational repair. XRCCI and XRCC3 have been investigated for lung and bladder 
cancer risk, relatively common types of cancers positively correlated with smoking. Smoking 
causes oxidative stress and directly or indirectly damages DNA and XRCC I and XRCC3 are 
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involved in repair pathways dealing with base damage and DNA single  strand breaks. Two 
studies looked at the XRCC 1 Arg399GIn polymorphism and bladder cancer risk. Only one 
study found a protective effect of the homozygous variant genotype, whilst 399ArgIArg were 
at slightly higher risk, although the difference was not significant. A similar result was found 
in a lung cancer study, where 399ArgIArg was associated with increased risk. The XRCC3 
Thr24 1 Met polymorphism also showed association with bladder cancer, where the variant 
genotype was associated with high risk. No association has been found in another study on 
lung cancer and XRCCI and XRCC3 polymorphisms, where cases and controls had the same 
distribution of genotypes for both genes. 
It is known that reduced repair capacity is a risk factor for cancer and this is clearly 
seen in XP patients where defective NER increases the risk of skin cancer 1000 fold, when 
compared to the general population. Also several lines of evidence suggest that variation in 
DNA repair seen among individuals have a genetic basis. intra-individual variation in repair 
capacity is smaller in comparison to the variation among individuals (Crompton & Ozsahin. 
1997). Similar to the cancer patients, the relatives of cancer patients show reduced repair rates 
in cvtogenetic and UDS repair assays (Pero et al., 1989), (Knight et al., 1993) and (Parshad 
et al.. 1996). The variation of repair capacity has similar characteristics to the cancer 
susceptibility genes: both exist at polymorphic frequency within the general population, 
exhibit incomplete penetrance and have reduced function rather than complete loss of function. 
It is therefore possible that the polymorphisms may be responsible for the inter-individual 
DNA damage repair variations in the general population and for a low DNA repair capacity 
phenotype characteristic of cancer patients. Several studies addressed these hypotheses using 
different DNA repair capacity measuring assays and their results are inconsistent. Relevant to 
this study are XPD polymorphisms. The report where XPD 156 and 751 polymorphisms were 
associated with BCC, also stated that no difference in repair between the 75 ILys and 75 1Gm 
alleles had been found using host cell reactivation and comet assays (Dybdahi el al., 1999). 
Another study on lung cancer patients reported that variants 3 12 and 751 were associated with 
risk of sub-optimal repair, using HCR assay (Spitz et al., 2001). Lys751 was associated with 
reduced repair in an X-ray-induced chromosome aberration assay (Lunn et al., 2000). The 
inconsistency of results can be attributed to epidemiological factors, such as selection bias, or 
technical factors such as variability of measuring assays, of lymphocyte viability and 
ultimately the biologic relevance of the assays used to measure DNA repair capacity. 
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In conclusion, the association between XPD polymorphisms and risk of cancer is not 
yet clear, as a few studies, this thesis included, show association, whilst others do not. 
Similarly, XPD polymorphisms are not clearly correlated with reduced repair. 
Epidemiological studies on polymorphisms in repair genes have identified cancer susceptibility 
alleles, which increase risk of cancer, although often the results are contradictory. However, 
the susceptibility alleles are important risk factors as they exist at polymorphic frequencies 
and their interaction with carcinogens increases the risk of cancer in the general population. 
The results on repair gene polymorphisms are preliminary; further biochemical, biological and 
epidemiological studies are necessary in order to characterise these variants and their 
relationship to cancer susceptibility and DNA repair capacity. In addition relevant repair tests 
are required for a clear characterisation of the functional effects of the NER variant alleles on 
the DNA repair capacity. 
The outcome of studies on genetic susceptibility to cancer is important for 
understanding cancer aetiology and for public health. This is particularly important for 
melanoma, with reported increasing incidence rates around the world. In Scotland, melanoma 
is the third commonest cancer in young adults and the incidence is high and rising. Skin cancer 
aetiology is complex. The key environmental factor is IJV radiation, which coupled with a 
constitutional genetic factor, which can be cancer genes or susceptibility genes, leads to 
carcinogenesis. Therefore it is important to identify skin cancer predisposing alleles and their 
distribution in the population. Combination of these studies with estimation of carcinogenic 
exposure could provide a scientific risk assessment. Risk assessment studies permit identifying 
groups of the population at risk in relation to a particular carcinogen. In melanoma, the 
population at most risk could be those individuals with susceptibility repair alleles in 
combination with red hair and UV exposure. Surveillance and counselling programs of at risk 
individuals will lead to an early detection of disease and better prognosis. 
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It is known that p53 protein is involved in NER. It is known that p53 has protein-
protein interactions with XPB and XPD helicases. It is possible that subtle changes in these 
proteins might alter p53 interactions, leading to a reduced p53 response to UV-induced DNA 
damage and as a result increased risk of cancer. This links NER gene polymorphisms and UV 
light induced p53 response. If XPD polymorphisms correlate with p53 response to l.JV 
irradiation, then lymphocytes from individuals with genotype associated with increased cancer 
risk would have reduced p53 response. 
In order to study a potential correlation between XPD polymorphisms and p53 protein 
levels, 8 blood samples have been collected and lymphocytes have been isolated. Short term 
stimulated lymphocytes show normal inducible p53 response after UV radiation. The 8 
samples have also been genotyped for XPD LNs75lGln and 71 IAsp polymorphisms. 
Quantification of p53 response varies from Ito 15 and there was no correlation between XPD 
genotypes and p53 levels. The low values for the p53 response could be due to dead cells, but 
Western analysis and ECL probing show strong protein content for both p53 and actin. 
Therefore this is not a likely explanation and the fact that only 8 samples have been analysed 
does not allow for much interpretation of data. The positive side is that the p53 assay works 
on low volumes of blood and it is fast and reproducible. The results are prelmnarv and there 
are no other similar studies to compare them to. 
The majority of studies on cultured lymphocytes look at cellular DNA damage and 
repair capacity, using different repair assays. One study investigated the apoptosis rate in a 
XPD lvmphoblastoid cell line (LCL). Previous studies showed that XP-B and XP-D derived 
fibroblasts have attenuated p53-dependent apoptosis, which can be rescued by wild type XPB 
and XPD respectively (Wang et al., 1996). Considering the hypothesis of functional 
interaction between XPD and p53, LCL derived from XP-D patients will have altered XPD 
protein, which will impair p53-dependent apoptosis pathway. The three LCLs were: 
GM03249 (Gly602Asp and second allele not expressed), GM02253F (Arg683Trp and 
Asp68lAsn) and GM02485 (Arg683Trp and deletion exon 3). Their results show that 
apoptosis is delayed and reduced in three XPD LCLs after exposure to doxorubicin, a DNA 
damaging agent and topoisomerase II inhibitor. p53 accumulated by 6 hrs after drug treatment 
concurrently in normal and XP-D LCLs. The apoptotic response in site-specific cleavage of 
PARP occurred within 6 hrs after treatment in normal LCLs and 12 hrs in XP-D LCLs. These 
results indicate that the molecular basis for delayed apoptosis resides downstream of p53 
159 
stabilisation and upstream of caspase activation (Rabies et al., 1999). This study supports the 
functional interaction between XPD and p53 in a p53-mediated apoptosis pathway. In addition 
the results came from lymphoblastoid cells and show that normal and XP-D LCLs have 
normal p53 response upon drug treatment but delayed apoptosis. Delayed apoptosis as well as 
reduced DNA repair enhance chromosome instability and increase the risk for malignant 
transformation upon carcinogen exposure. Therefore, this study correlates with the study in 
this thesis, in terms of XPD and p53 interaction. It also shows that delayed and reduced p53 
response could be a risk factor for cancer development. 
Another report relevant to the melanoma and p53 work is a study on p53 stabilisation 
and response to UVC irradiation in human melanoma cell lines. Seven melanoma cell lines 
have been analysed, four with wild-type p53. two with mutant p53 and one with truncated 
p53. All melanoma cell lines expressed high endogenous p53 levels in comparison to low or 
negligible levels found in normal melanoc tes.  p21 has only been detected in wild-type p53 
melanoma cells. In response to 50J/m2 UVC radiation, all cell lines arrested. After 6hrs 
mutated p5 3 melanoma cell lines show less than 50% inhibition of DNA replication, whilst the 
cell lines with truncated p53 and wild-type p53 had 70-80% inhibition of DNA replication. 
After 16hrs. all cell lines had 60-80% inhibition of DNA replication. Similarly, apoptosis 
occurred in a p53 independent manner. UV-induced p53 accumulation occurred as expected in 
cell lines with wild-type p53, whilst in cell lines with mutant p53 there was no further increase 
in the levels of mutant protein. Similarly, p2l accumulated after 1 6hrs after treatment only in 
wild-type p53 cell lines, slower than in human and rodent fibroblasts (less than 6hrs). 
GADD45 mRNA induction occurred in all melanoma cell lines, 6hrs after UVC treatment, 
suggesting p53-independent activation in response to DNA damage similar to p53-null 
fibroblasts (Haapajarvi et al., 1999). These melanoma cell lines show an altered IJY induced 
p53 response: there is a high basal level of p53 protein, which is not functional and does not 
regulate its target genes, p2! and GADD45. 
Both studies investigated p53 correlation with two major cellular responses, arrest 
and apoptosis. Although there are differences in the cell system and carcinogen exposure, the 
results are to be taken into account for further p53 work on growth arrest and apoptosis. If the 
larger epidemiological study confirms association between XPD variants and melanoma it 
would be interesting to investigate if XP D genotypes influence the p53-dependent pathways. 
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The results of this pilot study, which shows association between XPD polymorphisms 
and melanoma are based on a small case-control study, designed to maximise the chance of 
there being a strong genetic component to the disease. The association observed between XPD 
and melanoma could be causally related to melanoma, or due to a false positive generated by 
population stratification, or linkage disequilibrium between the XPD locus and another genetic 
factor. To address and clarif' XPD association with melanoma a larger study with properly 
and completely matched cases and controls is required. The larger study should also comprise 
more melanoma subjects from all age groups, in order to observe the distribution of 
polymorphisms by age, which will support the hypothesis of a genetic factor associated with 
risk of skin cancer. The larger study will permit more precise OR estimates, in depth 
statistical analysis and as a result more accurate results. In addition an independent control 
group is required to repeat the association study. Further analysis of unlinked markers or 
alternatively a family-based control design, such as a transmission disequilibnum test would 
be useful to detect any population stratification. Typing of the XPD flanking genes, CKMM 
and ERCC1 is required and also other repair genes. Additional typing would start with 
XRCC3. for which an association with melanoma has been reported. Other genes, such as 
XRCC 1, XPF, XPB, DNA ligase would be potential candidate genes to look at in melanoma 
samples. 
In addition, a similar small case-control study on basal cell carcinoma and squamous 
cell carcinoma subjects and XPD polymorphisms would be interesting to approach, as current 
studies indicate an association between Arg156Arg, Asp3l2Asn and Lys751Gln and non-
melanoma skin cancer. Also, more work on the Asp3 1 2Asn polymorphism should be done, as 
it is a frequent polymorphism (allele frequency 0.42) and some studies report association with 
skin and non-skin cancer. In this thesis, this polymorphism could not be typed due to technical 
problems. 
Additional functional studies are required to identify the biological significance of 
XPD variants. Current studies have investigated the possibility that altered XPD protein with 
reduced function leads to reduced NER capacity and increased risk of skin cancer. Altered 
XPD protein could also have impaired protein-protem interactions with cell cycle control 
machinery, particularly with p53. A weaker p53-dependent response to UV induced DNA 
damage allows replication of damaged DNA template and increases the risk of cancer. 
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The increased risk of melanoma associated with the XPD polymorphisms reported in 
this study is modest. However, if the association is confirmed in a larger study and similar 
associations are found for other NER genes, then the combination of particular alleles of 
several different NER genes could combine to give a strong predisposition to skin cancer in 
the general population. 
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The nucleotide excision repair pathway has evolved to 
deal with UV light-induced DNA damage. Individuals with 
the rare inherited nucleotide excision repair deficiency 
disease xeroderma pigmentosum have a 1000-fold increased 
incidence of skin cancer. We are interested in the possibility 
that more subtle changes in nucleotide excision repair 
genes, resulting in either a reduced capacity for repair 
or in altered interactions between repair proteins and 
components of the cell cycle control machinery, might 
constitute important genetic risk factors for the develop-
ment of skin cancer in the general population. To investigate 
this hypothesis we have compared the frequency of poly-
morphisms in exons 6. 22 and 23 of the XPD gene in 
melanoma patients and a control group. For each of these 
two allele polymorphisms one of the alleles was over-
represented in the melanoma group and there was a 
significant association with melanoma. Importantly, this 
association did not extend to markers immediately flanking 
the XPI) gene, thus providing evidence that XPIJ gene 
polymorphisms might predispose to melanoma in the 
general population. There is a report that one of the 
polymorphic XPD alleles (exon 23 Lys). which is over-
represented in the melanoma group, has reduced repair 
proficiency and we discuss the possibility that this is 
the causal change to the XPD gene that predisposes to 
melanoma. 
Introduction 
The nucleotide excision repair (NER) pathway has evolved to 
deal with UV light-induced DNA damage. In a multi-step 
process, involving at least 25 proteins, the helix distorting 
lesion is first recognized, the double helix is unwound, a dual 
incision is made to release a lesion-bearing oligonucleotide and 
repair synthesis and ligation complete the process (reviewed in 
ref. I). NER does not operate in isolation: it is closely 
coordinated with other key cellular processes. such as transcrip-
tion and DNA replication. Although NER operates over the 
Abbreviations: 8CC, basal cell carcinoma: Cl. confidence interval; CKM, 
muscle creatine kinase: NER. nucleotide excision repair: OR. odds ratio; 
RFLP. restriction fragment length polymorphism: SCCHN. squamous cell 
carcinoma of the head and neck: SSCP. single-stranded conformational 
polymorphism: XP. xeroderma pigmentosum. 
entire genorne. there is preferential repair of actively transcribed 
genes (2), with some NER proteins also being essential 
components of the RNA polymerase II pre-initiation complex 
(3). UV-induced DNA damage leads to a p53-mediated cell 
cycle arrest at the G 1 /S and G2/M checkpoints. This key 
protective response at the G 1 /S checkpoint acts to prevent the 
initiation of replication on a damaged template, which can 
result in fixation of mutations, accumulation of double-strand 
breaks, chromosome instability and cancer (4). During arrest 
the damage may be repaired by NER and the cycle resumes 
or, alternatively, the apoptotic (5) or replicative senescence 
pathways may be triggered. Xeroderma pigmentosurn (XP) is 
the paradigm for human inherited diseases with DNA repair 
deficiency and cancer predisposition (for a review see ref. 6). 
In this autosomal recessive disease there is an NER deficiency 
and a 1000401d increased risk of skin cancer. 
Although study of the rare disease XP has identified complete 
NER deficiency as a dramatic genetic risk factor for skin 
cancer, we are interested in the possibility that more subtle 
changes in NER genes also constitute important risk factors 
for the development of skin cancer in the general population. 
The simplest way that we can envisage this is if the change 
resulted in a slight, but functionally significant, reduction in 
repair capacity. In the context of many years skin exposure to 
UV light and continual challenge to the repair system. even a 
slight reduction in repair capacity could result in a significantly 
increased risk of skin cancer. Some studies to compare DNA 
repair in cancer patients with a control population have reported 
significantly reduced repair capacity in the patient samples. 
The most relevant to our work involve basal cell carcinoma 
(BCC) (7.8), but reductions in repair have also been reported 
for lung cancer (9) and squamous cell carcinoma of the head and 
neck (SCCHN) (10). However, the correlation between reduced 
repair and cancer is not universal: it was not found in an 
independent study of BCC (II) nor in a study of cutaneous 
melanoma (12). The reliability of this type of epidemiological 
investigation and the difficulties of making comparisons 
between studies have been discussed in a recent review (13). 
According to this model XP heterozygotes (carriers), who 
will he much more frequent in the population than individuals 
with XP (-1 in 250 000 for XP, —1 in 300 for carriers) (14), 
would he expected to have reduced NER and a higher incidence 
of skin cancer. Conventional assays to measure NER have 
often been unable to discriminate reliably between carriers 
and controls 15; and references therein). However, a simple 
X-ray-induced chromosome aberration assay in blood lympho-
cytes., which has been used to show an association between 
reduced DNA repair and breast cancer (16). was able to detect 
XP carriers (17). A small excess incidence of skin cancer has 
been reported in some families of XP patients (18), but these 
findings have not been substantiated in more recent studies. 
This is not necessarily inconsistent with the suggestion that 
slight reductions in NER capacity might predispose to skin 
cancer, because there are seven complementation groups in 
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classical XP and only one step in the NER pathway will be 
rate limiting. Consequently. a reduction in activity of only one 
of the proteins involved may be functionally significant and 
this effect could be masked in small studies pooling XP carriers 
from the different complementation groups. 
With the appearance of reports of frequent polymorphisms 
resulting in both conservative and non-conservative changes 
to a number of NER genes [XPD (19.20). XPF (20.21) and 
ERCCI (20)] and genes involved in other repair pathways (20) 
there is renewed impetus to investigate the effect of repair gene 
alterations on cancer predisposition. An ERCC] polymorphism 
was associated with adult-onset glioma (22). Two XRCCI gene 
polymorphisms were associated with SCCHN (23) and one of 
these was correlated with increased levels of tobacco- and 
age-related DNA damage (24). 
Returning to NER, the proteins function in a series of 
complexes and XPB and XPD also interact with p53  (25). The 
XPB and XPD proteins are required for the p53-mediated 
apoptotic response (26). indicating that these interactions have 
functional significance. The other aspect of our hypothesis is 
that NER gene polymorphisms might predispose to skin cancer 
because of altered interactions with the cell cycle control 
machinery rather than through reduced DNA repair activity: a 
weaker p53-mediated cell cycle arrest response following 
UV-induced DNA damage to the skin could increase the 
likelihood of DNA replication proceeding on an unrepaired 
template, with a resulting increased likelihood of skin cancer. 
To test our hypothesis we have carried out a study to 
compare the frequency of polymorphisms at three different 
positions in the XPD gene in patients with malignant melanoma 
and a control group. For each polymorphism we have found 
a significant association with melanoma which does not extend 
to markers flanking the XPD gene. We discuss the evidence 
that one of these polymorphisms causes a functional change 
in the XPD protein that predisposes to melanoma. 
Materials and methods 
Subjects 
Patients were selected from those attending the melanoma clinic at the 
Dermatology Department at the Royal Infirmary of Edinburgh. To maximize 
the chance of there being a strong genetic. rather than environmental, 
component to the disease, patients chosen were under 50 with malignant 
melanoma and no history of excessive sun exposure. All chosen melanoma 
patients had Stage 1 disease at presentation, with no evidence of regional or 
distant metastases. The Breslow thickness of the melanomas varied between 
I and 2 mm and all were treated by wide surgical excision only. Patients 
chosen were either attending the clinic for the first time or were on follow-
up visits after surgery to remove the melanoma and were regarded as incident. 
rather than prevalent. cases. Control blood samples were selected entirely at 
random from donors to the Scottish Blood Transfusion Service in the 
same hospital. 
DNA isolation 
Blood samples (10 ml whole bloodIEDTA) were obtained from controls and 
melanoma subjects. Case and control specimens were handled similarly 
and analysed contemporaneously. DNA was isolated using a Qiagen genomic-
tip 100 and the manufacturer's protocol (Qiagen, UK). 
PCR and restriction fragment length po1vmorphisn (RFLP) assav.c 
Where possible primers were selected to be -50-60 bp away from exon/intron 
boundaries so that the DNA sequence of the entire exon could be conveniently 
obtained. The need to keep the size of the resulting PCR product within the 
resolving power of single-stranded conformational polymorphism (SSCP) 
analysis was also a consideration in the choice of primers for the XPD gene. 
Genomic DNA (-100 ng) was amplified in a 501.11 reaction volume containing 
300 ng each primer and 2.5 U Taq DNA polymerase (Promega. UK) in 5 mM 
KCI, 0.15 mM MgCl2. I mM Tris-HCI. 0.045% Triton X-100. 0.045% Tween 
20. 0,4 mM Na EDTA, 0.1 mM dNTPs. Cycle conditions for individual PCR 
reactions are given in Table 1. PCR products were used for SSCP analysis or 
restricted and analysed on agarose gels. Details of the polymorphisms detected 
by RFLP analysis are given in Table II. 
SSCP analysis 
SSCP analysis was used as a rapid and efficient screening method to detect 
single nucleotide changes in XPD exons. Each amplified fragment was mixed 
with loading buffer (95 17-c formamide. 0.25% bromophenol blue. 0.25% xylene 
cyanol. 20 mM EDTA). denatured by heating (5 min at 98°C) and placed on 
ice for 5 run prior to loading on a 12% native polyacrylamide gel. Gels were 
run overnight in TrislboratefEDTA buffer with water cooling in a cold room 
at 200 V. 66 mA. After visualizing the DNA bands by silver staining gels 
were dried on filter paper and photographed. 
Statistical analysis 
We first investigated whether the observed genotype distributions at each 
locus under study were consistent with a Hardy-Weinberg equilibrium. Having 
confirmed that this was the case, we assumed that alleles were independent 
at each locus and compared allele frequencies among cases and controls. 
These tests were performed using a X2 test with Yates correction. This analysis 
was then extended by carrying out a haplotype analysis using the linkage 
utility program EH (extended haplotype) available at URL hrtp:/flinkage.-
rockerfel!er.edu/soft/list.html (27). This program tests for association between 
several genetic markers and a disease locus or between genetic markers. 
Results 
To carry out an association study of XPD gene poly-
morphisms and melanoma, blood samples were obtained from 
28 melanoma patients attending the Dermatology Department 
at the Royal Infirmary of Edinburgh. The criteria for suitability 
were chosen to maximize the chance of there being a strong 
genetic component to the disease. Control blood samples were 
also obtained from 33 donors at the Scottish Blood Transfusion 
Service in the same hospital. The mean age of the patients was 
42 ± 10, compared with a mean age of 45 ± 10 for the controls. 
PCR assays were established for individual XPD exons and 
products were examined for variation by SSCP analysis. 
Variation was observed for exons 6. 18, 20, 22 and 23 and a 
detailed analysis was carried out for exons 6, 22 and 23. For 
each of these exons SSCP analysis indicated a two allele 
polymorphism, and this was confirmed by DNA sequencing. 
Once the single nucleotide changes responsible for the exon 
6, 22 and 23 polymorphisms had been identified it became 
clear that they had all been reported previously (20). Using 
the sequence data convenient RFLPs were then identified 
for each change to facilitate the analysis. Details of the 
polymorphisms and the RFLP analysis used are shown in 
Table II. The detection of these polymorphisms by SSCP and 
RFLP is shown in Figure 1. The genotypes at these three 
polymorphic positions within the XPD gene were determined 
for all the melanoma and control samples by SSCP and 
confirmed by RFLP analysis. 
The expected genotype distributions for exons 6, 22 and 23 
under Hardy—Weinberg equilibrium were derived for both 
melanoma cases and controls and compared with the observed 
distributions. This confirmed that the observed distributions 
were consistent with a Hardy—Weinberg equilibrium. We there-
fore assumed independence of alleles at these exons and 
compared allele counts, rather than genotypes, in melanoma 
cases and controls because of the resulting increased power 
of the statistical analysis. These allele counts are given in 
Table [II. The exon 23 (position 35931) A allele was 
significantly over-represented in melanoma patients [odds ratio 
(OR) 2.8. 95% confidence interval (CI) 1.2-7.0. P = 0.021. 
The exon 22 (position 35326) C allele was also significantly 
over-represented in the disease group (OR 2.6, 95% Cl 
1.1-6.7, P = 0.04), as was the exon 6 (position 22541) A 
allele (OR 2.0. 95% CI 0.9-4.5. P = 0.08). 
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Table I. Details of PCR products for polymorphism analysis 
Product Primer sequence Size (bp) Conditions 
XPD exon 6 (F)TGTCCAAAACCCCAGCCAGCTG 288 30 cycles: 94°C I mm. 69°C 1 mm. 72°C 30 s 
(R)CAGGGGTCAGGGAGGCTGCCTG 
XPD exon 22 (F)AATGACCTTCTGTCCCTGGCCTGCG 229 35 cycles: 94°C 1 mm, 72°C 30 s 
(R )AGAAGCTCAGCCTGGGAGGGTGCCG 
XPD exon 23 (F)TCAAACATCCTGTCCCTACTGGCCAT 344 35 cycles: 94°C 1 mm. 67°C 1 mm. 72°C 30 s 
(R)GTCACGTCCACAGCC1TFAATCGCAG 
ERCCI exon 4 (F)TCATCCCTATTGATGGCTFCTGCCC 252 35 cycles: 94°C 1 mm. 69°C 1 mm. 72°C 30 s 
(R )GACCATGCCCAGAGGCTI'CTCATAG 
CKM exon 8 and 3 (F)TGATCGGCTGGGCTCGTCCGAAGTAG 1098 35 cycles: 94°C 1 mm. 67°C 1 mm, 72°C I mm 
(R)CAGCTI'GGTCAAAGACATTGAGGTGG 
'Primer sequences were derived from GenBank entries: XPD. L47234: ERCCI. M63796; CKM. AC005781 
Table II. Details of RFLPs studied and fragment sizes 
Gene/exon 	 Enzyme 	 Polymorphism 	Position' Genotype Fragment sizes (bp) 
XPD exon 6 	 Hinfl 	 A to C 	 22541 AA 206+82 
AC 288+206+82 
CC 288 (no cut) 
XPD exon 22 	 FokI 	 C to T 	 35326 CC 229 (no cut) 
CT 229+135+94 
U 135+94 
XPD exon 23 	 PstI 	 A to C 	 35931 AA 234+110 
AC 234+172+110+62 
CC 172+110+62 
ERCCI exon 4 	BsrDI 	 G to A 	 19007 GG 252 (no cut) 
GA 252+179+73 
AA 179+73 
CKM exon 8 	 TaqI 	 I to C 	 23977 U 1099 (no cut) 
TC 1099±999+100 
CC 999+100 
CKM 3' 	 Ncoll 	 C to X 5 	 24800 CC 926+173 
CX 1099+926+173 
XX 1099 (no cut) 
Nucleotide positions are from the GenBank entries: XPD, L47234 	ERCCI, M63796: CKM, AC005781. 
This RFLP results in the loss of an NcoI site, but the nucleotide change has not been described. 
Table III. Association between XPD polymorphisms and melanoma 
XPD exon 6 allele counts 	 XPD exon 22 allele counts XPD exon 23 allele counts 
A 	 C 	C T A 	 C 
Melanoma cases 	30 	 26 	46 10 45 	 11 
Controls 	24 42 42 24 39 27 
OR 2.0 (95% Cl 0.9.5) P = 0.084 	OR 2.6 (95% Cl 1.1-6.7) P = 0.04a OR 2.8 (95% Cl 1.2-7.0) P = 0.02 
a2 analysis with Yates correction. 
Table IV. Lack of association between polymorphisms in XPD flanking markers and melanoma 
ERCCI exon 4 allele counts 	 CKM exon 8 allele counts 	 CKM 3' allele counts 
G 	 A 	T 	 C 	C 	 X 
Melanoma cases 16 	 40 	13 	 43 	41 	 15 
Controls 	26 40 19 47 47 19 
OR 1.6 (95% Cl 0.7-3.7) P = 0.3 	 OR 0.75 (95% Cl 0.3-1.8) P = 0.6a 	OR 0.9 (95% Cl 0.4-2.2) P = 0.97a 
° analysis with Yates correction 
405 
D.Tomescu et aL 
K14 U 
EXON 6 EXON 22 EXON 23 
AAACCC CCCTTT AAACCC 
9L. 
W W 	 W 
C,, 	I 	I 
WW 
Fig. 1. SSCP and RFLP analysis of XPD gene polymorphisms. The patterns 
obtained by SSCP (upper) and RFLP (lower) analysis for the three 
genotypes observed at the polymorphic sites analysed in exons 6. 22 and 23 
are indicated. Note that the 62 bp fragment, obtained by restricting the exon 
23 PCR product with Pstl, is not shown. 
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Fig. 2. Map of the region of human chromosome 19 containing the XPD 
gene. Map of a I Mb region of human chromosome 19ql3.2—q13.3. The 
direction of transcription (where known) is indicated by an arrowhead. 
APO, apolipoprotein gene complex: ASE-l. antisense ERCCI (CWe-
associated protein): C. unknown function: CKM, muscle creatine kinase: 
CLPTM I. cleft lip and palate-associated transmemhrane protein I: ERCC I 
NER gene: FOSB, transcriptional activator: KLC2, kinesin light chain 2; 
VASP, vasodilator-stimulated phosphoprotein. 
This analysis was extended by carrying out a haplotype 
analysis using the linkage utility program EH (27). This 
program tests for allelic association between loci by comparing 
the likelihoods of the data under the assumption of no 
association and of association. In the former case it is assumed 
that alleles at different loci occur independently, so haplotype 
frequencies are formed as the product of constituent allele 
frequencies. while if association is allowed for, haplotype 
frequencies are estimated from the data. The program estimates 
the haplotype frequencies under the assumption of no allelic 
association (1-1 11 ). allelic association between markers but not 
with disease (H 1 ) and association between alleles and disease 
as well as allelic association (H,). Analysis of allele counts 
with the linkage utility program EH for the following pairs of 
exons all confirmed very strong marker—marker association 
(H 1  x 2  values of 37.2. 42.1 and 87.1 for exon 22/exon 6. exon 
23/exon 6 and exon 23/exon 22, respectively, all P values 
<0.001). It also confirmed significant allele association 
between these three alleles and disease status (H—H 1  X2 
values with I degree of freedom of: 10.5 for exon 22/exon 6. 
P < 0.005: 12.0 for exon 23/exon 6, P < 0.001; 6.71 for 
exon 22/exon 23, P < 0.025). 
Thus, we have obtained clear evidence of a statistically 
significant positive association between three XPD poly-
morphisms and melanoma. Of course, in addition to an 
alteration in the XPD protein itself being responsible for the 
association there are a number of other possible alternative 
explanations: chance, artefact, linkage disequilibrium and 
population stratification. These competing explanations are 
discussed later, but in order to further explore linkage disequi-
librium as an explanation for the association we decided to 
analyse additional markers on either side of the XPD locus. If 
linkage disequilibrium was responsible for the association 
observed between XPD and melanoma we hypothesized that 
a similar association would also occur between the markers 
flanking XPD and disease status. A detailed map and extensive 
sequence information is available for human chromosome 
19ql3.2—q13.3 (28), which contains two other DNA repair 
genes. the NER gene ERCCJ and the single-strand break repair 
gene XRCCI. in addition to XPD (ERCC2). A map of a 1 Mb 
region around the XPD locus is shown in Figure 2. XRCCI is 
located 2 Mb proximal to XPD. The closest flanking markers 
to XPD for which RFLPs were available were muscle creatine 
kinase (CM, located 50 kb 3'. and ERCCI, located 200 kb 
5' to XPD. For CKM RFLPs which had been described in 
exon 8 and in the 3' flanking region (29) were typed. For 
ERCCI an RFLP assay was devised for a previously described 
polymorphism in exon 4 (20). Details of the ERCCI and CKM 
polymorphisms are given in Table II. As before, we first 
confirmed that the genotype distributions at these loci were 
consistent with those expected under Hardy—Weinberg 
equilibrium and then compared allele counts found in 
melanoma cases and controls (see Table IV). Contrary to the 
situation with XPD itself, no evidence of association was 
found between any of the flanking markers and melanoma. 
Discussion 
In a study of 28 melanoma patients we have found an 
association between three different polymorphisms at the XPD 
gene and disease. Samples were obtained from melanoma 
patients attending the Dermatology Department at the Royal 
Infirmary of Edinburgh. The inclusion criteria for the study 
were chosen to maximize the chance of a strong genetic 
component to their disease. Control samples were taken at 
random from donations made to the Scottish Blood Transfusion 
Service located in the same hospital. The mean ages of the 
patient (42 ± 10) and control groups (45 ± 10) were equivalent. 
All genotypes analysed in the control group were in Hardy—
Weinberg equilibrium and we consider that it constitutes an 
acceptable control group for this exploratory study. In addition, 
to strengthen the case for the suitability of our control group. 
the C allele frequencies at the polymorphic sites in exon 6 
(0.64) and 23 (0.41) of the XPD gene in our control group 
were not significantly different from those reported for the 
control group in a recent Danish study (exon 6. 0.58: exon 
23, 0.38) (30): for exon 6, x 2  with Yates correction = 0.68, 
P = 0.7 for exon 23, x2 with Yates correction = 0.06. P = 0.7. 
This work was undertaken to test a prior hypothesis based 
on a plausible biological model to explain a functional link 
between the XPD protein and predisposition to melanoma. 
We consider that chance is an unlikely explanation for the 
association observed since three separate polymorphisms 
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within the XPD gene all showed the association. In addition, 
while this study was being carried out a similar association. 
with the same direction of risk, was reported for the same 
exon 6 and 23 polymorphisms that we have analysed and 
basal cell carcinoma (30 see below). An artefactual explanation 
for the association, such as the genotypes obtained being 
affected by problems of storage or analysis, is equally unlikely. 
Control and case samples were obtained and processed 
contemporaneously and all the genotypes from the control 
group were in Hardy-Weinberg equilibrium. In addition, as 
mentioned above, the XPD exon 6 and 23 allele frequencies 
in our control group agree with a previous report. 
The association between these three different XPD poly-
morphisms and melanoma did not extend to the closest 
available polymorphic markers flanking the XPD gene on 
human chromosome 19q. This argues against the association 
being due to linkage disequilibrium or population stratification 
and indicates that the gene responsible for the association is 
located between CKM and ERCCI. Although there are four 
known genes within this segment. XPD is the only one with 
a clear role in a DNA repair pathway that protects against 
melanoma and we believe that our data provide evidence that 
the change to the XPD gene is causative, a functional change 
in the protein resulting in an increased risk of melanoma. 
A similar association between XPD and basal cell carcinoma, 
albeit with a less robust statistical analysis and no use of 
flanking markers, has been reported in a Danish study for the 
same exon 6 and 23 polymorphisms that we have studied (30). 
Of the three polymorphisms we have analysed only the exon 
23 change affects the coding sequence (Lys-4Gln change). 
The association was strongest for this region of the gene and 
it could indeed be causative. Lymphocytes with the Lys allele, 
which is over-represented in the melanoma group. showed 
reduced repair in an X-ray-induced chromosome aberration 
assay (31). The relevance to the measurement of NER of an 
assay involving ionizing radiation can be questioned, but it has 
been used to detect reduced repair activity in XP heterozygotes 
in situations where conventional assays for NER have failed 
(17). However, in a report of the association between XPD 
polymorphisms and BCC it was stated that no difference in 
repair between the Lys and Gin alleles had been found using 
host cell reactivation and Comet assays (30). It is possible that 
the causative change within the XPD gene remains to be 
identified. 
The findings reported here need to be repeated in a larger 
study to support our inference of causality over competing 
influences of linkage disequilibrium, chance or population 
stratification as explanations for the association between XPD 
polymorphisms and melanoma. Ideally a larger study would 
involve an improved control group with closer matching and 
attention to ethnic background. Concerns about false positive 
associations due to confounding by population stratification 
could be handled either by typing a group of 15-20 (unlinked) 
markers to detect population stratification (32) or by adopting 
a family-based control design. such as a transmission dis-
equilibrium test. Additional functional studies will also be 
required to identify an altered property for the form of the 
XPD protein associated with melanoma. Although current 
studies have focused on the possibility that the increased risk 
of melanoma results from reduced NER capacity of this form 
of the XPD protein, we wish to investigate the possibility that 
it could instead be due to an altered interaction between XPD 
and the cell cycle control machinery. Although the increased  
risk associated with the XPD polymorphisms that we have 
reported is modest, the allele frequency (and hence prevalence 
of exposure') is high and thus the population attributable 
risk (the impact on disease incidence in the population if 
the association is causal) could be high. Furthermore, if 
the association is confirmed in a larger study and similar 
associations are found for other NER genes, then the combina-
tion of particular alleles of several different NER genes could 
combine to give a stronger predisposition to skin cancer in the 
general population. 
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